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Summary
ADHD and schizophrenia are neurodevelopmental disorders that are more prevalent 
in males and show sex differences in age of onset or severity. The Y chromosome is 
potentially an important influence on male susceptibility to neuropsychiatric 
disorders. The way the Y chromosome could increase risk to neuropsychiatric 
disorders is directly or indirectly by interacting with autosomal genes expressed in the 
brain. In addition, it could modify the disease phenotype. However, due to difficulties 
arising from the lack of recombination and widely accepted nomenclature, the Y 
chromosome has been largely excluded from genetic and genomic studies of 
neuropsychiatric disorders.
To overcome this lack of knowledge, 9 Y chromosome markers were selected to 
represent the main Y chromosome haplogroups that are present in the U.K. and they 
were genotyped in a sample of 210 cases with ADHD, 313 cases with schizophrenia 
and 637 U.K. controls.
Statistical analysis of Y chromosome haplogroups revealed that although there was no 
significantly increased representation of any haplogroup in cases with ADHD or 
schizophrenia compared to controls, there was evidence of a possible modifying effect 
on the phenotype of ADHD and schizophrenia. Y chromosome haplogroup 3 was 
associated with higher performance and full scale IQ within the sample of patients 
with ADHD. Haplogroup 1 was associated with better outcome and higher 
educational level within die sample of patients with schizophrenia. There was no 
association of Y chromosome haplogroups with IQ in a population sample of 3,749 
individuals.
Y chromosome haplogroups were also tested for interaction with tyrosine hydroxylase 
SNPs because animal studies suggest this is biologically plausible. Although there 
was no evidence of interaction, three tyrosine hydroxylase SNPs showed nominally 
significant association in the sample of male patients with schizophrenia.
This study is one of the largest Y chromosome studies in the UK. It suggests that 
although Y chromosome variation does not appear to be associated with ADHD or 
schizophrenia, it may modify cognitive performance and clinical features.
Table of contents
Declaration and Statements...................................................................................................................... i
Acknowledgements.................................................................................................................................. iii
Summary...................................................................................................................................................iv
Table of contents...................................................................................................................................... v
Index of Figures..............................................................................„....................................................... xi
Index of Tables...................................................................................................................................... xiv
Chapter 1 Sex differences........................................................................1
1.1 Sex differences in psychopathology...........................................................................................1
1.1.1 Sex differences in ADHD and schizophrenia.......................................................................... 3
1.2 Sexually dimorphic effects of genes on psychiatric disorders................................................4
13 Sex differences in brain structure and function...................................................................... 6
1.4 Causes of sex differences in brain and behaviour................................................................... 8
1.4.1 Hormonal effects......................................................................................................................9
1.4.2 Genetic causes........................................................................................................................ 10
1.4.3 The effect of sex chromosomes on brain................................................................................10
1.4.3.1 X chromosome.............................................................................................................. 13
1.4.3.1.1 X chromosome inactivation....................................................................................15
1.4.4 Gene dosage effects................................................................................................................ 15
1.4.5 Mosaicism.............................................................................................................................. 17
1.4.6 X-linked imprinting................................................................................................................ 18
1.4.7 Environmental factors............................................................................................................ 18
Chapter 2 Attention deficit hyperactivity disorder (ADHD)................. 21
2.1 ADHD symptoms and diagnosis............................................................................................. 21
2.1.1 Epidemiology.........................................................................................................................21
2.1.2 Clinical presentation...............................................................................................................21
2.1.3 ADHD diagnosis....................................................................................................................22
2.1.4 Developmental course........................................................................................................... 25
2.1.5 Comorbidity...........................................................................................................................25
2.2 Brain structure and function in ADHD................................................................................. 27
23 Evidence of genetic component to ADHD.............................................................................. 29
2.3.1 Family studies........................................................................................................................29
2.3.2 Adoption studies.....................................................................................................................29
2.3.3 Twin studies...........................................................................................................................29
2.4 Identifying complex disorder susceptibility genes.................................................................30
2.4.1 Genome-wide linkage studies............................................................................................... 31
2.4.1.1 Linkage analysis principle........................................................................................... 31
2.4.1.2 Limitations of linkage studies......................................................................................32
2.4.2 Candidate gene association studies..............   32
2.4.2.1 Linkage Disequilibrium (LD)......................................................................................33
2.4.2.2 Marker selection...........................................................................................................33
2.4.3 Types of association study designs........................................................................................34
2.4.3.1 Case-control association studies...................................................................................34
2.4.3.2 Family-based association studies..................................................................................34
2.4.4 Genome-wide association studies (GWAS).......................................................................... 35
2.4.4.1 Allelic architecture of common diseases..................................................................... 35
2.4.4.2 Power of association studies.........................................................................................36
2.4.4.3 Limitations of genome-wide association studies......................................................... 38
2.5 Molecular genetics of ADHD...................................................................................................39
2.5.1 Genome-wide linkage studies................................................................................................39
2.5.2 Candidate gene association studies........................................................................................42
2.5.2.1 Dopamine D4 receptor gene (DRD4).......................................................................... 44
2.5.2.2 Dopamine D5 receptor gene (DRD5).......................................................................... 45
2.5.2.3 Dopamine transporter gene (SLC6A3 or DAT 1)......................................................... 45
2.5.2.4 Catechol-O-Methyltransferase (COMT)...................................................................... 47
2.5.2.5 Synaptosomal-associated protein of 25kD (SNAP25)................................................. 48
2.5.3 Genome-wide association studies (GWAS).......................................................................... 49
2.5.4 Copy number variants (CNVs)...............................................................................................51
2.6 The contribution of gene-environment interaction in ADHD............................................... 52
Chapter 3 Schizophrenia........................................................................ 56
3.1 Schizophrenia symptoms and diagnosis..................................................................................56
3.1.1 Epidemiology......................................................................................................................... 56
3.1.2 Clinical presentation...............................................................................................................56
3.1.3 Schizophrenia diagnosis......................................................................................................... 57
3.1.4 Prognosis................................................................................................................................ 58
3.1.5 Management of patients with schizophrenia......................................................................... 58
3.1.6 Phenotypic complexity...........................................................................................................58
3.2 Schizophrenia as a neurodevelopmental disorder................................................................. 60
33  Evidence of a genetic component to schizophrenia................  62
3.3.1 Family studies........................................................................................................................ 62
3.3.2 Adoption studies..................................................................................................................... 63
3.3.3 Twin studies........................................................................................................................... 64
3.3.4 Mode of transmission..............................;.............................................................................64
3.4 Molecular genetics of schizophrenia........................................................................................65
3.4.1 Genome-wide linkage studies................................................................................................65
3.4.2 Candidate gene studies...........................................................................................................67
3.4.2.1 Dystrobrevin-binding protein 1 (DTNBP1)................................................................. 67
3.4.2.2 Neuregulinl (NRG1)....................................................................................................68
3.4.2.3 SzGene: a database of association studies of schizophrenia........................................68
3.4.3 Genome-wide association studies (GWAS).......................................................................... 69
3.4.4 Copy number variants (CNVs)...............................................................................................73
Chapter 4 The Y chromosome.............................................................. 76
4.1 The evolution of sex chromosomes..........................................................................................76
4.2 The Y chromosome structure...................................................................................................77
4.2.1 Pseudoautosomal regions (PARs)..........................................................................................78
4.2.2 Male-specific region (MSY)..................................................................................................79
4.3 Markers and haplogroups to study the Y chromosome........................................................ 80
4.3.1 Y chromosome markers.........................................................................................................80
4.3.2 Y chromosome haplogroups.................................................................................................. 81
4.3.3 The Y Chromosome Consortium (YCC)............................................................................... 82
4.3.4 YCC nomenclature systems.................................................................................................. 84
4.3.5 YCC haplogroup tree 2008................................................................................................... 86
4.4 Geographical differentiation of Y chromosome haplogroups..............................................87
4.4.1 Lack of recombination and its importance............................................................................ 87
4.4.2 Effective population size....................................................................................................... 88
4.4.3 Social factors..........................................................................................................................88
4.4.4 Selection................................................................................................................................. 89
4.4.5 Geographical distribution of Y chromosome haplogroups in Europe and United Kingdom 
90
4.5 Y chromosome associations with phenotypes........................................................................ 91
4.5.1 Reproductive medicine.......................................................................................................... 94
4.5.2 Male cancers..........................................................................................................................95
4.5.3 Hypertension and lipid levels................................................................................................ 96
4.5.4 Psychiatric phenotypes.......................................................................................................... 97
4.6 Y chromosome and brain function..............----------- ..........------- ..........------------.....----- 98
4.6.1 Animal studies........................................................................................................................98
4.6.2 Four core genotypes model................................................................................................... 99
4.6.3 Y chromosome abnormalities in humans............................................................................ 100
4.7 SRY  (Sex-determining region of chromosome Y)................................................................100
4.7.1 SRY transcription regulation................................................................................................ 101
4.7.2 SRY expression.................................................................................................................... 102
4.8 The main function of SRY  is the initiation of male sex development.................................103
4.8.1 SRY mutations and the phenotype they cause...................................................................... 103
4.8.2 SRY and male sex differentiation......................................................................................... 104
4.9 SRY  involvement in brain function and behaviour.............................................................105
4.10 Other Y chromosome genes expressed in b rain .................................................................. 106
Chapter 5 Hypotheses and aims of the project.................................. 110
Chapter 6 Materials and Methods........................................................112
6.1 DNA samples........................................................................................................................... 112
6.1.1 DNA extraction and storage.................................................................................................112
6.1.2 DNA quantification and assessment....................................................................................112
6.2 Polymerase Chain Reaction (PCR).......................................................................................113
6.3 Agarose Gel Electrophoresis..................................................................................................114
6.4 Sample Processing...................................................................................................................114
6.5 Genotyping using iPLEX MassARRAY............................................................................... 115
6.5.1 Sequenom PCR.................................................................................................................... 115
6.6 Bioinformatic and Statistical analysis.................................................................................. 120
6.6.1 PLINK.................................................................................................................................. 120
6.6.2 HAPLOVIEW...................................................................................................................... 120
6.6.3 SPSS (Statistical Package for the Social Sciences)............................................................. 121
6.6.4 The International HapMap Project 121
Chapter 7 The role of Y chromosome in ADHD............................... 123
7.1 Introduction..............................................................................................................................123
7.2 Aims of the study......................................................................................................................124
73  Materials and methods........................................................................................................... 125
7.3.1 ADHD sample description................................................................................................... 125
7.3.2 ADHD sample assessment................................................................................................... 126
7.3.3 1958 UK birth cohort control sample................................................................................... 127
7.3.4 DNA samples and genotyping.............................................................................................. 127
7.3.5 Selection of Y chromosome SNPs....................................................................................... 127
7.3.6 Categorisation of individuals in haplogroups.......................................................................128
7.3.7 Phenotypic analysis.............................................................................................................. 132
7.3.8 Statistical analysis.................................................................................................................132
7.4 Results....................................................................................................................................... 134
7.4.1 Case-control association study............................................................................................. 134
7.4.1.1 Allelic analysis........................................................................................................... 134
7.4.1.2 Haplogroup analysis...................................................................................................134
7.4.2 Phenotypic analysis using haplogroups................................................................................135
7.4.3 Phenotypic analysis using Y chromosome SNP alleles........................................................138
7.5 Discussion.................................................................................................................................143
Chapter 8 The role of Y chromosome in schizophrenia...................... 148
8.1 Introduction..............................................................................................................................148
8.2 Aims of the study......................................................................................................................148
83 Materials and methods............................................................................................................149
8.3.1 Schizophrenia sample description........................................................................................ 149
8.3.2 Schizophrenia sample assessment........................................................................................ 149
8.3.3 1958 UK birth cohort control sample................................................................................... 150
8.3.4 DNA samples and genotyping................ .'...........................................................................151
8.3.5 Selection of SNPs and categorisation of individuals in haplogroups.................................. 151
8.3.6 Phenotypic analysis.............................................. .............................................................. 154
8.3.7 Statistical analysis.................................................................................................................154
8.4 Results....................................................................................................................................... 155
8.4.1 Case-control association study............................................................................................. 155
8.4.1.1 Allelic analysis........................................................................................................... 155
8.4.1.2 Haplogroup analysis...................................................................................................157
8.4.2 Phenotypic analysis using haplogroups................................................................................ 158
8.4.3 Phenotypic analysis using Y chromosome SNP alleles........................................................163
8.5 Discussion.................................................................................................................................168
Chapter 9 Investigating the role of Y chromosome in cognitive ability
using a population cohort....................................................................... 172
9.1 Aims of the study......................................................................................................................172
9.2 Materials and methods 173
9.2.1 ALSPAC sample and data description.................................................................................173
9.2.2 Selection of Y chromosome SNPs....................................................................................... 174
9.2.3 DNA samples and genotyping.............................................................................................. 175
9.2.4 Statistical analysis.................................................................................................................175
9 J  Results....................................................................................................................................... 176
9.3.1 Frequencies of Y chromosome haplogroups in ALSPAC....................................................176
9.3.2 Testing for association of Y chromosome haplogroups with IQ in a general population
cohort 177
9.3.3 Testing for association Y chromosome haplogroups with IQ in ALSPAC ADHD patients 
178
9.4 Discussion.................................................................................................................................179
Chapter 10 Testing for an indirect effect of Y chromosome variation 
on ADHD and schizophrenia -  Interaction with Tyrosine Hydroxylase 182
10.1 Introduction..............................................................................................................................182
10.1.1 SRY (Sex Determining Region of chromosome Y )........................................................182
10.1.2 Tyrosine Hydroxylase (77/) function..............................................................................183
10.1.3 TH gene............................................................................................................................186
10.1.4 TH associations............................................................................................................... 186
10.1.5 Interaction of SRY with TH..............................................................................................187
10.2 Aims of the study......................................................................................................................188
103 Materials and methods........................................................................................................... 188
10.3.1 ADHD sample description.............................................................................................188
10.3.2 Schizophrenia sample description..................................................................................189
10.3.3 1958 UK birth cohort control sample.............................................................................189
10.3.4 Selection of TH SNPs...................................................................................................... 189
10.3.5 DNA samples and genotyping........................................................................................190
10.3.6 Statistical analysis..........................................................................................................190
10.4 Results.......................................................................................................................................192
10.4.1 Case-control association study in ADHD..................................................................... 192
10.4.1.1 Allelic analysis..........................................................................................................192
10.4.1.2 Case-control association study within each sex........................................................193
10.4.2 Case-control association study in schizophrenia..............................................................195
10.4.2.1 Allelic analysis..........................................................................................................195
10.4.2.2 Case-control association study within each sex........................................................196
10.4.3 Testing for an interaction between Y chromosome and TH SNPs.................................199
10.5 Discussion................................................................................................................................ 200
Chapter 11 General discussion......................................................... 203
11.1 Summary of findings............................................................................................................... 203
11.2 Y chromosome haplogroup distribution in the UK............................................................. 205
113 The role of the Y chromosome on ADHD..................................................................... 207
11.4 The role of the Y chromosome on schizophrenia............................................................... 208
11.5 Y chromosome interaction with Tyrosine Hydroxylase (TH) ............................................209
11.6 Implications of research results.............................................................................................211
11.7 Moving from genetic association to understanding the biology........................................ 212
11.8 Future directions..................................................................................................................... 214
11.9 Conclusions.............................................................................................................................. 217
Chapter 12 References....................................................................... 218
Appendix I -  Quality Control information........................................................................................... i
Appendix I I ............................................................................................................................................... v
Appendix III -  Interactions....................................................................................................................vi
Index of Figures
Figure 1-1. Female/male ratios in selected psychiatric disorders. Ratios >1 represent disorders 
with a female preponderance while ratios <1 represent disorders with a male
preponderance. The data are based on a review by Holden et al. (2005)........................ 2
Figure 1-2. Sexually dimorphic brain structures. Data from Goldstein et al. (2001), where they 
measured the volume of brain regions relative to the cerebrum using MRI scans in 27 
men and 21 women. Structures that are larger in women are shown in red and structures
that are larger in men are shown in blue. Picture taken from Cahill (2006).................... 7
Figure 1-3. Interactions between genetic, hormonal and environmental factors contributing to
sex differences.............................................................................................................. 9
Figure 1-4. Diagram of sex chromosomes showing key genes with a homologue on both 
chromosomes. Pseudoautosomal regions are shown in black, and the heterochromatic 
region on the Y chromosome is shown in a darker colour. The euchromatic region of the 
Y chromosome is magnified (NLGN4: Neuroligin; PRK: Protein kinase; STS: Steroid 
sulfatase; KALI: Kallmann syndrome 1 protein; AMEL: Amelogenin; DB: Developing 
brain homeobox; UT: Ubiquitously transcribed tetratricopeptide repeat gene; MAOA: 
Monoamine oxidase A; SRY: Sex-determining region on Y chromosome; ZF: Zinc-
finger protein; PCDH11: Protocadherin 11.................................................................. 12
Figure 2-1. Effects of OR and allele frequency on sample size requirements. The total number 
of individuals (equal numbers of cases and controls) that are required for an association 
study to have 80% power to detect disease variants with allelic odds ratios of 1.2 (red),
1.3 (blue), 1.5 (green) and 2 (black) are shown. Significance level is set at p<10‘6. A 
multiplicative model and perfect LD between test markers and disease variants are
assumed. Adapted from Wang et al. (2005)..................................................................37
Figure 3-1. Risk of developing schizophrenia in relatives of patients with schizophrenia. The
data are based on a review of studies compiled by Gottesman (1991).......................... 63
Figure 4-1. The male-specific region of Y chromosome. The diagram shows the different 
types of euchromatic sequences regions in the MSY. Heterochromatic sequences are
also shown................................................................................................................... 80
Figure 4-2. The single most parsimonious Y chromosome tree including 245 markers and 153 
haplogroups. The arrow indicates the root of the tree. Capital letters are used to name 
major clades. The most inclusive is Y, where all haplogroups belong. Different colours 
are used for the different clades. Haplogroup names and YCC sample numbers are 
given on the right. Markers needed in order io capture a haplogroup are given along the 
branches. The length of each branch is arbitrary. The * symbol indicates a paragroup
(see text for explanation) (The Y Chromosome Consortium 2002).............................. 83
Figure 4-3. Haplogroup Hlb named according to 1st nomenclature system. Different colours
are used to indicate the levels of clades within the haplogroup.....................................84
Figure 4-4. The same haplogroup named with the two different nomenclature systems. The
figure shows what each letter and number represents................................................... 85
Figure 4-5. Diagram summarising the genes involved in SRY transcription regulation (SF1: 
Steroidogenic Factor 1; SP1: Specificity Protein 1; WT1: Wilms Tumour 1; IR: Insulin 
Receptor; IRR: Insulin-Related Receptor; IGF1R: Insulin-like Growth Factor 1 
Receptor; FOG2: GATA4-Friend of gata2; DAX1: Dosage-sensitive sex-reversal
adrenal hyperplasia congenital X chromosome 1)...................................................... 102
Figure 6-1. Screenshot from Typer analysis software showing two clusters of homozygotes 
(in green and blue), one cluster of heterozygotes (yellow) and failed samples or blanks
(red)........................................................................................................................... 119
Figure 7-1. Y chromosome haplogroup tree showing the relationship between genotyped
SNPs. Y chromosome haplogroups are represented by capital letters and SNPs start with
M. There were no individuals belonging in haplogroup F*......................................... 129
Figure 7-2. The Y chromosome haplogroups captured in this study were merged into three to 
facilitate phenotypic analysis. There were no individuals belonging in haplogroup F*.
Percentages represent the frequencies of the three Y chromosome haplogroups in 4,950
UK men genotyped in total in this study.....................................................................131
Figure 7-3. Total number of DSM-IV ADHD symptoms and DSM-IV hyperactive/impulsive 
symptoms (n=210) in 3 Y chromosome haplogroups within the sample of patients with 
ADHD, p values obtained from ANOVA comparing each of the variables separately in 3
Y chromosome haplogroups are shown on the graph..................................................136
Figure 7-4. Total number of DSM-IV CD symptoms (n=80) in 3 Y chromosome haplogroups
within the sample of patients with ADHD, p value obtained from ANOVA comparing
DSM-IV CD symptoms in 3 Y chromosome haplogroups is shown on the graph 136
Figure 7-5. Scores on the WORD Reading Test (n=192) in 3 Y chromosome haplogroups 
within the sample of patients with ADHD, p value obtained from ANOVA comparing 
scores on the WORD Reading Test in 3 Y chromosome haplogroups is shown on the
graph......................................................................................................................... 137
Figure 7-6. FSIQ, PIQ and VIQ scores (n=202) in 3 Y chromosome haplogroups within the 
sample of patients with ADHD, p values obtained from ANOVA comparing each of the 
variables separately in 3 Y chromosome haplogroups are shown on the graph; *:
significant at the p<0.05 level.................................................................................... 137
Figure 8-1. Y chromosome haplogroup tree showing the relationship between genotyped
SNPs. Y chromosome haplogroups are represented by capital letters and SNPs start with 
M. There were no individuals belonging in haplogroup F*. Figure is the same as in
Chapter 7 and is repeated to facilitate reading.............................................................152
Figure 8-2. The Y chromosome haplogroups captured in this study were merged into three to 
facilitate phenotypic analysis. There were no individuals belonging in haplogroup F*. 
Percentages represent the frequencies of the three Y chromosome haplogroups in 4,950 
UK men genotyped in total in this study. Figure is the same as in Chapter 7 and is
repeated to facilitate reading.......................................................................................153
Figure 8-3. Age at first psychiatric contact in 3 Y chromosome haplogroups within the sample 
of patients with schizophrenia.. p value obtained from ANOVA comparing age at first
psychiatric contact in 3 Y chromosome haplogroups is shown on the graph...............159
Figure 8-4. Number of positive, negative and disorganised symptoms in 3 Y chromosome 
haplogroups within the sample of patients with schizophrenia, p values obtained from 
ANOVA comparing each of the variables separately in 3 Y chromosome haplogroups
are shown on the graph..............................................................................................160
Figure 8-5. Worst ever global assessment score (GAS) (100=best function, 0=worst function) 
in 3 Y chromosome haplogroups within the sample of patients with schizophrenia, p 
value obtained from ANOVA comparing worst ever global assessment score (GAS) in 3
Y chromosome haplogroups is shown on the graph....................................................161
Figure 8-6. % of patients with schizophrenia in each of the three Y chromosome haplogroups
that have good or poor outcome of illness, p value obtained from Pearson chi-square test 
comparing % of patients with good and poor outcome in 3 Y chromosome haplogroups
is shown on the graph; *: significant at the p<0.05 level.............................................162
Figure 8-7. % of patients with schizophrenia in each of the three Y chromosome haplogroups 
that have low or high educational level (low education: no qualification or qualifications 
obtained at school up to but excluding A level, high education: A level or any further 
qualifications), p value obtained from Pearson chi-square test comparing % of patients 
with low and high education in 3 Y chromosome haplogroups is shown on the graph; *:
significant at the p<0.05 level.................................................................................... 163
Figure 9-1. The Y chromosome haplogroups captured in this study were merged into three to 
facilitate phenotypic analysis. There were no individuals belonging in haplogroup F*. 
Percentages represent the frequencies of the three Y chromosome haplogroups in 4,950 
UK men genotyped in total in this study. Figure is the same as in Chapter 7 and is
repeated to facilitate reading.......................................................................................174
Figure 9-2. FSIQ, PIQ and VIQ scores in 3 Y chromosome haplogroups within all available 
individuals from ALSPAC population cohort, p values obtained from ANOVA
comparing each of the variables separately in 3 Y chromosome haplogroups are shown
on the graph.............................................................................................................. 177
Figure 9-3. FSIQ, PIQ and VIQ scores in 3 Y chromosome haplogroups within 63 individuals
from ALSPAC that meet diagnosis for ADHD, p values obtained from ANOVA 
comparing each of the variables separately in 3 Y chromosome haplogroups are shown
on the graph.............................................................................................................. 178
Figure 10-1. Different developmental profile of SRY. Linear transcripts that are translated 
postnatally and circular transcripts that are not translated prenatally. Taken from Mayer
et al. (2000)............................................................................................................... 183
Figure 10-2. Catecholamine synthesis (Edinformatics.com 1999)
(http://www.edinformatics.com/interactive_molecules/info/adrenaline.htm)..............185
Figure 10-3. Pairwise LD between the SNPs genotyped. The Haploview LD plot shows the r2 
values between each SNP pair in the CEU population using data from HapMap Phases 1 
and 2.......................................................................................................................... 198
Index of Tables
Table 2-1. ADHD symptoms from the DSM-IV research diagnostic criteria........................ 24
Table 2-2. Summaiy of ADHD genome-wide linkage studies published so far (regions that
show overlap are in bold)............................................................................................ 40
Table 2-3. Meta-analysis and pooled studies for candidate gene association studies of ADHD
................................................................................................................................... 43
Table 3-1. Summary of meta-analyses of schizophrenia genome-wide linkage scans (regions
that show overlap are in bold)..............................................................................   65
Table 3-2. Summary of genome-wide association studies for schizophrenia published so far70
Table 4-1. Y chromosome association studies..................................................................... 93
Table 6-1. Sequenom PCR mix composition......................................................................116
Table 6-2. SAP mix composition....................................................................................... 117
Table 6-3. Extension primer mix composition....................................................................118
Table 7-1. Co-morbid disorders present in the sample of 210 boys with ADHD.................125
Table 7-2. Ancestral (0) and derived allele (1) for each Y chromosome SNP......................130
Table 7-3. Allelic analysis for 9 Y chromosome SNPs....................................................... 134
Table 7-4. Frequencies of Y chromosome haplogroups in 210 cases with ADHD and 637
controls-.................................................................................................................... 135
Table 7-5. Testing for association of Y chromosome SNP alleles and clinical characteristics
within the sample of patients with ADHD - Mann Whitney U test............................. 139
Table 7-6. Testing for association of Y chromosome SNP alleles and total score on the
WORD - Independent samples t-test..........................................................................140
Table 7-7. Testing for association of Y chromosome SNP alleles and cognitive measures
within the sample of patients with ADHD - Independent samples t-test......................141
Table 8-1. Allelic analysis for 9 Y chromosome SNPs....................................................... 157
Table 8-2. Frequencies of Y chromosome haplogroups in 313 cases with schizophrenia,
controls and 637 controls........................................................................................... 158
Table 8-3. Testing for association of Y chromosome SNP alleles with age at first psychiatric 
contact and worst ever global assessment score (GAS) (100=best function, 0=worst 
function) within the sample of patients with schizophrenia - Mann Whitney U test.... 164 
Table 8-4. Testing for association of Y chromosome SNP alleles with the number of positive, 
negative and disorganised symptoms within the sample of patients with schizophrenia -
Mann Whitney U test.................................................................................................165
Table 8-5. Testing for association of Y chromosome SNP alleles with the course of illness 
(good or poor outcome) within the sample of patients with schizophrenia -  Pearson chi-
square test (df=l).......................................................................................................166
Table 8-6. Testing for association of Y chromosome SNP alleles with educational level (low 
education: no qualification or qualifications obtained at school up to but excluding A 
level, high education: A level or any further qualifications) within the sample of patients
with schizophrenia -  Pearson chi-square test (df=l)...................................................166
Table 9-1. Combination of SNP alleles for each Y chromosome haplogroup. 0 represents the
ancestral state of each SNP and 1 the derived state.....................................................175
Table 9-2. Y chromosome haplogroup distribution in all individuals from ASLPAC 176
Table 10-1. SNPs in TH 35 kb area genotyped in ADHD cases, schizophrenia cases and
controls.............   190
Table 10-2. Allelic analysis for ADHD case-control association study............................... 192
Table 10-3. Allelic analysis for ADHD case-control association study in males only.......... 193
Table 10-4. Allelic analysis for ADHD case-control association study in females only....... 194
Table 10-5. Allelic analysis for schizophrenia case-control association study.....................195
Table 10-6. Allelic analysis for schizophrenia case-control association study in males only 196 
Table 10-7. Allelic analysis for schizophrenia case-control association study in females only
..................................................................................................................................197
Table 11-1. Frequencies of Y chromosome haplogroups in patients with ADHD, patients with 
schizophrenia and controls.........................................................................................206
Table 11-2. Frequencies of merged Y chromosome haplogroups in patients with ADHD,
patients with schizophrenia and controls from the 1958 Birth Cohort and ALSPAC.. 207
xv
Chapter 1 Sex differences
Being male or female is a fixed factor which can have an effect not only on 
morphological traits but also on the organisation of the brain. In addition, sex is one 
of the few externally observed factors that can be measured accurately and easily. 
Research on sex differences can not only provide an answer to the fundamental 
question “Why do men and women differ in susceptibility to a large number of 
disorders?” but more importantly, it can provide clues to the underlying mechanisms 
of devastating disorders.
It is well-established that quantitative traits such as blood pressure, obesity and lipid 
levels are sexually dimorphic (Weiss et al. 2006). The sex-specific nature of 
quantitative traits has been investigated in members of the Hutterite community, 
because they practise a communal lifestyle with remarkable similarities for both men 
and women. For 16 out o f 19 quantitative traits, including High-Density Lipoprotein 
(HDL), triglyceride levels, blood pressure and asthma, sex was a significant predictor 
(Pan et al. 2007; Weiss et al. 2006). Most importantly, complex diseases with a large 
impact on health tend to have different prevalence rates and courses in men and 
women. It is striking that it is actually difficult to find a human disease with no sex 
difference in prevalence, development, age of onset or severity. For example, 
cardiovascular disease and type 2 diabetes are more common in men compared to pre­
menopausal women (Choi and McLaughlin 2007; Woods et al. 2003). Asthma and 
autoimmune diseases also show age-sex interactions with a higher prevalence in 
females which is attenuated after puberty (Lockshin 2006; Postma 2007).
1.1 Sex differences in psychopathology
Psychiatric disorders are no exception to the rule of sex differences in diseases. The 
pattern of sex differences in psychopathology is that of two groups of disorders: early- 
onset neurodevelopmental disorders show a male preponderance, while emotional 
disorders with an onset during adolescence or later show a female preponderance. 
Following this pattern, autism, Asperger’s syndrome, Tourette’s syndrome, ADHD, 
dyslexia, developmental language disorders, conduct disorder and early-onset
schizophrenia are more common in males. Females are more likely to be affected by 
depression, eating disorders and anxiety (Holden 2005; Ober et al. 2008). Figure 1-1 
demonstrates the difference in prevalence of major psychiatric disorders between 
males and females. Antisocial behaviour appears to be an exception to this pattern, 
since it affects more males while peaking in adolescence. However, early-onset 
antisocial behaviour has an even higher male incidence with female antisocial 
behaviour rarely manifesting before adolescence (Rutter et al. 2003).
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Figure 1-1. Female/male ratios in selected psychiatric disorders. Ratios >1 represent disorders 
with a female preponderance while ratios <1 represent disorders with a male preponderance. 
The data are based on a review by Holden et al. (2005)
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1.1.1 Sex differences in ADHD and schizophrenia
Since this thesis focuses on the male excess in ADHD and schizophrenia, sex 
differences concerning these two neurodevelopmental disorders will be discussed 
further.
ADHD is one of the most common heritable childhood psychiatric disorders 
characterised by overactivity, impulsiveness and lack of concentration. It affects 1.4- 
5% of the population and places children at risk of poor educational attainment and of 
being antisocial.
There are consistently higher rates of males than females affected by ADHD. The 
male-to-female ratio in clinical samples can be as high as 6:1. However, sex 
differences are more profound in clinical samples than population cohorts due to 
referral bias, since boys with ADHD tend to be more disruptive than girls, making 
them more likely to be referred (Biederman et al. 2002). Although the male-to-female 
ratio in community samples is more difficult to assess, it is considered to be 4: 1 
according to a survey by the National Health Interview Survey (NHIS) (Cuffe et al.
2005). The disorder is also more severe and disruptive in boys. It is striking that boys 
tend to be more hyperactive, while girls are usually more inattentive (Cuffe et al.
2005). While there is no evidence of a sex difference in the efficacy of stimulant 
medication to treat ADHD (Spencer et al. 2001), it has been found that the response to 
stimulants is greater during the follicular phase of the menstrual cycle in adult patients 
(Justice and De Wit 2000).
Schizophrenia is another debilitating psychiatric disorder characterised by psychotic 
symptoms, altered emotional reactivity and cognitive impairment. It is a highly 
heritable disorder affecting approximately 1% of the population and imposing a great 
burden on sufferers and their relatives. According to two systematic reviews, the 
median male/female rate ratio is 1.4 (Aleman et al. 2003; McGrath et al. 2004). The 
most striking sex differences in schizophrenia are found in age of onset and 
morbidity. The age of onset for men is on average 21 years while the average age of 
onset for women is 25 years (Ober et al. 2008). Early age of onset is associated with 
worse outcome and more impaired cognition. Men with schizophrenia also experience 
more negative symptoms compared to women, they have a history of more obstetric
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complications and poorer premorbid adjustment (Preston et al. 2002). A longitudinal 
study following patients with schizophrenia over a period of twenty years found that 
women consistently showed better functioning, more periods of recovery, fewer 
hospitalisations and less likelihood of poor outcome even though the age of onset in 
these female patients was the same as in men (Grossman et al. 2006; Grossman et al. 
2008). It is interesting that sex differences in schizophrenia exist in relation to brain 
morphology. For example, it was found that increased prefrontal lobe volume was 
associated with more disorganised behaviour in women with schizophrenia, while the 
opposite was true for men (Cowell et al. 1996). Larger ventricles were found in men 
but not women with schizophrenia compared to healthy controls (Nopoulos et al.
1997). Hemispheric asymmetry is also reduced in men with schizophrenia compared 
to controls (Crow 2002).
To sum up, ADHD and schizophrenia are two highly heritable sexually dimorphic 
psychiatric disorders. The reasons behind the greater burden of these disorders in men 
compared to women deserve to be investigated, as they could provide clues to the 
pathophysiology of the disorders.
1.2 Sexually dimorphic effects of genes on psychiatric disorders
Sex differences in psychiatric phenotypes are well recognised and there has been 
interest in identifying gene variants that may be involved in them.
Of the few examples available, COMT (Catechol-O-Methyltransferase) stands out. 
The gene encoding COMT, an enzyme catalysing the degradation of dopamine, 
adrenaline and noradrenaline, is on chromosome 22ql 1.2. Interest in COMT comes 
from its involvement in dopaminergic pathways. In normal brain, COMT activity in 
prefrontal cortex is 17% higher in men than women (Chen et al. 2004) despite similar 
mRNA and protein levels in both sexes (Chen et al. 2004). A COMT knockout mouse 
model provided even more evidence for a sexually dimorphic effect of COMT. 
Dopamine levels in the frontal cortex were increased threefold in male COMT 
knockout mice compared with wild type controls. This difference was not found in 
female mice. However, female COMT knockout mice showed more anxiety compared 
to wild type controls (Gogos et al. 1998).
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The most studied polymorphism in COMT is a G/A transition found in codon 158, 
which results in a valine-to-methionine substitution (GenBank accession no. Z26491); 
Met(158) is coded by the low-activity (L allele), whereas Val(158) is coded by the 
high-activity variant (H allele). This polymorphism is functional and is associated 
with three- to four-fold differences in COMT activity between homozygous subjects 
with the val/val genotype and homozygous subjects with the met/met genotype 
(Lachman et al. 1996).
The sexually dimorphic effect of this COMT variant has been suggested in association 
studies of psychiatric disorders. The low activity allele was associated with 
Obsessive-Compulsive Disorder (OCD) in men in a meta-analysis (p<0.001, 
OR=1.88), while there was no effect in women (p=0.83, OR=0.98). There was also a 
significant interaction of this allele with gender (p<0.0001) (Pooley et al. 2007). The 
G allele of SNP rsl 65599 in COMT was found to be associated with schizophrenia in 
women (p=6.8xl0'6) (Shifman et al. 2002) but this finding was not replicated 
(Craddock et al. 2006b). Interestingly, there are reports of COMT association with 
anxiety (Stein et al. 2005) and panic disorder (Domschke et al. 2007) in women but 
not men. This could suggest that COMT predisposes to anxiety in both sexes, but 
other factors lead to the manifestation as anxiety disorder in women and OCD in men 
(Harrison and Tunbridge 2007). In ADHD, the COMTWal allele showed a nearly 
significant association (p=0.054) in the Cheuk and Wong (2006) meta-analysis for 
males only. A statistically significant gender effect for for the COMT Val allele 
association in ADHD was also found by pooling the results of two studies (Biederman 
et al. 2008; Qian et al. 2003).
Evidence suggesting another interesting sexually dimorphic gene came from a recent 
genome-wide association study for schizophrenia (Shifman et al. 2008). SNP 
rs7341475 in an intronic region of the reelin gene was associated with schizophrenia 
in women (p=9.8xl0'5) but not in men (p=0.47). A significant gene-sex interaction 
was also found (p=1.8xl0'4). To confirm the results, four other samples were used and 
although the predicted direction of effects was present in all of them, the results were 
significant for females in only one of the samples (Shifman et al. 2008). The reelin 
gene is expressed in the brain and it is reduced in the superficial interstitial white-
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matter neurons in men but not women with schizophrenia (Eastwood and Harrison
2005).
Recent advances in identifying genes for psychiatric disorders have demonstrated that 
each susceptibility gene has a small effect in the risk of developing the disorder.
There is no reason to doubt that this is the case for sex differences. This means that 
identifying genes contributing to sex differences will be even harder since any 
existing samples will have to be stratified by sex, further reducing the power to detect 
effects.
1.3 Sex differences in brain structure and function
The brain is a sexually dimorphic organ and its dimorphism is evident in both 
structural and in neurotransmitter system differences.
In terms of brain structure, sex differences exist in every brain lobe (Figure 1-2). The 
ratio of grey to white matter is different between the two sexes (Cahill 2006). The 
hippocampus, a brain region involved in learning and memory, is the most obviously 
sexually dimorphic brain region. It is larger in women than in men when adjusted for 
total brain size (Goldstein et al. 2001). Many neurotransmitter systems, such as 
serotonergic, adrenergic and cholinergic pathways within the hippocampus also show 
sex differences (Madeira and Lieberman 1995). Oestrogens can affect hippocampal 
cells by influencing their dendritic structure and they also modulate memory 
processes (Packard et al. 1996). The role of the hippocampus in learning is different 
between the two sexes (Rucker et al. 2004). It is interesting that the hippocampus 
reacts differently to chronic stress in the two sexes. Animal models showed that 
chronic stress causes damage to the hippocampus in males, but not in females 
(McEwen 2000). This resistance of female hippocampal cells to stress deserves to be 
studied in relation to female susceptibility to depression and anxiety disorder.
Figure 1-2. Sexually dimorphic brain structures. Data from Goldstein et al. (2001), where they 
measured the volume of brain regions relative to the cerebrum using MRI scans in 27 men and 
21 women. Structures that are larger in women are shown in red and structures that are larger 
in men are shown in blue. Picture taken from Cahill (2006)
The amygdala, a brain region involved in emotional behaviour, is significantly larger 
in men than in women, when adjusted for total brain size (Goldstein et al. 2001). The 
amygdala is involved in the storage of memories of emotional events probably 
through interaction with stress hormones (McGaugh 2004). This function is sexually 
dimorphic in terms of hemispheric lateralisation. The left amygdala is involved in 
storage of emotional events in women while the right one performs the same function 
in men (Cahill et al. 2004). Hemispheric lateralisation of the amygdala according to 
sex has been found for reactivity to emotional facial expressions. The left amygdala 
was more active when women responded to happy faces, while the opposite was true 
for men (Killgore and Yurgelun-Todd 2004). This sexually dimorphic functional 
lateralisation of amygdala correlates with the pattern of amygdala dysregulation in 
certain diseases. In women with Turner’s syndrome the left amygdala is less reactive 
to emotional faces (Skuse et al. 2005), while left amygdala activity is increased in 
women with depression (Drevets 2003).
The prefrontal cortex (PFC) is involved in working memory and decision making 
processes. It has also a high concentration of sex hormone, and especially oestrogen, 
receptors (Cahill 2006). In terms of decision making, it has been found that lesions in
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the right PFC impair this process in men while the opposite is true for women (Tranel 
et al. 2005).
Finally, a large number of neurotransmitter systems are sexually dimorphic. Sex 
differences have been found in the serotonin system in both animal and human brain 
(Nishizawa et al. 1997). Monoamine levels are higher in many brain regions in 
women compared to men (Cahill 2006) and the locus coeruleus, which is very rich in 
monoamines, is more responsive to stress in female compared to male rats (Curtis et 
al. 2006). Sex differences also exist for vasopressin, GABA and opioids (Cahill
2006).
1.4 Causes of sex differences in brain and behaviour
It is generally accepted that sex differences exist not only in susceptibility to diseases 
but also in brain and behaviour. However, the factors that contribute to these sex 
differences and especially the extent to which each of them is responsible is always a 
debate. Hormones have been considered a primary candidate for a long time, since 
they are straightforward to study and can be very potent. Nevertheless, accumulating 
evidence has drawn attention to genetic factors contributing to sex differences and 
they not only include sex chromosome differences but also differences in gene 
expression. A microarray analysis of gene expression in mouse brain found that more 
than 600 genes are differentially expressed in brain according to sex (Yang et al.
2006). Adding to that are the consequences of being genetically male or female due to 
differential exposure and differential susceptibility to risk and environmental 
protective factors. Finally, it is highly unlikely that any of these factors acts in 
isolation; as Figure 1-3 shows, they interact making the delineation of specific factors 
contributing to sex differences difficult.
G enetic factors
X and Y chromosome 
genes
Differential gene 
expression
Mosaicism -------►
Increased variability in 
males
X chromosome 
inactivation escapee genes
 ► Gene dosage
effects
X-linked imprinting
 ► Paternally
expressed imprinted 
genes affect only females
Sex differences
H orm onal factors
•Organizational effects 
•Activational effects
Environm ental
factors
•Different biological 
maturation
•Different experiences and 
relationships
•Differential susceptibility to 
risk and protective factors
Figure 1-3. Interactions between genetic, hormonal and environmental factors contributing to sex
differences
1.4.1 Hormonal effects
Hormones provide the classic example of factors contributing to sexual 
differentiation. This differentiation starts early in prenatal life and is determined by 
the presence or absence of the Y chromosome gene, Sex determining Region of 
chromosome Y (SRY). When SRY is present, the development of testes is initiated and 
testosterone is produced (Polanco and Koopman 2006). When testosterone reaches the 
brain, it is converted to estradiol by aromatase or to dihydrotestosterone (DHT) by 5a- 
reductase leading to masculinisation and defeminisation of the brain. In females the 
SRY gene is absent and so ovaries develop and produce oestrogens, but these bind to 
alpha-fetoprotein. The same happens to oestrogens produced by the mother, in order 
to protect the female foetus from the masculinising effect of oestrogens on the brain 
(Bakker et al. 2006). Hormones during development leave permanent “marks” on the 
brain, called organisational effects. Nonetheless, some of the hormonal effects can be 
- reversed when hormones are not present and they are called activational effects. Of 
course, the effect of hormones does not stop in prenatal life. Levels of circulating 
hormones differ massively between the two sexes and especially in women they
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fluctuate cyclically, which could result in sex differences in certain characteristics 
being more profound during certain parts of the cycle.
Hormonal and genetic factors are intertwined and they interact with each other to 
contribute to sex differences. For example, the androgen receptor gene is on the X 
chromosome and thus it could be sexually dimorphic in its expression. At the same 
time, its function is influenced by hormones, since it binds androgens which differ in 
concentration between the two sexes.
1.4.2 Genetic causes
While there is no denying the influential role of gonadal hormones on the brain, 
elegant research designs have shown that they do not account for all sexual 
dimorphism. The role of genetic factors in shaping the male and female patterns of 
brain function and behaviour can be as, or even more, important.
The obvious difference of the male and the female genome (with men having an X 
and a Y chromosome while women have two X chromosomes) would point to a 
potential involvement of sex chromosomes in sexual differentiation. Differential gene 
expression, not only from sex chromosome genes but autosomal genes as well, is 
important, since the phenotype is shaped by the level and pattern of gene expression. 
A phenomenon that has important implications in sex differences is X chromosome 
inactivation. The random inactivation of one of the two X chromosomes in all the 
cells of the female body compensates for the double dose of some X-linked genes in 
females compared to males. The random nature of inactivation means that females are 
mosaics of two populations of X chromosomes resulting in blunting of extreme 
phenotypes, which would be fully manifested in males. Finally, some X chromosome 
genes escape inactivation and thus there is a gene dosage difference between males 
and females.
1.4.3 The effect of sex chromosomes on brain
Despite hormones being considered the main candidate for sex differences, there is 
accumulating evidence that sex chromosome complement irrespective of the
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hormonal milieu plays a vital role. X-linked and Y-linked genes are transcribed 
differently between the two sexes, since Y-linked genes are only expressed in males 
and at least some of the X-linked genes are transcribed more highly in females (Xu et 
al. 2002). Even when there is a Y-linked homologue for X chromosome genes, 
expression levels tend to be lower than for X chromosome genes (Figure 1-4).
XNLGN4Y
DBY
UTY
ZFY
AMELY
SRY
PCDH11Y
PRKY
AMELX
STS
NLGN4X
PRKX
KAL1
ZFX
MAOA
PCDH11X
DBX
UTX
Figure 1-4. Diagram of sex chromosomes showing key genes with a homologue on both 
chromosomes. Pseudoautosomal regions are shown in black, and the heterochromatic region on 
the Y chromosome is shown in a darker colour. The euchromatic region of the Y chromosome is 
magnified (NLGN4: Neuroligin; PRK: Protein kinase; STS: Steroid sulfatase; KALI: Kallmann 
syndrome 1 protein; AMEL: Amelogenin; DB: Developing brain homeobox; UT: Ubiquitously 
transcribed tetratricopeptide repeat gene; MAOA: Monoamine oxidase A; SRY: Sex- 
determining region on Y chromosome; ZF: Zinc-finger protein; PCDH11: Protocadherin 11
There is evidence that sex chromosomes influence the sexual dimorphism of brain and 
behaviour. Dissociate cultures from rodent mesencephalon exhibit sexually dimorphic 
characteristics before gonadal differentiation is initiated (Carruth et al. 2002). Gene 
expression in the brain also differs between the two sexes. In the adult mouse brain 
approximately 650 genes are differentially expressed in males and females. Most of
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the genes that are over-expressed in females reside on the X chromosome while the 
over-expressed genes in male brain come from both sex chromosomes (Yang et al.
2006). Differential gene expression between the two sexes is crucial, since the level of 
expression of certain genes in the brain can have direct effects on the phenotype. The 
differences in gene expression are likely to be a consequence of gonadal hormones 
either directly or indirectly or they might be a result of sex-specific interactions with 
the environment. Another possibility is that there is differential gene expression 
linked to the sex chromosomes. The latter was proved by gene expression studies in 
mouse foetal tissue prior to gonadal differentiation. Using microarrays Dewing et al. 
(2003) detected 36 genes upregulated in female brain and 18 upregulated in male 
brain at the developmental stage of 10.5 days post coitum (dpc), when there is no 
gonadal hormone influence. Six of the genes were located on the sex chromosomes 
(Dewing et al. 2003). The same results were obtained for chicken embryos (Scholz et 
al. 2006).
The evidence that sex chromosome genes could contribute to sexual differentiation of 
brain and behaviour without the involvement of gonadal hormones is strengthened by 
other animal models as well. In the zebra finch, only males sing a courtship song and 
thus they have larger forebrain neural song circuits than females. However, 
genetically female zebra finches with testes do not sing (Wade and Arnold 1996). The 
opposite is true for genetically male finches without testes and an ovary (Arnold 
1997). It appears that neural song circuits in zebra finches are sexually differentiated 
due to the action of factors other than gonadal iiormones, most likely sex 
chromosomes. This notion is supported by studies on a gynandromorphic finch which 
is genetically male on the right side of the body and genetically female on the left 
side. Although both sides of the brain are exposed to the same hormonal environment, 
the neural song circuit of the right side is more masculine than that of the left side of 
the brain (Agate et al. 2003).
1.4.3.1 X  chromosome
The sex chromosomes have evolved from a pair of autosomes. The emergence of a 
gene responsible for testes differentiation restricted the presence of the Y 
chromosome in males. The consequence of this was that the Y chromosome
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developed a set of genes that were advantageous for males without the need for any 
advantage for females. The presence of genes involved in spermatogenesis on the Y 
chromosome supports this notion. The Y chromosome is also involved in sex 
differences and the evidence pointing to its involvement is discussed in Chapter 6, 
since it is the main topic of this thesis.
The X chromosome is a different story. It is found in only one copy in men and this 
means that alleles conferring an advantage to males would be expressed even if 
recessive. Females will be protected from the effect of these alleles by the presence of 
a dominant allele. Since any gene that is “bad” for females could not survive on the X 
chromosome, it has a higher proportion of female-biased genes (Arnold 2004).
The human X chromosome contains more than 800 genes and has an important 
contribution to brain function. Firstly, the number of X chromosome genes expressed 
in brain is disproportionately high with 40% of X chromosome genes expressed there 
(Ropers and Hamel 2005). The importance of X chromosome genes for brain function 
is also highlighted by the fact that expression of the single active X chromosome is 
upregulated in the brain so that it is similar to the level of expression of autosomes 
(Nguyen and Disteche 2006). In addition, the X chromosome is considered to be 
involved in cognitive ability. Compared to the autosomes it contains a significantly 
higher number of genes implicated in mental retardation. The fact that most of the X 
chromosome genes that are expressed in the brain are also conserved in distantly 
related organisms makes it possible that they play an important role in brain function 
(Zechner et al. 2001). It has been hypothesised that female sexual selection of 
intelligent men contributes to that (Zechner et al. 2001).
1.4.3.1.1 X  chromosome inactivation
The fact that females possess two X chromosomes while males possess only one 
creates a need to balance expression between the two sexes. This is achieved by X 
chromosome inactivation, a mechanism for silencing gene transcription of one of the 
two X chromosomes in females. This takes place in all somatic cells in a random 
fashion, so that females have a mixture of two different populations of X 
chromosomes in their cells. A non-coding RNA gene called XIST  (X-inactive specific 
transcript) is responsible for silencing X chromosomes. XIST is expressed only from 
the inactivated chromosome and it covers the chromosome in a cis interaction.
Histone modifications and DNA methylation ensure that no transcription is possible 
from this chromosome and it remains inactive in all subsequent cell divisions (Xu and 
Disteche 2006). X chromosome inactivation can have important implications for sex 
differences, since females have two different populations of X chromosomes resulting 
in mosaicism, which will be discussed later. In addition, some genes escape 
inactivation and, as a consequence, females will have increased expression of them 
compared to males. X chromosome inactivation varies according to tissue type and 
developmental stage with important consequences for differences in phenotypes 
between men and women.
1.4.4 Gene dosage effects
Taking into account the balancing effect of X chromosome inactivation, expression 
should be the same in the two sexes. However, this is not true in two instances. First 
of all, during prenatal life after the paternal imprints are wiped and before X 
inactivation starts, both X chromosomes are expressed in females. It is possible that 
this imbalance is responsible for the higher rate of growth in female embryos (Xu and 
Disteche 2006).
Secondly, not all genes on the X chromosome are inactivated. It is thought that up to 
15% of human X chromosome genes escape inactivation (Carrel and Willard 2005). 
Because of these X escapees, expression of some genes would be higher in females 
compared to males possibly contributing to sexual dimorphism. It is not yet clear how 
many genes escape inactivation in the brain, since inactivation varies according to
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tissue type and developmental stage (Brown and Greally 2003). It is also possible that 
expression is compensated by the presence of a Y-linked homologue (see Figure 1-4 
for some of the Y-linked homologues). In mouse, all X escapees have a Y-linked 
homologue but in human there are X escapees without a Y-linked homologue (Xu and 
Disteche 2006). However, this homologue is not always able to compensate for the 
increased expression in females. In a study of X escapees with a Y-homologous gene 
in mouse brain, Xu et al. (2002) found that in five cases expression of Y-homologues 
in males was not sufficient to reach equal levels of expression to females. In three 
cases genes were differentially regulated indicating that they might not be 
functionally equivalent (Xu et al. 2002).
The fact that there is increased expression of some X chromosome genes in females 
compared to males does not necessarily mean that the protein level would be higher. 
Indeed, there are reports that protein levels of X escapees in mouse brain did not 
differ between males and females, although there was a significant difference in 
mRNA levels (Xu et al. 2006).
A “natural experiment” of the involvement of X escapees in brain function is possible 
with women affected by Turner’s syndrome (45,XO karyotype). The syndrome is 
characterised by short stature, ovarian degeneration and interestingly 
neuropsychological impairments with problems in visual perception and facial 
emotion recognition, as well as anxiety (Ross et al. 2006). Not all of these problems 
are alleviated with oestrogen treatment. Impairments are also found in memory, 
attention and social interaction, and women with Turner’s syndrome are more 
susceptible to ADHD (Russell et al. 2006) and autism (Skuse 2000). This 
susceptibility to classically male-biased disorders poses the question whether 
haploinsufficiency of X chromosome genes that usually escape inactivation (a 
common characteristic between men and women with Turner’s syndrome) is 
implicated in the increased risk for neuropsychiatric disorders (Davies and Wilkinson 
2006). Brain imaging has shown that the volumes of amygdala and hippocampus are 
enlarged in women with Turner’s syndrome compared to healthy controls (Davies and 
Wilkinson 2006). Good et al. (2003) performed deletion mapping analysis and 
considered that haploinsufficiency of genes in a small region on Xpl 1.3 is responsible 
for the enlarged brain volumes.
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Animal models of Turner’s syndrome have shown that 39,XO mice are more fearful 
than controls and they also show response accuracy and reaction time deficits (Davies 
et al. 2005a). To examine the involvement of X escapees in behaviour, female mice
* Ycarrying an X chromosome and a Y chromosome, consisting of an X centromere 
and a very small X-specific region immediately adjacent, were generated.
Interestingly, the behavioural phenotype was rescued in these mice. The authors 
suggested that gene dosage by an X escapee gene expressed in the brain was 
responsible for the results (Davies et al. 2005a). Their most likely candidate was Sts, a 
PAR (pseudoautosomal region) gene encoding the enzyme steroid sulfatase. In 
humans, the STS gene is located on the X chromosome outside the PAR region and it 
escapes inactivation (Li et al. 1996). There is a Y-linked homologue but it constitutes 
a pseudogene (Yen et al. 1988). Deletion of STS leads to X-linked ichthyosis, a 
metabolic syndrome. Individuals with X-linked ichthyosis have a higher prevalence of 
ADHD and autism, which implies that STS could be implicated in attentional 
mechanisms in humans (Kent et al. 2008). In a recent study, ADHD was associated 
with polymorphisms within the STS gene (Brookes et al. 2008). The fact that STS 
escapes X-inactivation and that it has no functional Y homologue means that, in 
theory at least, it should be expressed approximately twice as highly in female brain 
than male brain. This potential sex difference in STS expression could explain why 
males and females are differentially vulnerable to disorders of attention and impulse 
control such as ADHD and pathological gambling.
1.4.5 Mosaicism
A consequence of the random nature of X chromosome inactivation is mosaicism. If 
an X chromosome gene is polymorphic, female organs are a mosaic of cells where 
two different alleles are expressed. Given the large number of X chromosome genes 
expressed in the brain, mosaicism could contribute to sex differences in brain 
function. Because males are hemizygous for all alleles on the X chromosome, they are 
more likely to be influenced by alleles associated with extreme phenotypes (either 
showing exceptionally high or low abilities). Extreme phenotypes become blunted in 
females. This could be contributing to the increased variability of cognitive 
performance in males (Skuse 2005).
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1.4.6 X-linked imprinting
Imprinting is a mode of inheritance which does not involve the DNA sequence. 
Certain genes are epigenetically marked so that they are only expressed if they are 
transmitted from the mother or the father. Imprinted genes are expressed in the brain 
and they can be involved in mental disorders (Davies et al. 2005b).
Imprinting can result in sex differences, if it affects the X chromosome. Since only 
females inherit an X chromosome from the father, paternally expressed X-linked 
imprinted genes would only affect one sex. On the other hand, maternally expressed 
X-linked imprinted genes would be expressed in both sexes but their level of 
expression would be reduced in females due to random X chromosome inactivation. 
The first study to link X chromosome imprinting with mental disorders stratified 
women with Turner’s syndrome according to whether they had inherited their X 
chromosome from the father or the mother and compared their cognitive profile. It 
found that when the X chromosome was maternally inherited (as is the case with 
males as well) there was impairment in social cognition and a higher susceptibility to 
autism (Skuse et al. 1997). These results are in agreement with the better social skills 
and reduced autism susceptibility in females (Skuse 1999). Mouse models provide 
support for the contribution of X-linked imprinted genes to sexually dimorphic 
neurobiological phenotypes (Davies et al. 2005a). Nevertheless, no X-linked 
imprinted genes have so far been discovered oh the human X chromosome.
1.4.7 Environmental factors
Apart from purely biological factors, environmental factors also contribute to sexual 
dimorphism in behaviour. Males and females are exposed to different environmental 
factors and also have different susceptibility to risk and protective factors.
.Firstly, biological maturation is different in the two sexes. Boys develop slower than 
girls and puberty occurs approximately two years later in boys compared to girls. The 
consequences are that boys are asked to take part in demanding tasks for which they 
are not developmentally ready. For girls, the early development of secondary sex
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characteristics results in different social responses from other people compared to 
boys of the same age (Rutter et al. 2003).
Secondly, the two sexes have different experiences which are either more common or 
unique to one sex. Females experience pregnancy and childbirth and these 
experiences, coupled with the accompanying hormonal effects, are contributing to 
postpartum mental disorders (Rutter et al. 2003). On the other hand, males are more 
likely to be involved in criminal activity and suffer physical attacks, while females are 
more likely to suffer sexual abuse (Rutter et al. 2003). Social and cultural factors 
increase differential experiences. Parents, siblings and teachers respond differently 
according to the sex of the child. Friendship patterns differ between the two sexes.
Thirdly, it is important to realize that risk and protective factors do not affect the two 
sexes equally. Males are more vulnerable to physical adversities, such as infections, 
obstetric complications and malnutrition. The higher mortality of male infants 
balances the greater rate of male conceptions to create an equal sex ratio. In terms of 
parent-child relationships, there is a stronger association of mother-child relationship 
and depression in females than in males (Veijola et al. 1998) and there is evidence, 
although not strong, that coercive parenting can lead to more externalising behaviours 
in boys (McFadyen-Ketchum et al. 1996). Problems in relationships with other people 
can be more damaging for women, while men are more sensitive to unemployment 
and work-related problems (Rutter et al. 2003). Marriage is more protective against 
depression for men than for women (Kiecolt-Glaser and Newton 2001).
It is interesting that biological mechanisms explaining susceptibility to specific risk 
factors have started to emerge. For example, it was found that a polymorphism on the 
X-linked gene MAOA (Monoamine Oxidase) increases MAOA activity in the brain 
and makes boys more resilient to antisocial behaviour following maltreatment (Caspi 
et al. 2002). Epigenetics can also be the mediating mechanism in the differential 
susceptibility to environmental factors. Evidence shows that early psychosocial 
adversity can have an effect on DNA methylation and thus alter gene expression (Mill 
•and Petronis 2008). It is tempting to hypothesise that this could be the mediating 
mechanism for the effect of environmental adversity on ADHD.
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Despite the fact that sex differences in psychopathology are well-established, research 
on the factors that lead to this sexual dimorphism has been limited. Hormonal effects, 
genetic factors relating not only to the sex chromosomes, but also to phenomena such 
as X chromosome inactivation, and environmental factors contribute to sex 
differences but the extent that each factor is involved and the way it interacts with 
other factors is still not know. However, more research is required in this field 
because it can provide important information about the pathways involved in 
psychiatric disorders.
Chapter 2 Attention deficit hyperactivity disorder (ADHD)
2.1 ADHD symptoms and diagnosis
Attention deficit hyperactivity disorder (ADHD) is one of the most common 
childhood-onset psychiatric disorders affecting up to 6% of children. The behaviour 
of children with ADHD is characterised by impulsiveness, lack of concentration and 
overactivity. This pattern of behaviour puts children at risk of developing antisocial 
behaviour, receiving poor education and is very disruptive for family and teachers.
2.1.1 Epidemiology
The reported prevalence of ADHD ranges from 1.5-6% depending on the population 
and the method of diagnosis (Cuffe et al. 2005; Polanczyk et al. 2007). The 
prevalence of ADHD and especially treatment in the UK tends to be lower than in the 
USA, although it is still higher than other European countries (Rutter et al. 2008).
There is a significantly increased prevalence in males compared to females. The sex 
ratio ranges from 1:4 in population samples to 1:6 in clinical samples. See Chapter 1 
for more information on sex differences in ADHD.
2.1.2 Clinical presentation
The three main characteristics of children with ADHD are inattention, impulsiveness 
and overactivity.
Inattention involves lack of concentration and persistence, leading to inability to 
complete tasks. The degree and presentation of inattention varies with age and it is a 
symptom that puts children at risk of educational failure. It is also the most salient 
aspect of the disorder as children with ADHD enter adulthood (Millstein et al. 1997). 
Attention can be improved with immediate rewards and sufferers can show sustained 
attention in certain tasks, such as computer games.
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Impulsiveness involves acting without thinking about the consequences. It leads to 
children putting the health and safety of themselves and others in danger. Severe 
impulsiveness can be very difficult for people to tolerate, although it is difficult 
(especially in adolescents) to distinguish oppositional behaviour from impulsiveness.
Overactivity is excessive movement and that can present itself as restlessness and 
fidgetiness. Although it is usually the most noticeable feature of children with ADHD, 
it does not usually persist into adolescence and adulthood.
2.1.3 ADHD diagnosis
The diagnosis of ADHD relies on reported symptoms. The use of internationally 
accepted diagnostic criteria has increased diagnostic reliability resulting in ADHD 
being one of the best-validated clinical diagnoses (Faraone et al. 2005). There are two 
sets of diagnostic criteria used to define ADHD: the Diagnostic and Statistical Manual 
of Mental Disorders, fourth edition, text revision (DSM-IV-TR) and the International 
Classification of Diseases, tenth edition (ICD-10). DSM-IV-TR was published by the 
American Psychiatric Association in 2000 (American Psychiatric Association 2000) 
and ICD was first published by the World Health Organisation in 1993 and has since 
been revised many times (World Health Organisation 1993). Both sets of diagnostic 
criteria are based on the same symptoms but they describe the disorder differently.
DSM-IV-TR uses the term ADHD and bases diagnosis on two categories of 
symptoms: inattention and hyperactivity-impulsivity (see Table 2-1 for a list of 
symptoms). It recognises three ADHD subtypes. The combined type is diagnosed 
when six or more symptoms from each symptom category are present, while the 
inattentive or overactive-impulsive type is diagnosed when six or more symptoms 
from only one of the two categories are present. All types require that symptoms are 
present for at least six months and before the age of seven and they are 
developmentally inappropriate. Symptoms must also be associated with impaired 
functioning in two or more settings.
ICD-10 uses the term hyperkinetic disorder and does not recognise subtypes. It bases 
diagnosis on three symptom categories: inattention, hyperactivity and impulsivity. It 
requires six or more symptoms of inattention, three or more symptoms of
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hyperactivity and one or more symptom of impulsivity for a diagnosis to be reached.
It also requires that symptoms are present before the age of seven and they are 
developmentally inappropriate. However, in contrast to DSM-IV-TR, symptoms (and 
not only impaired functioning) should be present in two different settings, usually 
both at home and at school. The other difference between the two sets of diagnostic 
criteria is that in ICD-10, hyperkinetic disorder is excluded if other disorders, such as 
autism and anxiety are present, while in DSM-IV-TR, ADHD is excluded only if the 
symptoms are better explained by a co-existing disorder.
Hyperkinetic disorder, according to ICD-10, can be considered as a subgroup of 
ADHD and it is usually a narrower phenotype than ADHD combined type. Children 
with hyperkinetic disorder are also at higher risk of neurodevelopmental abnormalities 
such as language problems (Taylor and Sonuga-Barke 2008) suggesting that 
hyperkinetic disorder indicates a more extensive brain impairment than ADHD. For 
research purposes DSM-IV-TR diagnoses tend to be used more often, usually 
requiring both parents and teachers reports. Individuals with autism, learning 
disabilities and depressive disorders are usually excluded. It should be noted that both 
sets of diagnostic criteria merely describe the disorder and there is no reason to 
believe that the underlying aetiology is different.
Although subdividing ADHD into subtypes can be useful for diagnostic purposes, it is 
not clear whether they are stable over time (Todd et al. 2008) or whether there are 
distinct genetic and environmental factors acting upon the different subtypes 
(McLoughlin et al. 2007; Thapar et al. 2006). Clinically, ADHD is usually defined 
categorically. For research purposes, ADHD is frequently treated as a dimension 
showing that genetic factors are important for normal variation in ADHD scores as 
well as extreme scores (Derks et al. 2008; Thapar et al. 2006). In both cases, it has 
been shown that ADHD is highly heritable.
Table 2-1. ADHD symptoms from the DSM-IV research diagnostic criteria
A. Inattention (six or more symptoms required)
Often fails to give close attention to details or makes careless mistakes in school
work, work or other activities 
Often has difficulty sustaining attention in tasks or play activities 
Often does not seem to listen when spoken to directly 
Often does not follow through on instructions and fails to finish schoolwork, chores or 
duties in workplace (not to oppositional behaviour or failure to understand)
Often has difficulty organising tasks and activities 
Often avoids, dislikes or is reluctant to engage in tasks that require sustained mental
effort
Often loses things necessary for tasks or activities 
Is often easily distracted by extraneous stimuli 
Is often forgetful in daily activities 
B. Hyperactivity-impulsivity (six or more symptoms required)
Hyperactivity 
Often fidgets with hands or feet or squirms in seat 
Often leaves seat in classroom or in other situations in which remaining seated is
expected
Often runs about or climbs excessively in situations in which it is inappropriate 
(subjective feelings of restlessness for adolescents or adults)
Often has difficulty playing or engaging in leisure activities quietly 
If often ‘on the go’ or often acts as if ‘driven by a motor’
Often talks excessively 
Impulsivity
Often blurts out answers before questions have been completed 
Often has difficulty awaiting turn 
Often interrupts or intrudes on others (e.g. butts into conversations or games) 
Symptoms must have persisted fo r  at least six months, must be developmentally 
inappropriate and present before the age o f  7. Symptoms are o f  a degree that is 
maladaptive, associated with impairment in functioning that is present in two or
more settings
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2.1.4 Developmental course
Half of children with ADHD will still meet full diagnostic criteria in adolescence 
(Klein and Mannuzza 1991). The levels of overactivity and impulsiveness tend to 
decrease, while inattentiveness is more persistent. During adolescence the problems of 
antisocial behaviour and substance abuse also emerge. Longitudinal studies have 
shown that there is persistence of symptoms into adulthood (Taylor and Sonuga- 
Barke 2008). Comorbid antisocial behaviour also tends to persist. Twin studies have 
shown that there are genetic influences not only on ADHD but also on the continuity 
of the disorder (Larsson et al. 2006) and there is the suggestion that persistent ADHD 
may index a stronger family history (Faraone et al. 2005).
2.1.5 Comorbidity
ADHD is often comorbid with other disorders especially of a neurodevelopmental 
nature but not limited to that. Conduct disorder and anxiety can also co-exist with 
ADHD. It is striking that two thirds of children with ADHD have a diagnosis of 
another psychiatric disorder as well.
Although the symptoms of ADHD and autism differ, the disorders often co-exist. 
ADHD can also co-exist with Tourette’s syndrome. One common characteristic of 
neurodevelopmental disorders is that they tend to affect more commonly males (Costa 
e Silva 2008; Cuffe et al. 2005) and they are of childhood-onset. This is especially 
true for ADHD and autism. For this reason, it has been suggested that there might be a 
set of common risk factors affecting brain development during critical stages. Twin 
studies indeed do find that ADHD and autism symptoms are influenced by a shared 
inherited liability (Ronald et al. 2008). Further genetic or environmental factors are 
then responsible for the manifestation of symptoms leading to diagnosis of specific 
disorders. It is striking that children with autism are excluded from having a diagnosis 
of hyperkinetic disorder according to ICD-10 criteria, although they could benefit 
from treatment for their ADHD symptoms. They are also excluded from research 
designs despite the fact that they could represent one extreme of the distribution of 
neurodevelopmental disorders.
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Specific learning disabilities such as dyslexia are also very common in ADHD with 
up to 40 % of children with ADHD presenting with them (Willcutt et al. 2000). The 
same is true for intellectual disability. Children with ADHD and intellectual disability 
(IQ<70) are excluded from most research studies, thus there is not enough knowledge 
about the aetiology of their disorder. Problems in keeping up with learning at school 
can trigger attention difficulties or it could be that lack of attention causes children to 
have problems learning. The other possibility is that they represent a different group 
which should be studied separately.
The conditions that show the greatest comorbidity with ADHD are Conduct Disorder 
(CD) and Oppositional Defiant Disorder (ODD). Their prevalence in children with 
ADHD ranges from 20% to 40% (Goldman et al. 1998; Thapar et al. 2001) and they 
represent a risk factor for poor outcome for children with ADHD. It has been 
considered that the group of children with ADHD and childhood-onset CD is distinct 
from the groups of children with ADHD or CD only. In this group of children, ADHD 
is more severe and shows greater persistence in adult life (Moffitt 1993). Family 
history is also stronger (Faraone et al. 2005) and the presence of CD indicates higher 
genetic loading in ADHD (Thapar et al. 2001). Early onset CD also represents a risk 
factor for poor outcome for children with ADHD (Taylor et al. 1996). Specific genetic 
factors have been found to operate only in children with ADHD and early-onset CD 
(Caspi et al. 2008; Thapar et al. 2005), as discussed later.
Anxiety and mood disorders are also found to accompany ADHD at a rate of about 
20% (Cuffe et al. 2001; Pliszka 2000). In addition, children with ADHD are more 
prone to accidents and injuries and are more likely to have worse academic 
performance (Cuffe et al. 2005).
During adolescence and adulthood, ADHD co-exists with a number of psychiatric 
disorders. Substance abuse is more common in adolescents with ADHD than in 
unaffected individuals (Taylor and Sonuga-Barke 2008), although this could be a 
result of the comorbid CD. It has been suggested that bipolar disorder is more 
common in adults with ADHD. However, the issue is whether symptoms of 
hyperactivity and irritability that characterise ADHD are misinterpreted as manic 
episodes that indicate bipolar disorder (Taylor and Sonuga-Barke 2008). Adults with 
ADHD have a higher incidence of motor accidents; they are more likely to change
26
jobs, smoke and use substances or alcohol (Cuffe et al. 2005). It is interesting that a 
survey in prison populations showed that 45% of incarcerated young adults had a 
history of or had current ADHD (Rosier et al. 2004).
2.2 Brain structure and function in ADHD
Studies of the structure and the function of the brain in ADHD have provided 
evidence of abnormalities in different brain regions as well as neurocognitive deficits 
and dysregulation in neurotransmitter pathways. It is not easy to say whether these 
deficits occur before the onset of disorder, since ADHD has a very early age of onset 
but they provide evidence of the neurodevelopmental nature of the disorder.
The brain volume of children with ADHD is reduced by 5% with both white and grey 
matter affected (Seidman et al. 2005). Based on similarities between people with 
ADHD and those with disorders caused by frontal lobe lesions (Taylor and Sonuga- 
Barke 2008), research has focused on the prefrontal cortex and striatum. Functional 
Magnetic Resonance Imaging (fMRI) studies comparing patients with ADHD and 
controls have found reduced activation in the prefrontal cortex (Durston et al. 2004) 
and the neostriatum (Vaidya et al. 2005) in patients. Reduced glucose metabolism has 
been shown by Positron Emission Tomography (PET) (Schweitzer et al. 2003). 
Structural differences have also been found in the corpus callosum (Seidman et al.
2005), the cerebellum (Castellanos et al. 2002) and the amygdala (Plessen et al.
2006). fMRI studies have contributed to evidence for altered function in the 
cerebellum and parietal and temporal lobes (Vaidya et al. 2005).
Individuals affected by ADHD show neurocognitive deficits. It is considered that 
executive function is their main weakness. Executive functions are neurocognitive 
processes aiming to maintain relevant information so that it can be easily accessed 
and used during problem solving. They include working memory, response inhibition, 
vigilance, planning and set-shifting amongst others. It has been proposed that 
-executive control weaknesses are the primary deficit necessary to cause ADHD 
(Castellanos and Tannock 2002; Schachar et al. 2000). In a meta-analysis of 83 
studies on executive functions and ADHD, it was found that children with ADHD 
performed significantly worse on all executive function tasks compared to controls
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(controlling for intelligence and comorbidity) (Willcutt et al. 2000). Strongest effects 
were obtained for response inhibition, vigilance and spatial working memory but 
effect sizes were moderate. However, a large study assessing executive functions 
showed that only half of the children with ADHD exhibit an impairment in any task 
of executive function (Nigg et al. 2005). Furthermore, the variance of ADHD 
symptoms cannot be explained by executive function impairment, since ADHD 
symptoms are only weakly correlated with executive function task performance 
(Willcutt et al. 2001). In summary, executive function impairments are significantly 
associated with ADHD and this is true for both clinical and population-based samples 
(Willcutt et al. 2005). However, it is highly unlikely that they are the primary deficit 
causing ADHD.
There is evidence that dopaminergic pathways are implicated in the pathophysiology 
of ADHD. The most robust evidence comes from studies of medication used to treat 
ADHD. Stimulant medication, such as methylphenidate and amphetamine, reduces 
ADHD symptoms by increasing the availability of extracellular dopamine and 
noradrenaline (Volkow and Swanson 2003). Neuroimaging studies have also provided 
evidence that dopaminergic regions are implicated in ADHD (Spencer et al. 2005). It 
is very interesting that animal studies, such as work on the DAT knockout mouse 
which manifests ADHD-like behaviour, have also implicated dopaminergic systems 
(Gainetdinov 2007). For this reason, a number of genes involved in the dopaminergic 
pathway have been studied using association study designs, as will be discussed later.
ADHD is a complex disorder and it involves impairments in different brain substrates 
but it can be very difficult to delineate whether the impairments are causal or are the 
result of shared risk factors. However, the pattern of impairment in different areas 
coupled with the early age of onset points to a neurodevelopmental origin. Brain 
abnormalities can start early in life, probably during prenatal life, in individuals 
already susceptible to ADHD triggered by an environmental insult.
2.3 Evidence of genetic component to ADHD
Heritability of ADHD is high in the range of 75-91%. This has been proven using 
family, twin and adoption studies.
2.3.1 Family studies
Family studies examine the rate of a disorder in relatives of individuals with the 
particular disorder compared to relatives of healthy or individuals with another 
disorder. The design of these studies utilises parents of children with a disorder or 
offspring from parents with a disorder. A number of family studies of ADHD have 
reported increased risk of ADHD among parents and siblings of children with ADHD. 
The relative risk in first degree relatives is considered to be between 4 and 5.4 
(Faraone et al. 2005). It is very interesting that half siblings of children with ADHD 
have a lower risk of developing the disorder than full siblings, further highlighting the 
important role of the genetic background in ADHD (Goodman and Stevenson 1989).
2.3.2 Adoption studies
Adoption studies are suitable for disentangling genetic and environmental factors 
contributing to ADHD. In adoption studies the risk of developing the disorder is 
compared in biologically related relatives and non-biologically related (adoptive 
family) relatives. The fact that all adoption studies have shown that the risk is greater 
in biologically related relatives provides strong evidence for a genetic contribution to 
ADHD (Cantwell 1975; Sprich et al. 2000).
2.3.3 Twin studies
Twin studies examine the heritability in genetically identical or monozygotic (MZ) 
and non-identical or dizygotic (DZ) twins. The extent of disease concordance in the 
two twin types is used to calculate heritability. Their advantage lies in the fact that 
they have generally used population-based and not clinical samples. They have all 
shown a high degree of heritability and indicated that 60-90% of variance in ADHD
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can be explained by genetic factors (Faraone et al. 2005; Thapar et al. 1999). It is 
striking that the heritability is not 100%, suggesting contribution from non-shared 
environmental factors, epigenetic effects, stochastic effects or measurement 
inaccuracies.
2.4 Identifying complex disorder susceptibility genes
Before discussing the molecular genetic studies of ADHD, the methods used in 
molecular genetic studies of complex disorders should be introduced.
Psychiatric disorders are considered complex disorders, which means that, although 
they are genetic disorders following Mendel’s laws, they are the result of multiple 
gene co-action, gene-gene and gene-environment interactions. As a result, identifying 
susceptibility genes for psychiatric disorders is challenging, but it has the potential to 
provide an understanding of the largely unknown pathophysiology of these disorders. 
This process has been based on the DNA variation that normally exists in different 
individuals without necessarily being pathogenic. This variation provides 
polymorphic genetic markers. The most widely used genetic markers are Single 
Nucleotide Polymorphisms (SNPs). The use of SNPs has revolutionised the field 
because there are large numbers of them covering a substantial part of the genome, 
and their genotyping is cheaper and more robust than with other markers. Advances in 
technology have made mass genotyping of large numbers of SNPs for large samples 
possible and more economical. Information (which is still growing) about a large 
number of SNPs can be found in a public database called HapMap (International 
HapMap Consortium http://www.hapmap.org/). There are three methods for 
identifying susceptibility genes for psychiatric disorders (Thapar and Stergiakouli 
2008):
• genome-wide linkage studies
• candidate gene association studies
• Genome-Wide Association Studies (GWAS)
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2.4.1 Genome-wide linkage studies
2.4.1.1 Linkage analysis principle
Linkage studies are based on the phenomenon of genetic linkage which is the result of 
recombination. Recombination occurs during meiosis when homologous pairs of 
chromosomes form chiasmata or crossovers and exchange genetic material. Thus, 
recombination produces new chromosomes where maternal and paternal loci are 
reshuffled to produce new combinations which are different to parental alleles 
(Strachan and Reed 2003). The importance of recombination is attributed to this 
reshuffling, which increases diversity in the human species.
If two loci are on different chromosomes or further apart on the same chromosome, 
the probability that their alleles will be inherited together is 0.5, according to 
Mendel’s law of independent assortment. However, when two loci are near to each 
other, they are more likely to be inherited together because a crossover would be 
unlikely to form between them. This departure from the law of independent 
assortment is called genetic linkage (Strachan and Reed 2003).
The principle of linkage studies is that, if an allele of a marker is linked to a 
susceptibility locus, affected relatives will share this allele more often than expected. 
So when a genetic marker is co-inherited with a disease phenotype within many 
independent families or over many generations in an extended pedigree, there is an 
indication that susceptibility loci could be on the same chromosomal region. 
Genome-wide linkage studies aim to identify broad regions in the genome that could 
harbour susceptibility genes. Linkage analysis in large multiplex families is known as 
parametric analysis because it requires the specification of a genetic model. For this 
reason, it is challenging to apply to complex disorders, where the mode of inheritance 
is unknown. Non-parametric analysis, such as the Affected Sibling Pair (ASP) design, 
is more suitable. In this approach, instead of comparing affected and unaffected 
family members, allele sharing is only examined in affected siblings (Sham and 
McGuffin 2002).
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2.4.1.2 Limitations o f  linkage studies
Linkage studies have been very successful in identifying genes that cause Mendelian 
traits. They have also been applied in complex disorders including psychiatric 
disorders. However, fine mapping of their results had limited success in identifying 
susceptibility genes for psychiatric disorders. One of the reasons is that linkage 
studies are better at picking up regions that harbour genes of larger effect sizes and 
not genes of modest or small effects, which are the rule in psychiatric genetics 
(Plomin et al. 2008). In addition, the set of markers used for linkage studies might be 
not dense enough to extract complete inheritance information. Finally, larger sample 
sizes would certainly be required to increase success, although for most complex 
disorders it is extremely difficult to collect thousands of affected sibling pairs 
(Hirschhom and Daly 2005).
2.4.2 Candidate gene association studies
Candidate gene association studies are based on selecting specific genes based on 
evidence from other research findings and then comparing the frequencies of the 
marker alleles or genotypes in two different groups: one group of affected individuals 
(cases) and one group of matched healthy individuals (controls). There are two types 
of candidate gene studies:
• Positional -  where the genes are selected following significant findings from linkage 
studies or by studying families who present with a disorder and a specific 
chromosomal rearrangement.
• Functional -  when selection is based on assumptions about the pathophysiology of 
the disorder derived from animal, pharmacological, or imaging studies.
Before discussing the different types of association study designs, it is important to 
introduce the concepts of linkage disequilibrium (LD) and marker selection.
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2.4.2.1 Linkage Disequilibrium (LD)
When a significant association is found between a SNP and a disease, it could be 
because this SNP is the causal variant (direct association) or it could be because it is 
correlated with the causal variant (indirect association). This non-random correlation 
of two loci that are inherited together for many generations is called Linkage 
Disequilibrium (LD) (Cardon and Bell 2001).
The degree of LD between two loci can be evaluated by using one of the two 
measures, D or r2. For both measures a value of 0 indicates no correlation between 
two loci and a value of 1 indicates that loci are co-inherited and are in complete LD. 
They are both based on the pairwise-disequilibrium coefficient D, which is a measure 
of covariance between two loci. It should be noted that the limitation of D is that 
when a difference in allele frequency between two markers exists, a D =1 can occur 
even though the two loci are not always co-inherited. Thus, i^=l is a better indicator 
of a perfect correlation between two markers (Mueller 2004).
2.4.2.2 Marker selection
When selecting markers for an association study of a particular gene or chromosomal 
region, knowledge of the LD structure of this gene or region is important. When the 
LD structure is known, it is possible to select “tag markers” which account for all the 
known variation at a particular chromosomal region. The HapMap 
(www.hapmap.org/) is a public database created by the International Haplotype Map 
Consortium (International HapMap Consortium 2003). It contains information, 
including LD, on 3.1 million SNPs (phase II) which have been genotyped in 270 
individuals from four different populations.
Selection of tag SNPs depends on the Minor Allele Frequency (MAF) and degree of 
LD between the markers. It is common to use a pairwise tagging method, where 
markers are selected based on LD between each pair, and setting MAF at >0.05 and 
^>0.8. The tagging approach is advantageous for association studies, since it reduces 
cost. There is no need to genotype all polymorphisms in the region, so fewer markers 
are genotyped without losing information. In addition, false negative rates are
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reduced, since all known genetic variation is assayed. The main limitation of the 
tagging approach is that rare variants are not covered.
2.4.3 Types of association study designs
There are two types of association study designs: family based and case-control 
association studies.
2.4.3.1 Case-control association studies
Case-control association studies involve comparing the frequency of alleles in a 
sample of affected individuals (cases) with that of a sample of unaffected individuals 
(controls). The main advantage of this design is that it is easier to collect larger 
samples because there is no requirement for family members and thus power is 
increased. However, population stratification can be an issue. In this case, differences 
in allele frequency between cases and controls appear but they are due to the 
populations not being ethnically matched rather than the alleles being causal (Cardon 
and Palmer 2003).
2.4.3.2 Family-based association studies
Family-based association studies use family members of affected individuals as 
controls, thus overcoming the problem of population stratification. Alleles are 
associated when they are transmitted more often than expected by chance from a 
heterozygous parent to an affected offspring. Although with family-based association 
studies population stratification is not an issue, the requirement of parents reduces the 
number of individuals available for ascertainment, especially for disorders with late 
onset. In addition, because only heterozygous parents provide informative 
transmissions, some genotyping information is discarded (Cardon and Bell 2001).
2.4.4 Genome-wide association studies (GWAS)
Genome-wide association studies (GWAS) are now the most promising method for 
systematically searching for susceptibility genes. They are basically association 
studies examining most of the genome for susceptibility variants. In genome-wide 
association studies usually several thousand or millions of SNPs are tested across the 
genome without an a priori hypothesis. For this reason they are suited to psychiatric 
disorders where the pathophysiology is not yet understood. Another advantage of 
genome-wide association studies is that the genotyping arrays can be used to examine 
Copy Number Variants (CNVs) at the same time. CNVs are DNA segments that differ 
in number when comparing genomes from two different individuals.
What made genome-wide association studies possible were the large numbers of 
polymorphisms in the human genome that have been discovered in recent years, the 
understanding of LD patterns across the genome through the HapMap project and 
advances in technology that considerably decreased the cost of genotyping. Although 
genome-wide association studies are designed to cover the entire genome, genotyping 
arrays used for genome-wide association studies have not usually included Y 
chromosome SNPs (see following chapters for more information). Genome-wide 
association studies have been published for bipolar disorder (Wellcome Trust Case 
Control Consortium 2007), schizophrenia (O’Donovan et al. 2008; Shifman et al.
2008; Sullivan et al. 2008), autism (Weiss 2009) and ADHD (Neale et al. 2008).
2.4.4.1 Allelic architecture o f common diseases
Although for many common disorders, including psychiatric disorders, the allelic 
frequency and the effect sizes of susceptibility variants are unknown, two polarised 
hypotheses exist. The common disease/common variant hypothesis supports the view 
that common diseases are caused by several susceptibility variants of high frequency 
and small to moderate effect sizes. These variants are also present in unaffected 
individuals (Reich and Lander 2001). The alternative hypothesis suggests that 
common diseases are highly heterogeneous in their causes with distinct susceptibility 
variants in different individuals. These variants are rare and they are usually of large 
effect sizes (Liu et al. 2005). However, the most likely scenario is that for most
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common diseases both hypotheses are valid and common as well as rare variants need 
to be investigated to increase understanding of the pathophysiology.
2.4.4.2 Power o f association studies
The power of an association study to detect a susceptibility variant depends mainly on 
the effect size and the frequency of the risk allele in the population. Power increases 
as effect sizes and frequency increase. This means that genome-wide association 
studies are more powerful when picking common alleles and /or alleles of large effect 
sizes (Wang et al. 2005). Since the effect sizes and frequencies of alleles cannot be 
manipulated, researches are left with the option to increase sample sizes in order to 
have adequate power. Figure 2-1 shows that genome-wide association studies have 
little power to detect rare variants when their effect sizes are small. For example to 
have 80% power to detect a variant with a MAF of 0.1 and an OR of 1.3 the sample 
size would have to increase to more than 10,000 cases and 10,000 controls which is 
probably not feasible for some disorders. Even having 80% power to detect a variant 
with MAF of 0.1 and a modest effect size of 1.5, would require a sample of just fewer 
than 1,000 cases and 1,000 controls.
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Figure 2-1. Effects of OR and allele frequency on sample size requirements. The total number of 
individuals (equal numbers of cases and controls) that are required for an association study to 
have 80% power to detect disease variants with allelic odds ratios o f 1.2 (red), 1.3 (blue), 1.5 
(green) and 2 (black) are shown. Significance level is set at p<10'6. A multiplicative model and 
perfect LD between test markers and disease variants are assumed. Adapted from Wang et al.
(2005)
In addition, genome-wide association studies are usually performed by genotyping 
hundred of thousands or even millions of SNPs at the same time. This means that an 
enormous amount of tests are performed in a single experiment and it requires a p
o t
value <5x10' in order to exclude false positives results (Pe'er et al. 2008). In order to 
achieve this level of significance, even larger samples might be required than are 
presently available. For most research centres these sample sizes cannot be achieved 
without forming collaborations. The Wellcome Trust Case Control Consortium 
(WTCCC) is an example of this type of collaboration examining -2,000 individuals 
for each of seven major complex disorders (bipolar disorder, coronary artery disease, 
Crohn’s disease, hypertension, rheumatoid arthritis, type 1 and type 2 diabetes) and 
-3,000 shared controls (Wellcome Trust Case Control Consortium 2007). In the case 
of type 2 diabetes, a pooled sample of -60,000 subjects was required to definitively 
implicate a large set of genes (McCarthy and Zeggini 2009).
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2.4.4.3 Limitations o f genome-wide association studies
Although genome-wide association studies have resulted in a number of exciting 
findings, they have not yet explained a great amount of the genetic component of 
psychiatric disorders. There are several factors that could contribute to that.
First of all, as discussed previously, several common variants with small effect sizes 
are likely to be increasing risk to psychiatric disorders. In order to find them without 
increasing false positive results, a stringent p value is required. For this reason, large 
sample sizes are needed to increase power to detect associations and this has not been 
achieved yet for many psychiatric disorders (for example ADHD). In addition, as 
discussed previously, rare variants are very difficult to capture in genome-wide 
association studies.
In most cases, genome-wide association studies assume an additive model for risk, so 
that the presence of two risk factors in an individual increases risk by the sum of these 
two factors. However, this might not be the case in some instances. Epistatic 
interactions, like gene-gene and gene-environment interactions, are difficult to find in 
genome-wide association study designs. Other factors, such as epigenetic inheritance 
and CNVs that are not detected by current methods, could also contribute to the 
“missing heritability” (Hardy and Singleton 2009).
Finally, one of the main issues faced by genome-wide association studies of 
psychiatric disorders is that, unlike other complex disorders, they are highly clinically 
heterogeneous. Diagnosis of psychiatric disorders depends on a set of criteria, which 
although reliable, might not always lead to a cohort of patients with the same 
underlying causes (Craddock et al. 2008). For these reasons, ascertainment of patients 
in genome-wide association studies of psychiatric disorders deserves special mention, 
as it is essential that comorbidities and other factors contributing to heterogeneity are 
recognised.
As the cost of conducting genome-wide association studies decreases, studies 
involving larger sample sizes are being reported. Interesting findings pointing to 
pathways that have not been considered before have already appeared for psychiatric 
disorders. However, it is important to remember that replication in independent
samples is required before a variant is considered a true susceptibility variant and is 
further investigated.
2.5 Molecular genetics of ADHD
2.5.1 Genome-wide linkage studies
Genome-wide linkage studies are based on families with multiple affected 
individuals, mainly affected sibling pairs, and aim to identify broad regions in the 
genome that could harbour susceptibility genes.
Genome-wide linkage scans have been based either on the affected sibling pair (ASP) 
or the extended pedigree approach. At the time of writing, results of seven linkage 
studies of ADHD have been published (Table 2-2); five using ASPs and two using 
multiplex families. As Table 2-2 suggests, there is some overlap in significant linkage 
peaks. Evidence for at least nominally significant linkage has been found more than 
once for chromosomal regions 5pl3, 16pl3 and 17pl 1.
Table 2-2. Summary of ADHD genome-wide linkage studies published so far (regions that show
overlap are in bold)
Study Size and Sample Chromosomal Evidence
design origin regions of linkage 
(LOD)
Fisher et al. (2002) 126 ASPs USA No evidence of 
linkage
-
Smalley et al. 
(2002)
203 ASPs USA 16pl3 4.2
Ogdie et al. (2003) 270 ASPs USA 16pl3 4
Ogdie et al. (2004) 308 ASPS USA 5pl3
6ql2
16pl3
17pll
2.55
3.3
3.73
3.63
Ogdie et al. (2006) 424 ASPs USA and 
Dutch
5pl3 3.67
Bakker et al. (2003) 164 ASPs Dutch 15ql 5
7pl3
5pl3
3.54
3.04
1.43
Arcos-Burgos et al. 16 extended Colombian 17pll MLS=1.4
(2004) pedigrees 2
Hebebrand et al. 155 ASPs German 5p (at 17cM) 2.59
(2006) 17p 3.37 (for 
inattention 
only) 
Nominally 
significant
Faraone et al. 601 ASPs USA No evidence of -
(2007) linkage
Romanos et al. 8 extended German 5ql3 4.16
(2008) pedigrees
-
14ql2
2q35
4.5
3.4
Asherson et al. 142 ASPs IMAGE 16q23 3.1
(2008) sample 9q22 2.13
Zhou et al. (2008) Meta-analysis 
of 7 linkage 
scans
16 (between 64 
and 83 Mb)
pSK=0.000
34,
pOR=0.04
ASPs: Affected Sibling Pairs; LOD: Logarithm o f the odds; MLS: Maximum Multipoint LOD;
IMAGE: International Multi-centre ADHD Gene; SR: Summed Rank; OR: Odds Ratio
A study of 126 ASPs from the USA provided weak evidence for linkage at 16pl3 
(Fisher et al. 2002), which has also been implicated in autism. Stronger evidence for 
16pl3 [LOD (Logarithm Of the Odds) score 4.2] came from an expanded sample of 
203 ASPs (Smalley et al. 2002). The same region also came up in a study of 308 
American ASPs with an MLS (Maximum Multipoint LOD) of 3.73 (Ogdie et al. 
2004).
The chromosomal region at 5pl3 also came up in the latter study (Ogdie et al. 2004). 
Modest evidence for linkage for the same region (MLS=1.43) appeared in a study of 
164 Dutch ASPs (Bakker et al. 2003). Pooled analysis of the American and Dutch 
samples (Ogdie et al. 2006) yielded significant evidence of linkage (MLS=3.67) for 
5pl3, although the signal appeared to be coming mainly from the American families 
suggesting sample heterogeneity had an impact on the results. Finally, Hebebrand et 
al. (2006) studied 155 ASPs from Germany and found weak evidence of linkage 
(MLS=2.59) on chromosome 5p at 17cM.
Another interesting region is 17pl 1, as there is evidence of linkage in both the study 
of 308 ASPs from the USA (Ogdie et al. 2004) with an MLS of 3.63, as well as from 
the study of German ASPs (Hebebrand et al. 2006). A study with a different design 
using 16 multigenerational and extended pedigrees from Colombia also reported weak 
evidence of linkage at 17pl 1 (Arcos-Burgos et al. 2004).
A meta-analysis of seven independent linkage scans yielded a significant association 
for chromosome 16 between 64 and 83 Mb [pSR=0.00034, pOR=0.04) (Zhou et al. 
2008). Interestingly, the same region came to light from a genome-wide association 
study of quantitative traits of ADHD (Lasky-Su et al. 2008). This region harbours the 
CDH13 (Cadherin 13) gene which has been implicated in substance use disorders 
(Uhl et al. 2008).
In summary, genome-wide linkage studies have yielded some interesting results for 
chromosomal regions that need to be further investigated. It seems difficult to achieve 
replication of genome-wide significant results, suggesting that there are no 
susceptibility genes of large effect for ADHD. For this reason, an association 
approach is likely to be more suitable, since it can identify genes of smaller effect.
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2.5.2 Candidate gene association studies
Candidate gene association studies have not been very successful in complex 
disorders, possibly because the assumptions about the pathogenesis were not correct. 
One notable exception is ADHD, where selection of candidate genes has been 
informed by animal, imaging, and pharmacological studies.
Due to the large number of such studies, I will only focus on genes where significant 
findings have stood up to meta-analyses or pooled analyses or where there have been 
replications (Table 2-3 summarises all the meta-analyses for the genes discussed). 
Many of these functional candidate genes have been selected because they code for 
proteins or enzymes involved in the dopamine pathway. Interest in the dopaminergic 
system in ADHD has come from pharmacological, animal and imaging studies. First, 
stimulant medication, such as methylphenidate, reduces ADHD symptoms and 
inhibits the reuptake of dopamine thus increasing its extracellular concentration 
(DiMaio et al. 2003). In addition, imaging studies of patients with ADHD provide 
evidence of changes in brain regions where dopaminergic systems are more active 
(Spencer et al. 2005). Finally, animal studies, such as work on the DAT knockout 
mouse which manifests ADHD-like behaviour, have also implicated dopaminergic 
systems (Gainetdinov 2007). All this evidence has led to the investigation of DRD4, 
DRD5, DAT1 and COMT which will be discussed. Other genes such as those 
encoding dopamine beta hydroxylase (.DBH), monoamine oxidase A (MAOA), the 
dopamine D2 (DRD2) and dopamine D3 (DRD3) receptors have also been 
investigated but the results are not conclusive. Nearly all the published molecular 
genetic studies of ADHD have been based on clinical cases where ADHD has been 
defined according to DSM-IV diagnostic criteria. A few studies have examined 
ADHD defined dimensionally but the association findings here have generally been 
weaker (Mill et al. 2005).
Table 2-3. Meta-analysis and pooled studies for candidate gene association studies of ADHD
Gene Reference Type of studies included OR 95% Cl p value
Faraone et Case-control 1.9 1.4-2.2 <0.001
al. (2001) Family-based 1.4 1.1-1.6 0.02
Faraone et Case-control 1.45 1.27-1.65 -
DKD41- al. (2005) Family-based 1.16 1.03-1.31
repeat allele Li et al. 
(2006)
Case-control and 
family-based 1.34 1.23-1.45 2x1 O'12
Gizer et al. 
(2009)
Case-control and 
family-based 1.27 1.16-1.39 <0.00001
DRD4 5- 
repeat allele
Li et al. 
(2006)
Case-control and 
family-based 1.68 1.17-2.41 0.005
Maher et al. 
(2002) Family-based 1.57 1.25-1.96 0.00008
DRDS 148- 
bp
Lowe et al. 
(2004) Family-based 1.24 1.1-1.4 0.00005
microsatellite
repeat
Li et al. 
(2006)
Case-control and 
family-based 1.34 1.21-1.50 8 xlO’8
Gizer et al. 
(2009)
Case-control and 
family-based 1.22 1.1-1.36 0.000095
Maher et al. 
(2002) Family-based 1.27 0.99-1.62 0.063
Faraone et 
al. (2005) Family-based 1.13 1.03-1.24 -
DAT1 480-bp
Purper- 
Ouakil et 
al. (2005)
- 1.19 0.99-1.41 0.21
VNTR Li et al. 
(2006)
Case-control and 
family-based 1.04 0.98-1.11 0.20
Yang et al. 
(2007)
Family-based 1.7 1.05-1.30 0.004
Case-control 0.95 0.8-1.12 0.54
Haplotype-based 1.5 0.97-2.33 0.07
Gizer et al. 
(2009)
Case-control and 
family-based 1.1 1.03-1.17 0.002
Faraone et 
al. (2005)
Case-control and 
family-based 1.0 - -
COMT
Val158Met
Cheuk and 
Wong
Case-control and 
family-based 0.99 0.88-1.12 0.87
Gizer et al. 
(2009)
Case-control and 
family-based 0.99 0.92-1.06 0.62
. SNAP25
Faraone et 
al. (2005)
Case-control and 
family-based 1.19 1.03-1.38 -
T1065G Gizer et al. 
(2009)
Case-control and 
family-based 1.15 1.01-1.31 0.03
OR: Odds ratio; Cl: Confidence Interval; DRD4: Dopamine D4 receptor gene; DRD5 Dopamine D5 
receptor gene; DAT1: Dopamine transporter gene; COMT: Catechol-O-Methyltransferase; SNAP25: 
Synaptosomal-associated protein o f  25kD
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2.5.2.1 Dopamine D4 receptor gene (DRD4)
The DRD4 gene is on chromosome 1 lp l5.5. The D4 receptor binds both dopamine 
and noradrenaline. Most studies have focused on a variable number tandem repeat 
(VNTR) polymorphism in exon III of the gene. The number of repeats ranges from 2- 
11 with different populations having different alleles. This polymorphism is supposed 
to be functional, since the 7-repeat allele reduces the ability of the receptor to bind 
dopamine according to in vitro studies.
The first meta-analysis of the DRD4 gene in ADHD found significant association 
between the 7-repeat allele and ADHD in both case-control studies [OR (odds ratio) 
=1.9, 95% Cl (confidence interval) 1.4-2.2] and family-based studies (OR=1.4, 95% 
Cl 1.1-1.6) (Faraone et al. 2001). The same group conducted a pooled analysis and 
found that the association with ADHD was still significant in both case-control 
studies (OR=1.45, 95% Cl 1.27-1.65) and family-based studies (OR=1.16, 95% Cl
1.03-1.31) (Faraone et al. 2005). Li et al. (2006) included 33 association studies in 
their meta-analysis and also obtained strong evidence that the 7-repeat allele (P=2 x 
10'12, OR=1.34, 95% Cl 1.23-1.45) is associated with ADHD. They suggested that the 
5-repeat allele (P=0.005, OR=1.68, 95% Cl 1.17-2.41) also confers increased risk for 
ADHD and concluded that the 4-repeat allele has a protective role (P=0.004,
OR=0.90, 95% Cl 0.84-0.97) (Li et al. 2006) but that evidence is not clear-cut. More 
recently, the previous meta-analytic results on the 7-repeat allele were replicated in 
the meta-analysis by Gizer et al. (2009). They found a significant, moderate 
association between ADHD and the 7-repeat allele (P<0.00001, OR-1.27, 95% Cl 
1.16-1.39), although they also reported evidence of substantial heterogeneity of effect 
sizes across the studies (Gizer et al. 2009).
The DRD4 7-repeat allele has also been reported to influence cognitive performance 
but findings here are mixed with some studies showing that those with the 7-repeat 
allele perform worse on measures of accuracy and cognitive ability and other groups 
finding better performance in those with the risk allele, so no conclusions can yet be 
drawn (Thapar et al. 2007d). There have also been longitudinal studies suggesting that 
those with ADHD who possess the DRD4 7 repeat allele show a poorer outcome (El-
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Faddagh et al. 2004; Langley et al. 2008; Mill et al. 2005). However again, findings 
have not been entirely consistent (Shaw et al. 2007).
Another polymorphism on DRD4 that has been investigated is a 120 bp 
insertion/deletion in the promoter region, however there was no association of this 
polymorphism with ADHD in the meta-analysis by Gizer et al. (2009).
2.5.2.2 Dopamine D5 receptor gene (DRD5)
Another dopamine receptor gene, DRD5, on chromosome 4p 15.1-15.3 also appears to 
be important. The associated polymorphism is a microsatellite (a dinucleotide repeat 
with variable number of copies) mapping 18.5 kb away from the 5' end of the gene 
(Daly et al. 1999). The first meta-analysis of DRD5 included 5 studies and showed a 
significant association with the 148-bp allele (Maher et al. 2002). Significant 
association (OR=1.24, 95% Cl 1.1-1.4) with the same allele was also reported by a 
joint analysis of 14 independent studies resulting in approximately 2000 ADHD cases 
(Lowe et al. 2004). Association was stronger in those with ADHD inattentive type. Li 
et al. (2006) included nine association studies of DRD5 and also concluded that the 
148-bp allele of DRD5 confers risk for ADHD, while a significant association 
(p=0.000095, OR=1.22, 95% Cl 1.10-1.36) with moderate heterogeneity in effect 
sizes was found in a subsequent meta-analysis (Gizer et al. 2009). Li et al. (2006) also 
suggested that the 136-bp allele of DRD5 has a protective role. However, a study of 
329 male twins examining a trait measure of ADHD found association with the same 
variant but in the opposite direction, i.e. the 148-bp allele had a protective role (Mill 
et al. 2005). Association with ADHD has also been shown for other polymorphisms in 
DRD5 including two microsatellites at the 5' end of the gene and a SNP in the 3'
UTR (Untranslated Region) of DRD5 but these have been less widely studied.
2.5.2.3 Dopamine transporter gene (SLC6A3 or DA Tl)
The dopamine transporter gene on chromosome 5pl3.3 was initially considered the 
most likely candidate gene for ADHD. The major reason is that it is responsible for 
the reuptake of dopamine in the presynaptic cleft and is the target of stimulant 
medication (DiMaio et al. 2003). Another reason for considering DAT1 an important
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candidate gene for ADHD is because DAT knockout mice exhibit hyperactivity and 
deficits in inhibitory behaviour. Treating these mice with stimulants reduces 
symptoms (Gainetdinov 2007). Despite these findings, association studies have not 
been able to produce clear evidence about the involvement of DAT1 in ADHD.
The best studied polymorphism is a VNTR in the 3' UTR of the gene. The first meta­
analysis of nine DAT1 studies in ADHD reported an OR of 1.27 with a trend for 
association with the 480-bp allele (p=0.063) (Maher et al. 2002). However, there was 
evidence of heterogeneity across samples. In a meta-analysis by Faraone et al. (2005) 
the association of the 480-bp allele was significant, although the OR=1.13 (95% Cl
1.03-1.24) was small. Another meta-analysis of twelve family-based studies the same 
year failed to find any association of the DAT1 with ADHD (Purper-Ouakil et al. 
2005). No association of the 480-bp allele of DAT1 with ADHD was also found in the 
meta-analysis by Li et al. (2006). Another meta-analysis showed a small but 
significant association (p=0.004, OR=1.17, 95% Cl 1.05-1.30) for family TDT 
(Transmission Disequilibrium Test) studies but not for haplotype-based studies or 
case-control studies (Yang et al. 2007). However, the number of haplotype-based and 
case-control studies was small (Yang et al. 2007). Finally, a significant association 
between the 480-bp allele and ADHD (P=0.002, OR=l.l, 95% Cl 1.03-1.17) was 
found in an updated meta-analysis by Gizer et al. (2009). The same meta-analysis 
found significant associations with other polymorphisms in the DAT1 gene. It is also 
interesting that they report evidence of substantial heterogeneity.
Apart from the 3' UTR VNTR, association has been also reported for a SNP 
(rs40184) in the IMAGE sample (Brookes et al. 2006a). Haplotypes that include the 
3' UTR VNTR and other microsatellite repeats have also been found to be associated 
with increased risk for ADHD (Asherson et al. 2007; Brookes et al. 2006b).
The evidence overall from an abundance of meta-analytic studies is inconsistent. It is 
worth noting that most of the meta-analyses have found evidence of sample 
heterogeneity. One possibility is that the effect size of this variant is very small. The 
polymorphism in question may not be directly responsible for increasing risk for 
ADHD but it could be in linkage disequilibrium with another functional 
polymorphism. After all, it is in the 3' UTR of the gene, which as the name suggests, 
is transcribed to mRNA but not translated into protein; thus its function is
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questionable. Another source of heterogeneity could be the presence of multiple 
polymorphisms within the DAT1 gene increasing risk to ADHD. Heterogeneity can 
also be the result of gene-environment interaction (Thapar et al. 2007c). Evidence of 
interaction between the haplotype containing the 3' UTR VNTR and exposure to 
maternal alcohol consumption during pregnancy has been found (Brookes et al. 
2006b) but this requires replication. Two studies suggested that those with the 480-bp 
(10 repeat) allele, who were exposed to maternal smoking in pregnancy, showed 
higher levels of ADHD symptoms (Becker et al. 2008; Kahn et al. 2003). However, 
another study found evidence of gene-environment interaction for the 9 repeat allele 
in relation to exposure to maternal smoking in pregnancy (Neuman et al. 2007) and a 
different group failed to replicate these findings (Langley et al. 2008).
2.5.2.4 Catechol-O-Methyltransferase (COMT)
The gene encoding COMT, an enzyme catalysing the degradation of dopamine, 
adrenaline and noradrenaline, is on chromosome 22ql 1.2. Interest in COMT comes 
from its involvement in dopaminergic pathways. The most studied polymorphism in 
COMT is a G/A transition found in codon 158, which results in a valine-to-methionine 
transition. This polymorphism is functional with the val/val genotype increasing 
enzyme activity. No individual study or two pooled analyses (Cheuk and Wong 2006; 
Faraone et al. 2005) have found evidence of association between this variant and 
ADHD. A recent meta-analysis also reports no evidence of association (Gizer et al. 
2009).
Interestingly, the COMTVal allele yielded an almost significant result in the male 
group of the Cheuk and Wong (2006) meta-analysis. Thus, it could potentially be 
involved in male susceptibility to ADHD (Cheuk and Wong 2006). In addition, there 
is evidence that the COMT val/val genotype is associated with conduct disorder 
symptoms in patients with ADHD (Thapar et al. 2005). Since this first report, the 
same genotype was subsequently found to be associated with antisocial behaviour in 
those with ADHD (but not in those without ADHD) in two independent populations 
from a UK and a New Zealand birth cohort (Caspi et al. 2008). A pooled analysis of 
four studies also showed significant association with the val/val genotype (Caspi et al.
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2008). These results suggest that some gene variants operate by modifying the ADHD 
phenotype rather than by increasing risk.
2.5.2.5 Synaptosomal-associated protein o f  25kD (SNAP2S)
SNAP25 is a neuron specific protein involved in the regulation of neurotransmitter 
release. It emerged as a candidate gene for ADHD when it was discovered that the 
coloboma mouse mutant, which lacks a chromosomal region containing SNAP25 as 
well as other genes, exhibits hyperactivity that could be reduced by the use of 
stimulant medication D-amphetamine. One meta-analysis including this gene reported 
a significant association with the T1065G SNP at the 3' end of the gene (Faraone et 
al. 2005). A polymorphism in the 3' UTR (rs3746544) of the gene was also 
significantly associated with ADHD in a meta-analysis across seven studies (P=0.03, 
OR=1.15, 95% Cl 1.01-1.31) (Gizer et al. 2009). Nominally significant association 
with SNAP25 was also reported using the IMAGE sample, although the group tested 
different markers (Brookes et al. 2006a). A study of 12 SNPs in SNAP25 using two 
independent samples also yielded evidence of association but in only one of the 
samples (Feng et al. 2005). Finally, Kim et al. (2007) reported a modestly significant 
association with two SNPs that have not been studied before in a TDT analysis. 
Interestingly, in this study, a stronger association with SNAP25 was found in patients 
with ADHD and comorbid depression possibly highlighting the importance of taking 
into account psychiatric comorbidity in association studies (Kim et al. 2007).
To summarise, the most robust evidence is for an association between the DRD4 
VNTR, the DRD5 microsatellite marker in ADHD and the DAT1 480-bp VNTR. It is 
still unclear whether the DRD4 VNTR is causal. The DRD5 148-bp microsatellite is 
18.5kb away from the gene but that does not mean it does not influence DRD5 in a yet 
unknown fashion. As for DAT1, there is significant evidence of heterogeneity across 
studies, although it initially appeared as the strongest candidate gene. One explanation 
could be that the DAT1 480-bp VNTR is not responsible for the association but is 
tagging the functional polymorphism which is yet to be found. The evidence that 
COMT val/val genotype has a modifying effect on antisocial behaviour in ADHD is 
strong. Further studies on SNAP25 are needed before conclusions can be drawn.
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2.5.3 Genome-wide association studies (GWAS)
Genome-wide association studies of ADHD and related phenotypes have been 
performed, although they are still in early stages compared to other complex 
disorders. The first study used a sample of 959 family trios collected as part of the 
IMAGE study (see Franke et al. 2009 for a review on genome-wide association 
studies on ADHD). This study included 600,000 genotyped SNPs (Neale et al. 2008). 
Although, none of the SNPs reached genome-wide significance (the highest p values 
were 7.45E-06), these results do not exclude the effect of genes that increase risk for 
ADHD. In the list with the top-25 SNPs, there are some interesting candidate genes 
for ADHD, including CNR1 (cannabinoid receptor 1) (Neale et al. 2008). This gene 
falls into a suggestive linkage region in a recent meta-analysis of linkage studies 
(Zhou et al. 2008) and it has been also associated with alcohol and drug abuse (Zuo et 
al. 2007). The most likely reason that there are no genome-wide significant results is 
that risk variants for ADHD have very small effect sizes and genome-wide scans will 
require 10,000-20,000 cases to have a good chance of finding them. In addition, rare 
variants with large effect sizes would be difficult to detect unless sample sizes 
increase. Sample homogeneity and the ascertainment of the disorder can also be 
crucial factors (Neale et al. 2008).
Results from the same genome-wide scan have been used to test for association with 
quantitative phenotypes generated from the ADHD symptoms (Lasky-Su et al. 2008). 
The authors tested three quantitative phenotypes (number of hyperactive-impulsive 
symptoms, number of inattentive symptoms and total number of symptoms) under 
three different genetic models, which increased the multiple testing burden. There 
were two genome-wide significant results; one of them is an intronic SNP in CDH13 
(Cadherin 13) associated with the total number of ADHD symptoms (Lasky-Su et al. 
2008) and the other one is an intronic SNP in GFOD1 (glucose-fructose 
oxidoreductase-domain containing 1) associated with the number of inattentive 
symptoms. CDH13 has been previously involved in substance abuse (Uhl et al. 2008) 
and is in the list with the top-25 SNPs from the previous genome-wide association 
study (Neale et al. 2008), although the two studies are not independent.
Based on a list of candidate genes for ADHD compiled a priori, SNPs within SLC9A9 
(solute carrier family 9), as well as other genes previously associated with ADHD, 
were associated with the disorder, although they failed to reach genome-wide 
significance (Lasky-Su et al. 2008). Apart from being the top hit, SLC9A9 also 
contains the largest number of associations in terms of SNPs and phenotypes. 
However, it is also the largest gene in the study.
A pooled genome-wide association study not associated with IMAGE analysed 343 
adult patients with persistent ADHD and 304 controls from Germany (Lesch et al.
2008). The authors used additional criteria to report their findings, including, to name 
just a few, SNPs localised within genes, presence in suggestive linkage regions, 
expression in the brain. Although there were no genome-wide significant findings, a 
large proportion of the top-ranked SNPs are located in genes expressed in the brain 
and, some of them, have also shown association with substance abuse disorders, 
which are found very frequently in adult ADHD patients (Lesch et al. 2008).
In terms of overlap of genome-wide association studies in ADHD, CDH13 on 
chromosome 16q24.2-24.3 stands out, since it is reported in two previous genome- 
wide association studies of ADHD (Lasky-Su et al. 2008; Neale et al. 2008). This 
gene is further supported by the fact that it falls in the only significant linkage region 
from the meta-analysis by Zhou et al. (2008). Although CDH13 is not a classic 
candidate gene for ADHD, it codes for a cell-cell adhesion protein and is also a 
regulator of neural cell growth. Other interesting findings in the top-ranks of these 
genome-wide association studies are TLL (Tolloid-like) genes (Lasky-Su et al. 2008; 
Lesch et al. 2008; Neale et al. 2008). They code for metalloproteases that cleave 
collagen and they are expressed in the brain. These findings highlight the fact that 
genome-wide association studies can point to pathways of the disorder that would not 
be explored otherwise.
The IMAGE dataset was used to perform a genome-wide association study on ADHD 
with comorbid CD (Anney et al. 2008), which is hypothesised to have a different 
aetiology to ADHD without CD (Thapar et al. 2005). There were no reported 
genome-wide significant associations, although fifty-four markers were nominally 
associated. Some of them are located near genes that could be interesting for ADHD.
However, the authors point out that their analysis was exploratory and any 
associations would require replication in an independent sample (Anney et al. 2008).
An interesting approach to genome-wide association studies has been taken by 
researchers investigating gene-environment interactions in such a setting. The 
association of maternal warmth and criticism with ADHD severity and comorbid CD 
were tested in the IMAGE dataset (CD was evaluated both as a categorical and a 
quantitative trait) (Sonuga-Barke et al. 2008). Although no genome-wide significant 
results were produced, nominal effects were found both with and without main 
effects. Some of the observed interactions implicated the SLC1A1 (neuronal and 
epithelial glutamate transporter) and NRG3 (Neuregulin-3) genes, which have been 
implicated in psychiatric disorders previously (Sonuga-Barke et al. 2008).
The most recent genome-wide association study on ADHD has used samples from 
IMAGE II, which is a collaborative sample set and initial analysis suggests that there 
are no genome-wide significant associations (Neale 2009 personal communication). 
Unpublished data on a meta-analysis of genome-wide association studies of ADHD 
have again failed to produce genome-wide significant results (Neale 2009 personal 
communication). This again supports the notion that common gene variants of very 
small effects operate on ADHD and very large samples will be needed to have a 
chance of finding them. Rare variants of large effect size could also play a role but 
genome-wide association studies would require extremely large sample sizes to find 
them.
2.5.4 Copy number variants (CNVs)
Copy Number Variants (CNVs) are DNA segments, of at least 1 kb in size, that vary 
in number when genomes of different individuals are compared. They can be copy 
number gains (called insertions or duplications), when there is a relative gain of a 
DNA segment compared to the control genome, or they can be copy number losses 
(called deletions), when there is a relative loss of a DNA segment. The presence of a 
CNV in an individual does not necessarily mean that there would be an effect on the 
phenotype, since CNVs are part of the normal variation of the human genome 
(Scherer et al. 2007). However, it has emerged that CNVs can increase risk to
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disorders, especially those of a neurodevelopmental nature such as autism (Sebat et al.
2007) and mental retardation; thus the advances in technology that have made CNV 
detection more cost and time effective are very welcome.
There is only one study of CNVs in ADHD and it did not find increased numbers of 
deletions or duplications in ADHD compared to controls (Elia et al. 2009). However, 
the authors report that the gene set associated with inherited rare CNVs in cases was 
significantly enriched for genes studied in relation to autism, schizophrenia and 
Tourette’s syndrome (Elia et al. 2009). Another unpublished study on CNVs in 
ADHD coming from the Department of Psychological Medicine and Neurology in 
Cardiff University reports an increase of large rare CNVs in cases compared to 
controls (Williams 2009 Personal Communication). This excess of large rare CNVs is 
more profound in cases with ADHD and intellectual disability. In addition, the 
authors report an excess of chromosome 16p 13.11 duplications in cases and 
enrichment for CNVs previously reported in both autism and schizophrenia (Williams 
2009 Personal Communication).
Although CNV studies in ADHD are still in their infancy, they can point to new 
pathways of risk factors for ADHD and they highlight the overlap in risk factors 
operating in different neurodevelopmental disorders. They also suggest that rare 
variants can play an important role in the pathophysiology of ADHD.
2.6 The contribution of gene-environment interaction in ADHD
It is well-recognised that psychiatric disorders, as other complex disorders, are 
influenced by both genetic and environmental factors (Rutter 2007). Gene- 
environment interplay encompasses both gene-environment correlation and gene- 
environment interaction. Gene-environment correlation applies when exposure to a 
certain environmental factor depends on the genetic make-up of the individual. This 
means that genes increase risk of developing ADHD by influencing exposure to 
environmental factors. For example, maternal smoking and stress in pregnancy have 
both been linked to ADHD. However there is evidence to suggest that these
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environmental risks are influenced by maternally-provided inherited factors and index 
liability to ADHD (Thapar and Rutter 2009).
Gene-environment interaction takes place when a genetic factor exerts its effect only 
when the individual is exposed to a certain environmental factor (Thapar et al.
2007b). Genetic studies, such as case-control association studies with information 
about exposure to environmental factors and epidemiological studies can both assess 
the effect of gene-environment interaction. Twin or adoption studies on this topic 
have not been published for ADHD, although this could indicate a publication bias 
against negative results (Thapar et al. 2007b).
Several environmental factors have been discussed in relation to ADHD, including 
maternal smoking during pregnancy, low birth weight, alcohol consumption during 
pregnancy, maternal stress during pregnancy, poor maternal diet and toxins during the 
prenatal or neonatal period (Linnet et al. 2003). It is notable that the common 
characteristic of these environmental factors is that they require exposure during a 
critical period. For this reason it has been suggested that they might result in 
epigenetic processes being triggered during a developmental window (Mill and 
Petronis 2008).
Investigating gene-environment interaction in ADHD is still at an early stage and 
there is lack of robust replication studies. For this reason the discussion will only 
focus on the most promising interactions.
Maternal smoking has been considered the environmental factor that is most robustly- 
associated with ADHD. A meta-analysis has reported a pooled odds ratio of 2.38 
(95% Cl 1.61-3.52) (Langley et al. 2005). Animal studies have also suggested that 
prenatal exposure to nicotine is linked to low birth weight, increased locomotor 
activity and cognitive impairment (Ernst et al. 2001). A combination of maternal 
smoking during pregnancy and the DATl 148-bp allele has been associated with 
increased ADHD symptoms (Kahn et al. 2003). An interaction between maternal 
smoking and the DATl allele has been found by another study as well, although the 
association was with a different allele (Neuman et al. 2007). The same study also 
reported an interaction between smoking and the DRD4 7-repeat allele to increase
ADHD symptoms (Neuman et al. 2007). In contrast, there were two reports of no 
association between smoking and DATl (Brookes et al. 2006b; Langley et al. 2008).
Low birth weight is considered an important environmental risk factor for ADHD 
with an odds ratio of 2.64 from a meta-analysis (Bhutta et al. 2002). Low birth weight 
and possession of the val/val COMT genotype have been shown to increase 
susceptibility to ADHD (Thapar et al. 2005). There was also a modifying effect on the 
disorder by increasing conduct disorder symptoms (Thapar et al. 2005).
Prenatal exposure to alcohol was investigated in ADHD and it was found that it 
increased ADHD symptoms when a specific haplotype of SNP alleles in DATl was 
present (Brookes et al. 2006b).
Two markers in the same gene, DATl, have been reported to interact with 
psychosocial adversity (defined by measures of family and parental adversity) to 
increase ADHD symptoms (Laucht et al. 2007).
Finally, the interaction between the DRD4 7-repeat allele and season of birth in 
relation to ADHD have been investigated by two groups (Brookes et al. 2006b;
Seeger et al. 2004) but the results were in opposite directions.
To sum up, so far evidence in support of gene-environment for ADHD is not yet 
convincing. Most of the environmental factors that are considered to increase 
susceptibility to ADHD exert their effect during the prenatal period. For this reason, it 
is difficult to disentangle whether the factor responsible is the prenatal environment or 
the effect is mediated by shared genetic factors between the mother and the offspring.
A study with a novel design has tried to solve this problem by using data collected by 
families with children bom through in vitro fertilisation (IVF). By comparing children 
bom by mothers genetically related to them (homologous IVF) to children bom by 
mothers not related to their offspring (oocyte or embryo donation and gestational 
surrogacy), it is possible to conclude on the nature of the effect an environmental 
factor has. When the effect of an environmental factor is present both in the related 
and unrelated group, it means that it is a true environmental effect but when it is only 
present in the related group, it is a result of shared genetic factors (Thapar et al.
2007a). This new experimental design has been able to elucidate the nature of putative
environmental effects thought to be involved in psychopathology. It was found that 
some of them were not due to real environmental effects but they resulted from shared 
genetic factors between the mother and the offspring. One such factor was maternal 
smoking during pregnancy and ADHD, which was due to genetic factors conferring 
susceptibility to the mother to smoking during pregnancy and susceptibility to the 
offspring to developing ADHD (Thapar et al. 2009). The same was also true for the 
effect of maternal smoking during pregnancy and antisocial behaviour (Rice et al. 
2009a; Rice et al. 2009b). These studies highlight the complexity of studying the 
involvement of environmental factors in psychiatric disorders and the caution that 
should be exercised when interpreting such associations.
To conclude, ADHD is a childhood-onset neurodevelopmental disorder with high 
heritability. However, the genetic component of this disorder requires more research 
to be elucidated. Case-control association studies point to the involvement of 
dopaminergic genes while genome-wide association studies of larger sample sizes and 
careful ascertainment are required. Apart from common variants with small effect 
sizes, rare variants are likely to be involved in the pathophysiology of the disorder.
Chapter 3 Schizophrenia
3.1 Schizophrenia symptoms and diagnosis
Schizophrenia is a severe psychiatric disorder accounting for a significant proportion 
of psychiatric morbidity and requiring long-term medical help and social support. 
Patients with schizophrenia are often unable to work and sustain interpersonal 
relationships resulting in enormous economic and psychological burden for the 
patient, the family and the society.
3.1.1 Epidemiology
The lifetime risk for developing schizophrenia is ~1% and it is very stable across 
different countries and cultures. There is an increased rate of men affected by 
schizophrenia compared to women; the male/female ratio is ~1.4, although sex 
differences in the age of onset and the severity of the disorder are profound. Increased 
rates of schizophrenia have been found for migrants and those living in an urban 
versus rural environment (McGrath et al. 2004). Environmental factors that act early 
in life have also been studied in schizophrenia. These include obstetric complications, 
prenatal maternal psychological stress and maternal influenza exposure during 
pregnancy. There is also a link with season of birth, which could be mediated by the 
increased risk of influenza exposure during pregnancy in winter (Kinney et al. 1994). 
One of the strongest associated environmental factors is maternal nutritional 
deficiency. Data from two natural experiments, where women were exposed to severe 
malnutrition due to famine during pregnancy, showed that the relative risk for 
schizophrenia and schizoid personality disorder in their offspring was double 
compared to matched controls (St Clair et al. 2005; Susser et al. 1996).
3.1.2 Clinical presentation
The symptoms characterising schizophrenia can be categorised into two groups. 
Positive symptoms include hallucinations, delusions, thought disorder, as well as 
bizarre and disorganised behaviour. Negative symptoms, such as loss of motivation
and drive, flattened mood, social isolation, poverty of speech and poor personal 
hygiene are also present. Cognitive impairment (usually mild) is common with the 
most affected domains being attention, working memory and executive functions. IQ 
is generally a standard deviation lower than expected. Cognitive deficits are often 
present at the onset or even before the onset of the disorder and they tend to increase, 
even when there are no other symptoms. It has been suggested that they are caused by 
abnormal ffontotemporal interactions (Pearlson 2000). Depression is also common, 
usually following an acute episode.
3.1.3 Schizophrenia diagnosis
Since there are no biological markers to diagnose schizophrenia, the diagnosis is 
based on self-reported symptoms and behavioural observations. There are two sets of 
diagnostic criteria used to identify schizophrenia: the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) (American 
Psychiatric Association 2000) and the International Classification of Diseases, tenth 
edition (ICD-10) (World Health Organisation 1993). They both require that positive 
symptoms are present for at least one month causing dysfunction in everyday life. 
Drug-induced psychoses and organic causes should be excluded.
Although specific criteria should be met for a diagnosis of schizophrenia, there is still 
great heterogeneity and different subtypes are recognised:
• Paranoid type: the most common subtype where delusions and hallucinations 
are evident
• Catatonic type: Rarer, characterised by immobility, rigidity or purposeless 
movement.
• Disorganised (or hebephrenic) type: Characterised by unpredictable 
behaviour, usually the prognosis is poor.
• Undifferentiated type: Psychotic symptoms are present but the criteria for 
paranoid, disorganised or catatonic types have not been met.
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• Residual (chronic) type: there is a history of psychotic episodes but at the 
moment only negative symptoms and/or cognitive impairment is present
3.1.4 Prognosis
Cohort studies have found that -15% of patients recover completely, -50% have 
relapses but minimum impairment between the relapses, 25% have chronic illness and 
significant impairment and 10% commit suicide. The prognosis is worse in patients 
who discontinue medication, are socially isolated, have an earlier age of onset or 
abuse drugs. Men have a poorer prognosis than women and more negative symptoms 
(Katona et al. 2008). It is interesting that cognitive deficits increase with age in 
patients with schizophrenia, with 50% of older patients with schizophrenia meeting 
criteria for dementia but not Alzheimer’s disease (Pearlson 2000).
3.1.5 Management of patients with schizophrenia
Management of patients with schizophrenia requires administration of antipsychotic 
medication. There are two types of antipsychotics: typical and atypical; they are both 
effective in treating positive symptoms and preventing relapses. Adherence to 
medication is a problem and discontinuing medication increases the chance of a 
relapse. However, antipsychotics have side-effects which can be serious.
Psychological and social interventions are also beneficial.
3.1.6 Phenotypic complexity
Although the current diagnostic criteria provide diagnostic reliability, they are not 
valid disease entities. The complexity of the phenotype suggests that schizophrenia is 
actually a collection of conditions with different symptoms and outcomes. More 
importantly the underlying causes might be different with important consequences for 
treatment.
Genetic studies are especially susceptible to this lack of biological validity. Searching 
for genes conferring susceptibility to complex disorders is hard enough without the
58
heterogeneity of schizophrenia. If the current diagnostic criteria encompass a variety 
of conditions with different aetiology, then the situation resembles the hypothetical 
situation of considering fever a disorder on its own and looking for a cause.
The other side of this problem is that the phenotype extends beyond the diagnosis of 
schizophrenia to include schizoaffective disorder and schizotypal personality disorder, 
as shown by family studies (Owen et al. 2002). Then, the search for susceptibility 
factors would be confounded by the fact that individuals with these disorders would 
not be included in the “affected” group.
Another layer of complexity is added by the overlap of schizophrenia and bipolar 
disorder. Current diagnostic criteria have been based on the Kraepelinian dichotomy 
between schizophrenia and manic depressive disorders. However, family and twin 
studies have shown higher than expected rates of bipolar disorder in relatives of 
patients with schizophrenia and the opposite. A recent meta-analysis provides further 
evidence of familial coaggregation of schizophrenia and bipolar disorder (Van 
Snellenberg and de Candia 2009). Schizoaffective disorder occurs more often in 
families of patients of both disorders. In addition, the largest family study of 
schizophrenia and bipolar disorder involving 2 million Swedish families showed that 
relatives of patients with schizophrenia and bipolar disorder have increased risk of 
both disorders and they attributed this to partly shared common genetic causes 
(Lichtenstein et al. 2009). Similar to family studies, molecular genetic studies have 
found evidence of shared common genetic causes between schizophrenia and bipolar 
disorder. Overlapping regions have been reported by linkage scans of both disorders, 
while association studies of DISCI (Disrupted-in-Schizophrenia 1) and NRG1 
(Neuregulinl) suggest common susceptibility factors (see Craddock et al. 2006a for a 
review). Most interestingly the ZNF804A (zinc finger protein 804A) gene, which is 
the best-supported finding from a genome-wide association study on schizophrenia, 
shows evidence of association with bipolar disorder (O'Donovan et al. 2008). 
Additionally, the best-supported gene from a genome-wide association study on 
bipolar disorder, CACNA1C (calcium channel, voltage-dependent, L type, alpha 1C 
subunit), is suggested to be associated with schizophrenia as well (Ferreira et al. 2008; 
Green et al. 2009).
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The conclusion that can be made here is that schizophrenia is a very heterogeneous 
disorder and there is a possibility that schizophrenia and bipolar disorder have more 
similarities than differences. Until aetiology is better understood, categorising patients 
according to diagnostic criteria will be limiting for both clinicians and researchers.
The way molecular genetic studies can help advance the field of phenotype 
refinement and diagnostic validity is by “thinking outside the box” in terms of 
choosing cohorts with patients and controls. Instead of strictly relying on the 
diagnostic criteria, patients from a broad phenotype or across disorders can be chosen 
based on common characteristics (for example, performance on a cognitive task). This 
way the sample size will still remain large enough and common risk factors that are 
more likely to be closer to being causal can be identified.
3.2 Schizophrenia as a neurodevelopmental disorder
The fact that schizophrenia is currently described and diagnosed based only on 
symptoms does not mean that there is no underlying neuropathology, although this 
might be heterogeneous. Current views suggest that schizophrenia is a 
neurodevelopmental disorder with the cause of the abnormality occurring early in life, 
most likely during prenatal life. Cell migration abnormalities can start during foetal 
life in individuals already susceptible to schizophrenia due to genetic factors and they 
can be triggered by an environmental insult. Certain environmental factors have been 
found to be associated with schizophrenia, although the mechanism through which 
they trigger these brain abnormalities is not known. In addition, although brain 
abnormalities exist in patients with schizophrenia, it is very difficult to establish 
whether they are causal or they are caused by the disease or its treatment.
One of the neuropathological findings in patients with schizophrenia is that cortical 
thickness and brain weight is reduced by 5% (Pearlson 2000). Another consistent 
finding is that patients with schizophrenia have increased lateral ventricle size. This 
has been found in patients at the onset of the disorder making it less likely to be a 
disease consequence (Degreef et al. 1992). In a systematic review it was calculated 
that ventricular size was increased by 40% in patients with schizophrenia compared to 
controls (Lawrie and Abukmeil 1998). Family studies strengthen these results by 
showing that obligate carriers of susceptibility factors, such as children with two
affected parents also have larger ventricles (Harrison 1999). This finding, despite 
providing a glimpse into the pathology of this extremely complicated disorder, is not 
specific enough to be used as a biological marker because it can be found in healthy 
individuals as well.
Neuroimaging techniques have shown alterations in all brain regions in different types 
of patients with schizophrenia with or without medication (Pearlson and Marsh 1999). 
The prefrontal cortex is characterised by altered neuronal sizes and abnormal synaptic 
connections (Pearlson 2000). Functional imaging suggests abnormal activity in the 
fronto-hippocampo-parietal circuit when carrying out a set-shifting task. Deficit 
symptoms are more correlated with reduced activity in frontal and parietal cortex 
(Pearlson 2000).
Brain abnormalities have also been found microscopically with the most interesting 
being a decrease in neuronal size accompanied by increased neuronal density 
affecting the hippocampus and the dorsolateral prefrontal cortex (Harrison 1999).
Reported neurochemical abnormalities involve the dopamine, serotonin, GABA and 
glutamate systems. The dopamine hypothesis for schizophrenia suggests that the 
disorder is caused by increased dopaminergic transmission and it is based on 
neuropharmacological findings. Dopamine agonists, such as amphetamines, can 
provoke or exacerbate positive symptoms while the efficacy of conventional 
antipsychotic drugs is proportionate to blockage of dopamine receptors. It has also 
been suggested that the neurocognitive deficits in schizophrenia are linked to reduced 
dopaminergic activity in the prefrontal cortex (Pearlson 2000). The only safe 
conclusion that can be made from the literature is that neurotransmitter systems are 
definitely dysregulated in schizophrenia. However, treating this dysregulation treats 
the symptoms but not the cause of the disorder.
Neurocognitive deficits have been suggested to be the best candidate markers of 
schizophrenia. A large longitudinal study found that cognition in people who 
developed schizophrenia in adulthood was affected from as early as seven years of 
age. Reading and IQ were particularly impaired (Crow et al. 1996).
The neurodevelopmental hypothesis suggests that environmental influences can act 
early in life to modify risk to the disorder. Some of the environmental factors that
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have been studied in schizophrenia include obstetric complications, prenatal maternal 
psychological stress, maternal influenza exposure during pregnancy and maternal 
nutritional deficiency during pregnancy (Kinney et al. 1994; St Clair et al. 2005; 
Susseretal. 1996).
To sum up, schizophrenia is a disorder that occurs usually in early adulthood but its 
origin is neurodevelopmental with dysregulation starting in prenatal life. The 
following evidence strengthens this notion:
• Neuropathological evidence points to structural brain abnormalities
• Neuroimaging evidence suggests that anomalies exist in different brain areas 
in patients of all stages
• Neurocognitive deficits are present before the onset of the disorder from a 
very young age
• Environmental factors acting during prenatal life, such as pregnancy 
complications, have been linked to schizophrenia
3.3 Evidence of a genetic component to schizophrenia
Genetic epidemiological studies of schizophrenia have provided compelling evidence 
of a genetic component to schizophrenia.
3.3.1 Family studies
Family studies examining the risk of developing schizophrenia in relatives of patients 
with the disorder compared to the general population suggest that genetic factors 
increase risk. Using 40 reliable family studies conducted in Western Europe between 
1920 and 1987, Gottesman (1991) showed that the risk of developing schizophrenia 
increases from 1% in the general population to 6% in second degree relatives, 9% in 
siblings, 13% in children, 17% in dizygotic (DZ) twins and 48% in monozygotic 
(MZ) twins (Figure 3-1). In addition, the risk increases with the number of affected
relatives. Children with parents that both suffer from schizophrenia have 46% risk of 
developing the disorder (Gottesman 1991).
General population ■  1%
2%First cousins
2%Uncles/aunts
Nephews/nieces 4%
Grandchildren 5%
Half siblings 6%
6%Parents
Siblings 9%
Children 13%
Fraternal twins 17%
Identical twins 48%
0% 10% 20% 30% 40% 50% 60%
Figure 3-1. Risk of developing schizophrenia in relatives o f patients with schizophrenia. The data 
are based on a review of studies compiled by Gottesman (1991)
3.3.2 Adoption studies
By examining the risk of developing the disorder in biologically related relatives and 
non-biologically related (adoptive family) relatives, it is possible to disentangle the 
contribution of genetic and environmental factors, which is not possible in family 
studies. Adoption studies of schizophrenia agree that there is an increase in the risk in 
biological relatives of patients with schizophrenia compared to non-biological 
relatives. The Danish adoption study, for example, found that the rate of 
schizophrenia in first-degree biological relatives of adopted patients with 
schizophrenia was 7.9% compared with 0.9% for biological relatives of adopted 
control individuals (Kendler et al. 1994).
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3.3.3 Twin studies
The level of disease concordance in pairs of MZ twins compared to DZ twins has 
been used to calculate the heritability of schizophrenia. A review based on five 
systematically ascertained twin studies found a rate of concordance in MZ twins of 
41-65% and 0-28% in DZ twins (Figure 3-1), thus calculating a heritability of 80-85% 
(Cardno and Gottesman 2000).
To sum up, family, adoption and twin studies have confirmed a major role of genetic 
factors in the pathophysiology of schizophrenia. The risk of developing schizophrenia 
increases with the degree of relatedness (and thus the number of genetic factors 
shared). However, the rate of concordance in MZ twins, who share all of their genes, 
never reaches 100% providing strong evidence for the involvement of environmental 
factors in the aetiology of schizophrenia.
3.3.4 Mode of transmission
The rate of concordance of schizophrenia in MZ twins is approximately 48%, while 
the degree of genetic similarity is clearly more than that. This means that the same 
genetic factors do not always lead to the phenotype being expressed. Mechanisms 
involving interaction with environmental or stochastic factors are very likely to 
operate. The pattern of disease recurrence in relatives of patients with schizophrenia 
excludes the possibility of a single-gene Mendelian disorder (Owen et al. 2002). The 
mode of transmission of schizophrenia is most likely complex reflecting a polygenic 
model with a threshold effect. According to this model, each risk or protective allele 
exerts a small effect. These effects are combined in an additive manner along with 
environmental factors to lead to disease manifestation when a critical threshold is 
exceeded (Owen et al. 2002). It is likely that these risk factors are relatively common 
alleles of small effect and some rare alleles with relatively large effects (Owen et al.
2009). Risch (1990) studied the relative risk of schizophrenia in different families.
The relative risk (Xs for siblings) is a ratio of the probability of a relative of a patient 
with schizophrenia being affected to the probability of being affected in the general 
population. He concluded that the existence of one locus of Xs>3 is unlikely and that a 
model of two or more loci of ^ *<2 are more likely (Risch 1990). However, the current
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model of common variants of small effects does not exclude the existence of rare 
variants with larger effects acting on a small number of affected individuals. In 
addition, epistatic effects are likely to be involved in schizophrenia, including gene- 
gene and gene-environment interactions. Epistatic interactions mean that the 
susceptibility conferred by two factors (genetic or environmental) is greater than their 
individual susceptibilities (Frankel and Schork 1996). In general, although it has been 
demonstrated that schizophrenia is heritable, the number of susceptibility loci, the risk 
conferred by them and the degree of interaction between them remain unknown.
3.4 Molecular genetics of schizophrenia
3.4.1 Genome-wide linkage studies
Genome-wide linkage studies of schizophrenia started by using a small number of 
families with multiple affected individuals. Because of the lack of highly penetrant 
alleles, larger numbers of pedigrees have been used. However, it has not been possible 
to consistently replicate linkage findings (Owen et al. 2005). The large number of 
linkage scans made it possible for meta-analyses to be performed (Table 3-1).
Table 3-1. Summary of meta-analyses of schizophrenia genome-wide linkage scans (regions that
show overlap are in bold)
Meta-analysis No of No of Chromosomal Evidence of
studies
included
pedigrees regions linkage
Badner and 681 8p P=2*10'4
Gershon 18 I3q P=7* 10'5
(2002) 22q P=9*10'6
1,208 2q P=0.000417
Lewis et al. 
(2003)
20 5q, 3p, 1 lq, 6p, 
lq, 22q, 8p, 
20q, 14p
P<0.05
Ng et al. 32 3,255 5q P=0.0046
(2008) 2q P=0.00035
The first meta-analysis supported evidence of linkage on 8p, 13q and 22q (Badner and 
Gershon 2002). The second meta-analysis used more stringent criteria for the studies 
to be included (Lewis et al. 2003). The strongest signal from this meta-analysis was 
on 2q, while support was obtained for 5q, 3p, 1 lq, 6p, lq, 22q, 8p, 20q and 14p. They 
also found that the number of loci meeting the aggregate criteria for significance was 
greater than the number of loci expected by chance (p<0.001) (Lewis et al. 2003).
Two regions were common in both meta-analyses: 8p and 22q. The large number of 
non-overlapping regions can be attributed to the difference in the criteria for inclusion 
in the meta-analysis.
The most recent meta-analysis included 32 independent genome-wide linkage scans, 
comprising 7,476 genotyped cases. More nominally significant linkages than would 
be expected by chance were reported. Genome-wide evidence of linkage was detected 
on chromosome 2q, while suggestive evidence of linkage was observed on 
chromosome 5q (Ng et al. 2008). The region on chromosome 2q is of particular 
interest because it contains ZNF804A, the gene containing a SNP that has been 
significantly associated with schizophrenia in a recent genome-wide association study 
(O'Donovan et al. 2008). When the authors included only samples of European 
ancestry, suggestive evidence of linkage was detected on chromosome 8p (Ng 2008). 
Suggestive evidence of linkage was also found for this region in a recent genome- 
wide linkage scan involving eight clinical samples and 1,615 affected genotyped 
individuals (Holmans et al. 2009).
To sum up, the modest linkage signals show that it is unlikely that there are genes of 
large effects on the risk of developing schizophrenia. In the era of genome-wide 
association studies the usefulness of linkage scans is questioned. Although genome- 
wide association studies have better power to detect common SNPs and they can also 
detect some CNVs, linkage scans can find evidence of the aggregate effect of multiple 
rare and common variants as well as CNVs. Thus, following linkage regions up by 
high-throughput resequencing could be another way of finding genes that contribute 
to the risk of developing schizophrenia.
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3.4.2 Candidate gene studies
Candidate gene studies focus on selecting specific genes based on assumptions about 
the pathophysiology of the disorder derived from animal, pharmacological, or 
imaging studies (functional studies). The other approach is to choose genes following 
interesting areas that have come up from linkage scans (positional). There have been a 
large number of association studies based on hypotheses about the pathophysiology of 
schizophrenia but they have not been very successful, probably due to the fact that 
very little is known about the pathophysiology of schizophrenia. Positional candidate 
gene studies have been more successful in schizophrenia. Over 1,000 genetic 
association studies have been published about schizophrenia, thus I will be focusing 
on the studies that have provided the most convincing results.
3.4.2.1 Dystrobrevin-binding protein 1 (DTNBP1)
Dystrobrevin-binding protein 1 (DTNBP1) or dysbindin is located on chromosome 6 
and was first implicated in schizophrenia after Straub et al. (2002) followed up a 
linkage region on chromosome 6p22.3. The same group followed their finding by 
genotyping DTNBP1 in 203 German families (Schwab et al. 2003). Two large studies, 
one including 900 cases from United Kingdom and Ireland (Williams et al. 2004) and 
one including 488 families from Bulgaria (Kirov et al. 2004), also confirmed the 
association. The majority of published studies on DTNBP1 have found positive 
associations, thus rendering DTNBP1 one of the strongest candidates for involvement 
in schizophrenia (Kirov et al. 2005). However, there is a great deal of disagreement 
over the specific SNP alleles or haplotypes that confer risk or protection to 
schizophrenia. One of the reasons for the discrepancies could be that there are 
multiple risk or protective alleles in this gene (DTNBP1 is a large gene with over 300 
SNPs) (Williams et al. 2004). Interestingly, DTNBP1 cis-acting variants affect 
expression in the human brain (Bray et al. 2003; Bray et al. 2005). In addition, 
reduced mRNA and protein has been found in postmortem brain samples from 
patients with schizophrenia (Talbot et al. 2004; Weickert et al. 2004).
The mechanism through which DTNBP1 confers risk or protection against 
schizophrenia is not clear because its function is not entirely known. DTNBP1 binds
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to both a- and p-dystrobrevin which form the dystrophin glycoprotein complex. Its 
expression in the brain is confined to neurons where it is found both pre- and 
postsynaptically (Williams et al. 2005). The presynaptic DTNBP1 is reduced in 
glutamergic neurons of the hippocampus of patients with schizophrenia (Talbot et al.
2004). This finding coupled with evidence that glutamate is reduced in cultured 
neurons with reduced DTNBP1 expression suggests that DTNBP1 could confer risk to 
schizophrenia by influencing the glutamate system.
3.4.2.2 Neuregulinl (NRG1)
Neuregulin 1 (NRG1) was first considered to be involved in schizophrenia after fine- 
mapping across the 8p locus, to which linkage was observed in Icelandic families 
(Stefansson et al. 2002). The haplotype associated with schizophrenia in this first 
sample was also found to be associated in samples of different origin. There have 
been negative associations as well that could reflect the difference in the origin of the 
samples (Owen et al. 2005). The specific susceptibility variant has not been 
discovered yet, although there have been resequencing efforts (Stefansson et al.
2002). NRG1 codes for many different mRNA species resulting in 15 proteins with 
diverse functions in the brain. The possible mechanism of NRG1 involvement in 
schizophrenia is by altered mRNA expression supported by the finding that there are 
altered ratios of NRG 1 mRNA species in the brain of people with schizophrenia 
(Hashimoto et al. 2004) and findings from a mutant mouse model heterozygous for 
NRG1 (Stefansson et al. 2002).
3.4.2.3 SzGene: a database o f association studies o f schizophrenia
The literature on association studies of schizophrenia includes more than 1,000 
studies with very inconsistent results. The recent creation of an online database of all 
published genetic association studies of schizophrenia is an effort to systematically 
record this literature. This database, called SzGene, is regularly updated, free to 
access and where possible it provides meta-analyses (Schizophrenia Research Forum
2005) (www.schizophreniaforum.org/res/sczgene/default.asp). Using the data 
available on April 2007, Allen et al. (2008) performed 118 meta-analyses resulting in
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24 variants in 16 different genes being nominally associated. The strongest 
associations were with DRD2 (dopamine D2 receptor) gene and TPH1 (tryptophan 
hydroxylase 1). The authors, additionally, applied a set of guidelines developed by the 
Human Genome Epidemiology Network to assess the validity of these associations. 
Strongest credibility was found for SNPs in DRD1 (dopamine D1 receptor), DTNBP1, 
TPH1 and MTHFR (methylenetetrahydrofolate reductase) (Allen et al. 2008). The 
association of polymorphisms in two dopamine receptors is interesting given the 
hypothesis for excess dopamine in the brain of patients with schizophrenia and the 
correlation of efficacy of anti-psychotic drugs with the ability to block the DRD2 
receptor (Williams et al. 2009a). In addition, the polymorphism in the DRD2 receptor 
is functional resulting in altered mRNA stability (Duan et al. 2003). The 
DTNBPlgene is a strong candidate for involvement in schizophrenia, although there 
could be multiple risk and protective alleles or great heterogeneity in this gene. TPH1 
encodes for tryptophan hydroxylase, the rate limiting enzyme in the synthesis of 
serotonin. However, TPH2 (tryptophan hydroxylase 2) and not TPH1 is expressed in 
the brain (Walther et al. 2003).
3.4.3 Genome-wide association studies (GWAS)
Genome-wide association studies are considered very promising in the field of 
genetics of complex disorders, since they have the power to detect moderate to small 
effect sizes (provided that studies are large enough) while at the same time making no 
assumptions about the pathophysiology of the disorder. Markers are spread across the 
genome in order to achieve maximum coverage. However, the Y chromosome has 
been an exception up until recently (see following chapters for more information).
Genome-wide association studies on schizophrenia have been published (Table 3-2) 
using pooled DNA samples (Kirov et al. 2008b; Mah et al. 2006; Shifman et al. 2008) 
and individual genotyping (Lencz et al. 2007; O'Donovan et al. 2008; Shi et al. 2009; 
Stefansson et al. 2009; Sullivan et al. 2008; The International Schizophrenia 
Consortium 2009).
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Table 3-2. Summary of genome-wide association studies for schizophrenia published so far
Genome-wide Study
design
Evidence
association Cases Controls of P value OR
study association
Mah et al. DNA 320 325 PLXNA2 0.006 1.49(2006) pooling (chr 1)
Lencz et al. Individual 178 144 CSF2RA 3.7x1 O'7
3.23
(2.04-
5.15)(2007) genotyping (PARI)
Kirov et al. 
(2008b)
DNA
pooling 574 605
CCDC60 
(chr 12) 2x1 O'6
O’Donovan et Individual 479 2,937 ZNF804A 1.61x1 O'7 1.09al.(2008) genotyping (chr 11)
Shifman et al. 
(2008)
DNA
pooling 2,274 4,401
Reelin (chr 
7) 2.9x1 O'5
1.58
(1.31-
1.89)
No
Sullivan et al. Individual 738 733
genome-
wide
significant
results
(2008) genotyping
No
Need et al. Individual 1,460 12,995
genome-
wide
significant
results
(2009) genotyping
The
International
Schizophrenia
Consortium
Individual
genotyping 3,322 3,587
MHC genes
(6p22.1)
TCF4
9.5xl0'9
lxlO'7
1.22
(2009)
Shi et al. 
(2009)
Individual
genotyping 2,681 2,653 - - -
Shi et al. 
(2009)
Meta­
analysis 8,008 19,077
MHC genes
(6p22.1,
6p21.32)
9.54x10‘9 1.14
Stefansson et Individual 2,663 13,498al. (2009) genotyping
MHC, 1.4xl0‘12
Stefansson et 
al. (2009)
Meta­
analysis 12,945 34,591
PRSS16
MHC,
NOTCH4
NRGN
1.4x10'12 
2xlO'10
1.16
•PLXNA2: plexin A2; CSF2RA: colony stimulating factor, receptor 2a; CCDC60: coiled-coil domain 
containing 60; ZNF804A: zinc finger protein 804A; MHC: Major Histocompatibility Complex; TCF4: 
Transcription Factor 4; PRSS16: Thymus-specific serine protease; NOTCH4: Neurogenic Locus notch 
Homolog protein 4; NRGN: Neurogranin; OR: Odds Ratio
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In DNA pooling, samples from cases are mixed and samples from controls are mixed 
separately. The analysis involves looking for differences in allele frequencies. This 
method has the advantage of saving time and money but reduces power because it is 
prone to measurement error. It is very interesting that one of the pooling genome- 
wide association studies of schizophrenia achieved a sex-specific association. The 
association was female-specific for a SNP in the reelin (RELN) gene (p=2.9xl0'5) 
using an Ashkenazi Jewish population (Shifman et al. 2008). A significant gene-sex 
interaction was also found (p= 1.8x1 O'4). The same group attempted to replicate their 
initial association in four different populations. Although the effects were in the same 
direction in all the populations, they were significant in one of them achieving an 
overall relative risk for women carrying the common allele of 1.58 (p = 8.8 x 10'7; p =
1.6 x 10'5 for gene-sex interaction). This finding apart from its importance in studying 
sex differences in schizophrenia supports the idea of a neurodevelopmental nature to 
the disorder, since reelin is involved in corticogenesis and neuronal positioning 
(Shifman et al. 2008).
In terms of individual genotyping, the first genome-wide association study on 
schizophrenia was performed on 178 cases and 144 controls. The strongest result was 
for a SNP near the CSF2RA (colony stimulating factor, receptor 2a) gene in the 
pseudoautosomal region (p=3.7xl0'7) (Lencz et al. 2007). Sequencing in a smaller 
independent sample revealed association with both common haplotypes and rare 
variants in CSF2RA and the neighbouring IL3RA (interleukin 3 receptor alpha). 
Although the association is surprising in such a small sample, the link between 
schizophrenia and the immune system is one that definitely deserves further studying 
(Lencz et al. 2007) and appears in other genome-wide association studies, as will be 
discussed later.
The second genome-wide association study on schizophrenia involved genotyping 
738 cases and 733 controls but there were no SNPs achieving genome-wide 
significance (Sullivan et al. 2008). Follow-up studies might yield something 
interesting but the heterogeneity of the sample in terms of origin can be a problem. A 
genome-wide association study of 1,460 cases and 12,995 controls also failed to 
report any genome-wide significant findings (Need et al. 2009).
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Another genome-wide association study was designed to follow up all results from the 
initial sample of 479 cases and 2,937 controls surpassing a threshold of p<10'5 in a 
sample of 6,829 cases. The strongest result was for a SNP in ZNF804A (zinc finger 
protein 804A) (p=lxl0 '7), although it just fell short of genome-wide significance 
(O'Donovan et al. 2008). However, genome-wide significance was achieved when the 
samples included patients with bipolar disorder (p=9xl0*9, OR=1.09). ZNF804A is a 
transcription factor with unknown function. Its discovery through a genome-wide 
association study shows that this study design without any a priori hypothesis can 
point to genes that could not have been found otherwise. The other important point 
stemming from this study was that the observed pattern of replication was highly
o
improbable given the null hypothesis (p=9xl0' ) (O'Donovan et al. 2008). This means 
that there is at least one common variant increasing risk to schizophrenia and bipolar 
disorder, thus the hypothesis that common variants would be eliminated through the 
reduced fecundity of people with schizophrenia is not true. The most likely scenario 
would involve a large number of common variants with very small effects (<1.1) as 
well as rare variants of larger effects (Williams et al. 2009b).
More recently genome-wide association studies on schizophrenia have involved larger 
sample sizes and collaborative efforts to achieve them. The International 
Schizophrenia Consortium has published a genome-wide association study in 3,322 
cases and 3,587 controls with even larger numbers for the replication sample (The 
International Schizophrenia Consortium 2009). The most interesting finding involved 
a region on chromosome 6p22.1 spanning the major histocompatibility complex 
(MHC) (p=9.5xl0'9). The authors also evaluated the role of common variants in 
schizophrenia and provided evidence for a substantial polygenic component to the 
risk of schizophrenia and bipolar disorder. Thousands of common variants are likely 
to contribute to risk and collectively they explain at least one-third of the variability 
(The International Schizophrenia Consortium 2009).
No genome-wide significant results were reported in the study using the Molecular 
Genetics of Schizophrenia (MGS) case-control sample (2,681 cases and 2,653 
controls) (Shi et al. 2009). However, in a meta-analysis, which extended the original 
sample to 8,008 cases, SNPs on chromosomal region 6p22.1 were significantly 
associated with schizophrenia (p=9.54xl0'9). The region includes a histone gene
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cluster and MHC genes (Shi et al. 2009). Another study using the SGENE 
Consortium sample (2,663 cases and 13,498 controls) failed to report genome-wide 
significant results (Stefansson et al. 2009). However, in the meta-analysis, which 
included the International Schizophrenia Consortium (ISC), the SGENE Consortium 
and the MGS samples, five SNPs spanning the MHC region on chromosome 6p21.3-
22.1 reached genome-wide significance levels (strongest finding: p= 1.4x1 O'12,
OR=l. 16) as well as a SNP on chromosome 1 lq24.2 upstream of the neurogranin 
gene and a SNP in transcription factor 4 (TCF4) on chromosome 18q21.2 (Stefansson 
et al. 2009).
Despite the initial encouraging results from genome-wide association studies on 
schizophrenia it is clear that a large number of common variants remain to be found. 
As is the case for genome-wide association studies from other complex diseases, large 
scale endeavours are necessary. However, a potential problem with schizophrenia and 
other psychiatric disorders is that increasing the sample size could lead to an increase 
in heterogeneity, thus masking the already small effects.
3.4.4 Copy number variants (CNVs)
Copy number variants (CNVs) were first linked with schizophrenia due to the 
increased rates of schizophrenia in individuals with velo-cardio-facial syndrome, 
which is caused by microdeletions of chromosome 22ql 1 (Murphy and Owen 2001). 
The largest study of CNVs in schizophrenia involving 3,391 cases and 3,181 controls 
found that the total burden of CNVs is increased 1.15-fold in patients with 
schizophrenia compared to controls (The International Schizophrenia Consortium
2008). The increase was greater for rare and larger CNVs. Other studies report 
different effects but it is expected, since they differ in design and sample composition. 
However, it is not yet clear whether the increase in burden comes from a small 
number of highly penetrant CNVs or a large number of variants with small effects.
in terms of the rate of de novo CNVs in schizophrenia, studies have not been in 
agreement. Two studies reported a very low level of de novo CNVs in schizophrenia 
(Kirov et al. 2008a; Kirov et al. 2008b) and childhood-onset schizophrenia (Walsh et
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al. 2008), while in another study the rate of de novo CNV events was 10% in cases 
and 2% in controls (Xu et al. 2008).
CNVs in specific loci have been associated with schizophrenia, in some cases in more 
than one study. The most interesting is a rare transmitted deletion that affects neurexin 
1 (NRXN1) found by Kirov (2008a) in a patient with schizophrenia and an affected 
sibling. CNVs in NRXN1 were also reported in two other studies of schizophrenia 
(Rujescu et al. 2009; Walsh et al. 2008), as well as autism (Autism Genome Project 
Consortium 2007). CNVs have also been found in genes interacting with NRXN1, 
such asa.de novo duplication including the gene coding for amyloid beta A4 
precursor binding protein, which binds NRXN1 (Kirov et al. 2008a) and a rare CNV in 
neuroxophilin 2 (Kirov et al. 2009). In addition, there is a biological reason why 
disruptions in the NRXN1 gene caused by CNVs could lead to increased risk to 
schizophrenia, since it is involved in synaptic development and function.
Other interesting CNVs associated with schizophrenia are two rare deletions, one at 
1 q21.1 and the other at 15ql3.3 both with very strong effects (OR estimated to be 
around 10 across studies) (Kirov et al. 2009). These deletions have been reported by 
two large studies of CNVs in schizophrenia, one involving 1,443 cases (Stefansson et 
al. 2008) and the other 3,391 cases (The International Schizophrenia Consortium 
2008). These regions include a large number of genes and it is not clear at this point, 
which of them are responsible for increasing risk to schizophrenia. The same studies 
have reported another deletion at 15ql 1.2 with a smaller effect size (OR=3) (Kirov et 
al. 2009; Stefansson et al. 2008). Microduplications with large effect sizes (OR=14.5) 
at 16pl 1.2 (McCarthy et al. 2009) and 16p 13.1 (OR=3) have also been reported 
(Ingason et al. 2009).
The involvement of structural variants with low frequency in schizophrenia provides 
further support to the notion that schizophrenia is a neurodevelopmental disorder, 
especially since the same loci have been implicated in other neurodevelopmental 
disorders, such as autism and mental retardation (Mefford et al. 2008). However, 
these results show that the same structural variant can cause a variety of phenotypes, 
including healthy individuals and individuals with serious neurodevelopmental 
disorders. This means that none of the CNVs are sufficient to cause a disease and
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points to the involvement of other factors, such as the rest of the genetic background 
and environmental factors, interacting with CNVs to lead to a specific phenotype.
To conclude, schizophrenia is a psychiatric disorder with a neurodevelopmental 
nature and increased phenotypic heterogeneity. The pathophysiology of the disorder is 
still not clear. The genetic component of schizophrenia includes common variants of 
small effect sizes and rare variants of large effect sizes, although more research is 
required to elucidate the role of risk factors and their interactions.
Chapter 4 The Y chromosome
4.1 The evolution of sex chromosomes
In mammals sex is determined by two sex chromosomes, XX gives rise to females 
while XY with the sex-determining gene, SRY, results in males. Although pairs of 
autosomes are highly homologous in mammals, sex chromosomes are heteromorphic, 
which means that they share a very small amount of homology. However, they can 
pair during meiosis in male cells due to two homologous regions at both ends of the 
sex chromosomes, called pseudoautosomal regions (PARs). Homologous regions 
occur in other places on the two sex chromosomes, which suggests that sex 
chromosomes have evolved from an ancestral pair of autosomes. This happened when 
an allelic variation on a gene on one of the ancient autosomes resulted in the gene 
taking on control of sex determination. The autosome with this specific variation 
evolved into the male-specific chromosome, the Y chromosome, while the other 
autosome developed as the X chromosome (for more details see Graves 2006).
After the development of the sex determining gene, the two sex chromosomes started 
becoming increasingly dissimilar and recombination was repressed to preserve a male 
specific chromosome. This absence of recombination allowed the accumulation of 
mutations on the male specific chromosome and loss of homology between the two 
sex chromosomes. Lack of recombination resulted in degeneration of the Y 
chromosome. This explains the smaller number of genes on the Y chromosome and 
the fact that most of them are involved in male functions (Graves 2006).
In birds and reptiles, sex determination is either genetic or environmental. Distinct sex 
chromosomes have independently evolved not only in mammals but also birds (where 
females are the heterogametic sex, ZW, and males are the homogametic sex, ZZ) and 
certain species of fish and reptiles (although for most of them sex determination 
depends on environmental factors).
The sex determining gene is SRY (Sex-determining region of chromosome Y) in 
mammals and it was thought to have evolved 350 million years ago since the 
divergence of synapsid reptiles. This a branch of reptiles from which mammals 
evolved and which left no other descendants. It was thought that the SRY gene must
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have developed after the divergence of mammals from reptiles, as it is only found in 
mammals and no reptile species. Birds and snakes, for example, have a ZZ male and 
ZW female. The sex determining gene in birds is called DMRT1 (Doublesex and mab- 
3 related transcription factor 1) (Delbridge and Graves 1999).
However, the analysis of the platypus genome showed that the SRY must have 
evolved earlier, -1 6 5  million years ago (Veyrunes et al. 2008). The platypus belongs 
to the monotremes, which diverged from therian mammals (marsupials and placental) 
-165  million years ago and therefore falls evolutionary-wise between birds/reptiles 
and mammals. The platypus sex chromosomes have strong homology with bird, but 
not to therian sex chromosomes and orthologes of conserved genes on the X 
chromosome map on platypus chromosome 6. This means that this is probably the 
ancestral autosome from which the sex chromosomes evolved (Veyrunes et al. 2008).
The SRY gene evolved from SOX3 (SRY-related HMG-box 3), which is found on the 
X chromosome in mammals. Both SRY and SOX3 belong to a family of HMG (high- 
mobility group) domain transcription factors. The SRY sequence is poorly conserved 
outside the HMG box, which suggests that this is the most important region for sex 
determination. SOX3 is highly conserved in mammals and is expressed in the 
developing brain as well as other tissues of mice and humans. Thus, SRY evolved 
from a gene with a possible role in brain function.
To conclude, the sex chromosomes evolved from a pair of autosomes when a 
mutation in a gene appeared that enabled this gene to be responsible for male sex 
determination.
4.2 The Y chromosome structure
Although genome-wide linkage studies and genome-wide association studies are 
designed to achieve the maximum possible coverage across most of the genome, up 
until recently they did not include any marker on the Y chromosome. This means that 
the Y chromosome has been neglected in studies of complex disorders including 
psychiatric disorders and the association studies that have been performed of the Y 
chromosome in relation to psychiatric phenotypes have mostly used small and 
heterogeneous populations.
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The presence or absence of the Y chromosome defines the sex of an individual. It is 
60 Mb in length but it has been considered a genetic wasteland for many years 
because of the paucity of phenotypes showing solely father-to-son transmission and 
the small number of identified Y chromosome genes. The discovery of the sex 
determining gene, SRY (Sex Determining Region on chromosome Y) (Gubbay et al. 
1990; Sinclair et al. 1990), led to the notion that the Y chromosome was essential for 
sex differentiation but had lost all other important functions during evolution. 
Nowadays with the improvement of genomic technologies, it has emerged that the Y 
chromosome harbours a number of genes and informative polymorphisms.
The part of the Y chromosome found only in men is called the non-recombining 
region (NRY) or male-specific region (MSY). This region covers the vast majority of 
the Y chromosome (95%) and is passed unchanged from father to son apart from 
mutations because there is no recombination with the X chromosome.
4.2.1 Pseudoautosomal regions (PARs)
The pseudoautosomal regions (PARs) are located at both ends of the Y chromosome 
and they recombine respectively with PARI and PAR2 on the X chromosome. These 
regions cover only 2.7 Mb for PARI and 0.33 Mb for PAR2. There are 30 genes 
reported in the pseudoautosomal regions (Ross et al. 2005) and the SHOX (short 
stature homeobox) gene has been associated with short stature and bone 
malformations (Blaschke and Rappold 2006). Early linkage studies of the PAR 
regions in schizophrenia have failed to report significant results (Asherson et al. 
1992). In recent years, the PAR regions have been overlooked in linkage and 
association studies and have not been included in the early versions of SNP arrays 
used for genome-wide association studies. Due to the high level of recombination in 
these regions, the numbers of markers required to cover them should be larger than 
for autosomal regions of the same size (Flaquer et al. 2008). Nevertheless, the cost 
would not increase considerably compared to the overall cost of genome-wide 
association studies and for this reason the latest Illumina HumanlM-Duo chip 
(http://www.illumina.com/pages.ilmn?ID=40) covers the PAR regions adequately.
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4.2.2 Male-specific region (MSY)
Since the MSY is the factor on the Y chromosome that differentiates the sexes, it 
should be discussed in more detail. The MSY comprises both heterochromatic 
sequences and euchromatic sequences. Heterochromatic DNA remains highly 
condensed throughout the cell cycle and genes on it are silenced through histone 
methylation. Euchromatic DNA, however, is lightly packed and is responsible for all 
gene transcription from the Y chromosome. The latter cover 8 Mb on Yp and 14.5 Mb 
on Yq. Currently, 156 transcription units have been found on the human euchromatic 
MSY. The number of protein-coding genes is 78 and they code for 27 proteins or 
protein families. It is interesting that only 18 genes are found in a single copy. The 
remaining genes have several copies with at least 98% sequence identity (Skaletsky et 
al. 2003). Genes in the MSY fall into two categories: genes that are expressed 
throughout the body (including the brain) and genes that are expressed mainly or 
exclusively in testes.
In terms of euchromatic sequences in the human MSY, there are three different types 
(Figure 4-1) (Skaletsky et al. 2003):
• X-transposed sequences have 99% homology to X chromosome, although they 
do not recombine and they are characterised by low gene and high repeat 
density. They are thought to be the remnants of the ancient autosomes from 
which the Y chromosome, as well as the X, have evolved.
• X-degenerate sequences include single-copy genes and pseudogenes with an X 
chromosome homologue which are ubiquitously expressed. It is striking that 
no ubiquitously expressed gene has been found in the other two types of 
sequences. Only one gene that is expressed predominantly in testes belongs in 
this category, the sex determining gene SRY.
• Ampliconic sequences (named like that due to the large number of repeats and 
palindromes) exhibit a high degree of similarity (99.9%). They include the 
largest number of both coding and non-coding genes, although their 
expression is, most of the time, limited to testes. They are characterised by 
eight massive palindromes covering 25% of the euchromatic sequences. Also 
present on ampliconic sequences are inverted repeats and long tandem arrays.
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These regions are usually large allowing for gene conversion, a phenomenon 
of non-reciprocal recombination between Y chromosome sequences. This has 
resulted in the large number of repeats on the Y chromosome. It is argued that 
gene conversion is as frequent in MSY as recombination is in autosomes with 
multiple events taking place per generation.
M S Y
|  X-transposed |  Ampliconic |  Pseudoautosomal
□^-degenerate ■  Heterochromatic □  Other
Figure 4-1. The male-specific region of Y chromosome. The diagram shows the different types of 
euchromatic sequences regions in the MSY. Heterochromatic sequences are also shown.
4.3 M a rk e rs  and  hap log roups to study  the Y chrom osom e
The unique property of the absence of recombination in most of the Y chromosome 
means that traditional approaches, such as genetic mapping, are not useful. Thus, the 
availability of the complete euchromatic Y chromosome sequence is having an impact 
on the way it is studied.
4.3.1 Y chromosome markers
Studies of the variation on the Y chromosome have revealed a large number of 
polymorphisms which can be used as molecular markers of Y chromosome diversity. 
The lack of recombination, which means that polymorphisms remain unchanged apart 
from mutations for a large number of generations, provides the Y chromosome with
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the best haplotypic resolution in the human genome. There are two categories of 
molecular markers for the Y chromosome:
• Biallelic markers, which are mainly SNPs and an Alu element insertion, with 
low mutation rate
• Multiallelic markers, which are microsatellites and minisatellites, with higher 
mutation rates
4.3.2 Y chromosome haplogroups
SNPs on the Y chromosome are used to define haplogroups. While a haplotype is a 
combination of alleles at multiple loci that are transmitted together, a haplogroup is a 
stable lineage of Y chromosomes that share a common ancestor. In other words, a 
haplogroup is a group of similar but not identical haplotypes. A combination of SNPs 
appropriate for the population in question is used to define haplogroups while 
microsatellites can be used to detect diversity within a given haplogroup and increase 
the resolution. Groups of closely related haplogroups are called hypergroups.
The number of SNPs on the human Y chromosome was small until Underhill et al. 
(1997 ) used DHPLC (Denaturing High-Performance Liquid Chromatography) to 
discover 19 novel SNPs. Employment of the same method has led to the discovery of 
205 SNPs that can be typed using PCR methods (Shen et al. 2000; Underhill et al.
2000). Nowadays, genetic databases, like UCSC (WJ et al. 2002, 
http://genome.ucsc.edu/) and Ensembl (Hubbard et al. 2009, 
http://www.ensembl.org/index.html), report a large number of Y chromosome 
polymorphisms but unfortunately most of them are not verified and they have to be 
considered with caution. Moreover, the nomenclature of Y chromosome SNPs has 
been inconsistent with researchers following up to seven different nomenclature 
systems making any comparison between studies very difficult (The Y Chromosome 
Consortium 2002).
4.3.3 The Y Chromosome Consortium (YCC)
These issues were addressed by the Y Chromosome Consortium (YCC), a 
collaborative effort to study variation in the human Y chromosome. This consortium 
was initiated in 1991 by Michael Hammer and Nathan Ellis with the following goals:
• ‘to establish a repository of lymphoblastoid cell lines derived from a sample of 
males representing worldwide populations’
• ‘to provide DNA isolated from these cell lines to investigators searching for 
polymorphisms on the non-recombining region of the Y chromosome’
• ‘to establish a common database containing the results of typing DNA from 
these cell lines’ (The Y Chromosome Consortium 2002)
The YCC has produced a nomenclature system incorporating all verified Y 
chromosome markers with the flexibility to include newly discovered ones. In 
addition, by genotyping 245 Y chromosome SNPs in a common, globally 
representative sample of the male population they were able to construct a single most 
parsimonious phylogenetic tree including 153 Y chromosome haplogroups (Figure 4- 
2) (The Y Chromosome Consortium 2002). This tree should be considered as a set of 
nested lineages sharing a common ancestor, which is the derived state of one or more 
SNPs. The state of each SNP (derived or ancestral) is determined by sequencing 
homologous regions of closely related non-human primates. The root of the tree is 
indicated with an arrow and each major haplogroup is named with a capital letter (A- 
R). Haplogroup Y is the one that all men belong to, since it includes all known 
haplogroups (Figure 4-2). Although the assignment of the letters to haplogroups can 
be considered arbitrary, haplogroups on the lower part of the tree are thought to have 
appeared more recently in evolution compared to haplogroups on the upper branches 
of the tree. This means that haplogroups that are more close to each other 
alphabetically are also more closely related in terms of their evolutionary origin.
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Figure 4-2. The single most parsimonious Y chromosome tree including 245 markers and 153 haplogroups. The arrow indicates the root of the tree. Capital letters are used to name major clades. The most inclusive is Y, where all haplogroups 
belong. Different colours are used for the different clades. Haplogroup names and YCC sample numbers are given on the right. Markers needed in order to capture a haplogroup are given along the branches. The length of each branch is 
arbitrary. The * symbol indicates a paragroup (see text for explanation) (The Y Chromosome Consortium 2002)
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4.3.4 YCC nomenclature systems
The YCC has proposed two nomenclature systems for the MSY haplogroups. An 
example will be used to illustrate the way the two nomenclature systems work. Let us 
consider haplogroup H lb according to the first nomenclature system. The capital 
letter H is the name of the major haplogroup. The numbers and letters that follow H 
are used to specify the subclades within this major haplogroup. H lb will refer to 
subclade HI and specifically the ‘b’ part of subclade HI (Figure 4-3). Nested 
subclades within a major clade or haplogroup are named using this alphanumerical 
alternating system until reaching ‘the tip of the branch’. Notice that in some subclades 
the name includes an asterisk, for example HI* (Figure 4-3). This is called a 
paragroup and indicates that this Y chromosome belongs to haplogroup HI but not in 
any of the known subclades of HI. The most likely explanation is usually that there 
are more subclades within this haplogroup but the SNPs that define them have not 
been discovered yet.
Major C la d e  Subclade 1 Subclade b within subclade 1
MB MH
M39
M i l
H1 a
H1b
H1c
H aplogroup
Figure 4-3. Haplogroup H lb  named according to 1 ** nomenclature system. Different colours are 
used to indicate the levels o f clades within the haplogroup
The second nomenclature system again uses the same capital letters for naming major 
haplogroups. However, instead of naming the subclades alphanumerically it uses the 
name of the terminal SNP that defines the subclade. Thus, the example haplogroup 
H lb will be named H-M39 (Figure 4-4) (note that the use of the dash indicates that 
the name is produced using the second nomenclature system). The same rules apply 
for paragroups as well.
Figure 4-4. The same haplogroup named with the two different nomenclature systems. The
Another rule has been put in place for instances where not all markers needed to reach 
‘the tip of the tree’ have been typed in a study. Then, for both nomenclature systems a 
parenthesis following the name is introduced. This includes an ‘x’ and the name of 
subclades (first nomenclature system) or SNPs (second nomenclature system) that the 
Y chromosome does not belong to according to typed markers.
It might appear that the nomenclature systems and the YCC haplogroup tree add 
another layer of complexity to this already unusual chromosome. However, when they 
are compared with the previous nomenclature systems, it becomes clear that they have 
major advantages and can facilitate research and exchange of knowledge between 
researchers. First of all, haplogroups are named systematically and there is no need to 
change their names even if new mutations are discovered, although this may lead to 
clades being split or joined. The hierarchical nature of the nomenclature system 
provides inherent information about the evolutionary relationship between different 
haplogroups and clades within the same haplogroup. Paragroups are clearly indicated, 
so that we know that no safe conclusions can be drawn about their evolutionary
Major
clade
Subclade 
b within 1
Major
clade Terminal
SNP
Subclade
figure shows what each letter and number represents
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relationship with other clades within the major haplogroup they belong to. At present 
the YCC nomenclature committee oversees the expansion of the haplogroup tree, 
when new SNPs are discovered, and is responsible for naming the new haplogroups 
and clades (http://ycc.biosci.arizona.edu.). The same website provides a table which 
can be used as a cross-reference to previous nomenclature systems, although direct 
comparisons are not possible in some cases due to the inconsistencies displayed by the 
nomenclature systems.
4.3.5 YCC haplogroup tree 2008
The YCC phylogenetic tree and nomenclature received minor modifications in 2003 
(Jobling and Tyler-Smith 2003). In 2008, the latest revised version of the tree 
containing 311 haplogroups and approximately 600 SNPs was published (Karafet et 
al. 2008). The SNPs genotyped came mainly from Michael Hammer and Peter 
Underhill’s group. SNPs in public databases were also utilised. The SNPs were 
genotyped and further confirmed by sequencing in 33 males from three different 
populations. The most important changes in the haplogroup tree are the following 
(Karafet et al. 2008):
• P I43 SNP unites haplogroups C and FT
• Haplogroups I and J are joined to the IJ clade
• Haplogroups N and O are joined to the NO clade
• P256 merges haplogroup M with 2 K haplogroups into M hypergroup
• 2 K clades are named as haplogroups S and T
Since the publication of the YCC 2008 haplogroup tree there have been yet more Y 
chromosome SNPs discovered (Repping et al. 2006). As the authors of the YCC 2008 
haplogroup tree point out, the quality and reliability of Y chromosome studies would 
benefit from a set of publicly available positive controls. Since the YCC cell lines 
typed in 2002 do not exist any longer, it would be worth typing the known Y 
chromosome SNPs in CEPH individuals (Karafet et al. 2008).
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4.4 Geographical differentiation of Y chromosome haplogroups
The geographical differentiation of Y chromosome haplogroups is higher than for any 
other part of the genome. It can differ even between populations of the same country. 
The factors contributing to this differentiation are:
• Lack of recombination
• Small effective population size
• Social factors
• Selection
4.4.1 Lack of recombination and its importance
As mentioned before, the Y chromosome consists of the MSY region and two 
pseudoautosomal regions (PARI and PAR2). The PAR regions recombine with the 
relevant regions on X chromosome during meiosis. However, the rate of 
recombination in these regions in men is much higher than in women and they exhibit 
the highest recombination frequencies of the genome (Flaquer et al. 2008). 
Consequently, the PAR regions have very low levels of linkage disequilibrium.
The opposite is true for the MSY. This region does not recombine and it is passed 
unchanged from father to son apart from mutations. The sequence of the MSY can 
only change by mutations, thus providing a stable record of the Y chromosomes of the 
male ancestors of an individual.
There are rare occasions when the MSY can recombine. These include individuals 
that carry two Y chromosomes. Nevertheless, they are either infertile (Chevret et al.
1997) or they have eliminated one Y chromosome in their germline (Solari and Rey 
Valzacchi 1997), so the product of this recombination never makes it to the next 
generation. Another instance when recombination in the Y chromosome can occur is 
between the normal Y chromosome and segments of the Y chromosome carried on 
another chromosome as asymptotic translocations or between the Y chromosome and 
highly homologous X chromosome sequences (Cooke and Noel 1979). However,
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these events are extremely rare and have yet to be found in humans (Pecon-Slattery et 
al. 2000). Although recombination does not exist in the MSY, there is evidence of 
frequent gene conversion or intrallelic recombination. Gene conversion is the process 
of nonreciprocal transfer of sequence information between a pair of nonallelic DNA 
sequences. It has been calculated that on average 600 nucleotides in the MSY per 
generation undergo gene conversion (Rozen et al. 2003).
4.4.2 Effective population size
A factor that influences the geographical distribution of the Y chromosome is its 
effective population size. Only one copy of the Y chromosome is carried by men. This 
results in the effective population size of Y chromosomes being one quarter of all the 
other autosomes (carried in two copies by both sexes) and one third of the X 
chromosome (carried in two copies by women and in one copy by men). The 
significantly smaller effective population size means that mutations have fewer 
‘chances’ to change the sequence of the Y chromosome. This is observed as lower 
sequence diversity on the Y chromosome than anywhere else in the genome 
(Thomson et al. 2000).
Furthermore, the smaller effective population size renders the Y chromosome more 
susceptible to genetic drift. This phenomenon is the accumulation of random 
changes in the abundance of genetic variants. Since the number of Y chromosomes is 
smaller, random changes can result in significant differentiation between Y 
chromosomes of different populations.
4.4.3 Social factors
Social factors also influence the geographical distribution of the Y chromosome. Men 
tend to stay closer to their birthplace compared to women who usually follow them 
after marriage. Patrilocality results in further increases of the differentiation between 
Y chromosomes of different populations. It is striking that the opposite is true for 
societies that practice matrilocality, like Thailand. In these cases, mitochondrial DNA 
is the one that displays significant differentiation between populations (Oota et al. 
2001).
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4.4.4 Selection
In the absence of recombination, an advantageous mutation would affect the entire 
chromosome and increase the frequency of a specific haplogroup more rapidly than 
expected. The opposite would be true for non-advantageous mutations.
All these factors lead to a high degree of geographical differentiation, more than 
anywhere else in the human genome. The consequences are very interesting. First of 
all, the study of Y chromosome haplogroups is a powerful tool for population 
geneticists seeking to detect population migration patterns that shaped the human 
race. However, there are serious threats to studying the Y chromosome posed by this 
differentiation. Because of the low frequency of some Y chromosome variants, it is 
almost certain that there are polymorphisms that have not been discovered yet. If a set 
of Y chromosome variants that have been discovered in a certain population is used in 
a genetically distinct population, the erroneous conclusion could be drawn that the 
variation in the second population is much less than in the first one. Of course, this is 
not true. It is just a result of the fact that other markers are more suitable for 
characterising this population. Unfortunately, the geographical differentiation of the Y 
chromosome is so high that even populations within the same country can be very 
different in terms of their Y chromosomes. Researchers trying to associate Y 
chromosome variation with particular phenotypes should also be cautious about the 
geographical differentiation of the Y chromosome. It is vital that a well-matched 
control with the same geographical origin is used to avoid associations that are merely 
the result of population stratification. Examples of such studies will be discussed later.
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4.4.5 Geographical distribution of Y chromosome haplogroups in Europe and 
United Kingdom
The Y chromosome distribution in Europe has not been studied extensively. Early 
studies were limited by the availability of markers and difficulty in comparing 
between the studies due to the problematic nomenclature systems.
Y chromosome markers are the ideal tool for deciphering the population history of 
Europe. The largest study of European Y chromosomes has involved genotyping 11 Y 
chromosome SNPs in 47 European populations. These define 10 haplogroups. Spatial 
autocorrelation analysis showed that the pattern of geographical distribution in Europe 
is highly non-random and that two haplogroups represent 45% of all the Y 
chromosomes in the European continent (Rosser et al. 2000). Although this study was 
published before the YCC haplogroup tree and nomenclature, these two haplogroups 
roughly correspond to paragroup P*, which includes a part of haplogroup R, and 
haplogroup J. The presence of two haplogroups in such high numbers in Europe 
provides evidence for population migration events. The same study has shown a 
significant correlation between Y chromosome diversity and geography but not 
language. However, the effects of genetic drift and natural selection acting on the Y 
chromosome cannot be excluded (Rosser et al. 2000). This study included Scottish, 
Cornish and East Anglian populations and showed that haplogroups P*, R la  and BR* 
made up the majority of the Y chromosomes in the UK. However, the number of Y 
chromosome markers used was not enough to provide a clear picture of the Y 
chromosome haplogroup distribution in the United Kingdom (Rosser et al. 2000).
A study focusing only on the British Isles used a combination of Y chromosome SNPs 
and microsatellites covering approximately the same haplogroups as before (Wilson et 
al. 2001). Populations from Wales, Ireland and Orkney were chosen and compared. 
They were also compared with a Scandinavian population, representing the Viking 
contribution, a Basque population, which is considered to be descended from the 
Palaeolithic inhabitants of Europe and an Asian population from the Near East. This 
study found that the Irish and the Welsh populations were not significantly 
differentiated. The Scottish populations showed an intermediate pattern between 
Celtic and Scandinavian populations. In addition, the similarity between Celtic and
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Basque populations was striking. According to the authors, this supports the notion of 
a Palaeolithic component in the British Isles and it indicates that there has been no 
effect on the paternal genetic component during the Neolithic and Iron Age 
transitions. On the other hand, the Scandinavian invasion has left its signature on the 
Y chromosomes of the inhabitants of the British Isles (Wilson et al. 2001).
Evidence for substantial Anglo-Saxon male migration into Central England but not 
North Wales was provided by a study that genotyped Y chromosome SNPs and 
microsatellites in samples collected along an east-west transect from East Anglia to 
North Wales (Weale et al. 2002).
A very detailed approach was followed by Capelli et al. (2003) with typing of 11 Y 
chromosome SNPs and six microsatellites in 1,772 men from 25 small urban locations 
of the British Isles. The most frequent haplogroups in their group were I(xllb2), 
R(xRlal) and Rial .  These authors argued that the Anglo-Saxon contribution to the 
male genetic heritage of the British Isles is small and more obvious in the Central- 
Eastern part of England. They also showed evidence of heterogeneity in all 
populations (Capelli et al. 2003).
Although some of these studies have been very detailed and their contribution was 
valuable in terms of population genetics, they have failed to provide a consensus of Y 
chromosome markers and the haplogroups they define for use in medical genetic 
studies. The key issue in medical genetic studies is that sample collection depends 
highly on availability of affected individuals. For this reason, the Y chromosome 
markers need to be representative of the British population as whole. A high degree of 
haplogroup breakdown would be undesirable because it would be useful for 
identifying distinct populations within the United Kingdom but not for comparing 
individuals that do not necessarily come from the same region of the country.
4.5 Y chromosome associations with phenotypes
The fundamental property of absence of recombination in the MSY is important for 
studies seeking Y-linked phenotypes. The MSY essentially behaves as a chromosomal 
block in complete linkage disequilibrium. With that in mind, any functional
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polymorphism predisposing to a disease or affecting any phenotype would be 
correlated with the SNPs that define the haplogroups. In order to perform a Y 
chromosome association study, it is important to choose a well-matched control 
sample with the same geographical origin as the group of patients. The next thing 
needed is a set of SNPs defining the most frequent haplogroups in the population in 
question. By comparing the frequencies of haplogroups in the group of patients and 
healthy controls, it can become apparent whether individuals belonging to certain Y 
chromosome haplogroups are more susceptible than others to develop a disease or 
have a specific phenotypic manifestation. There can be two possible explanations for 
this association. One of them is that the functional polymorphism responsible for this 
association has appeared before the SNPs that define the associated haplogroup. Thus, 
all Y chromosomes belonging to these haplogroup would carry the causal variant. 
However, it is most likely that the functional polymorphism has appeared against a 
specific haplogroup background and for this reason, only certain individuals within 
this haplogroup will have it (Krausz et al. 2004).
Unfortunately, some of the associations with Y chromosome haplogroups that have 
been reported are down to differences in geography or language. It should also be 
noted that due to high geographical differentiation of Y chromosome haplogroups the 
absence or presence of association in one population cannot be generalised in other 
populations without appropriate replication. A summary of the association studies 
performed on the Y chromosome so far can be seen at Table 4-1.
Table 4-1. Y chromosome association studies
Phenotype Population
No of 
Y chr 
SNPs
Use of other 
Y chr 
markers
Result Reference
XX maleness with 
infertility European 2
1
microsatellite
Association
with
haplogroup
Y*(xP)
(Jobling et 
al. 1998)
Reduced sperm 
count\azoospermia Japanese 3 -
Association 
with 
haplogroup D
(Kuroki et 
al. 1999)
Reduced sperm 
count\azoospermia Japanese 10
5
microsatellites No association
(Carvalho 
et al. 2003)
Infertility Italian 8 - No association (Previdere et al. 1999)
Reduced sperm 
count Danish 3 -
Association
with
haplogroup
K(xP)
(Krausz et 
al. 2001)
Testicular cancer English 7 6 No association
(Quintana- 
Murci et al. 
2003)
Prostate cancer Japanese 0 1microsatellite
Association 
with one 
microsatellite 
allele
(Ewis et al. 
2002)
Prostate cancer 4 ethnic groups 118 -
Association 
with a 
haplogroup 
found only in 
Japanese 
populations
(Paracchini 
et al. 2003)
Hypertension Australian - Hindlll Association with Hindlll(-)
(Ellis et al. 
2000)
Hypertension PolishScottish - Hindlll
Association 
with HindIII(+)
(Charchar 
et al. 2002)
Hypertension European 5 2microsatellites No association
(Rodriguez 
et al. 2005)
Autism
Norwegian
Swedish
French
10 - No association (Jamain et al. 2002)
Alcohol
dependence Finnish 1 7
Association 
with 3 Y chr 
clades
(Kittles et 
al. 1999)
Aggressive
behaviour Pakistani 49 -
Association of 
haplogroups R2 
and Rial with 
increased 
aggression
(Shah et al. 
2009)
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4.5.1 Reproductive medicine
The Y chromosome has been an obvious candidate for reproductive phenotypes in 
males, since it harbours the sex-determining gene, SRY, and genes affecting 
spermatogenesis.
Sex-reversed XX infertile males can appear because of ectopic recombination 
between genes PRKX (Protein Kinase X-linked) and PRKY (Protein Kinase Y-linked) 
resulting in the translocation of extra Y-chromosomal material, including SRY, to the 
X chromosome. Men with this translocation lack the Y chromosome genes 
responsible for the formation of active sperm and they are infertile. By studying the 
translocated part of the Y chromosome and paternal Y chromosomes, a frequency of 
90% of haplogroup Y*(xP) has been found in individuals with this condition, while it 
only represents one third of the population they come from. This should be considered 
as a true association because cases and controls were well-matched and also because 
there is a plausible mechanism explaining this association. The control population not 
belonging to the risk haplogroup carries an inversion protecting them against this 
particular translocation (Jobling et al. 1998)
A Japanese population has been used in order to test for association of Y chromosome 
haplogroups with reduced sperm counts and azoospermia. A haplogroup specific to 
East Asian populations has been found to be associated with reduced sperm count and 
increased risk of azoospermia (Kuroki et al. 1999). However, another study of men of 
Japanese origin failed to replicate the association (Carvalho et al. 2003). It is 
important to note that the associated haplogroup varies geographically even within 
Japan adding another layer of complexity.
A study of Italian men with idiopathic infertility proves just how important it is to 
take into account the geographical differentiation of the Y chromosome. While an 
association was found between a certain Y chromosome haplogroup and idiopathic 
infertility, the control sample was later subdivided to better reflect the cases who all 
came from Central Italy and the association disappeared (Previdere et al. 1999).
Reduced sperm count was also associated with a Y chromosome haplogroup in a 
group of Danish men. The rarity of this haplogroup in the normal Danish population 
and the reduced reproductive fitness poses the possibility of negative selection acting
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on this haplogroup. The authors hypothesise that structural rearrangements in this 
haplogroup affect the normal expression of a gene involved in spermatogenesis 
(Krausz et al. 2001).
4.5.2 Male cancers
Deletions and structural changes on the Y chromosome have been associated with 
various types of cancers suggesting that the Y chromosome harbours tumour 
suppressor genes or oncogenes (Center et al. 1993; Hunter et al. 1993; Sauter et al. 
1995). It has also been suggested that poor spermatogenic function is present in 
patients with testicular cancer a long time before diagnosis suggesting that there is a 
general testicular dysfunction. Thus, it is likely that a Y chromosome variant is 
involved (Boisen et al. 2001).
The role of Y chromosome haplogroups in testicular cancer has only been 
investigated in an English population without producing significant results. However, 
the geographical differentiation of the Y chromosome and the multifactorial nature of 
cancer do not exclude its involvement in another population (Quintana-Murci et al. 
2003).
Prostate cancer was investigated in a Japanese population using one microsatellite 
marker and a significant association was reported with one of the alleles (Ewis et al. 
2002). Although the results are not very convincing, since they are based on one 
microsatellite with high mutation rate, they are supported by a multi-ethnic cohort of 
four populations. An increased frequency of patients suffering from prostate cancer in 
one haplogroup was found only in the Japanese population (Paracchini et al. 2003).
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4.5.3 Hypertension and lipid levels
The Y chromosome has been studied in relation to phenotypes showing higher 
incidence in males, since it harbours a chromosomal region, MSY, unique to men.
Hypertension is such a phenotype with males having significantly increased blood 
pressure compared with pre-menopausal women. Consequently, males are at 
increased risk of cardiovascular disease.
The role of the Y chromosome in increased blood pressure is supported by both 
animal and human studies. The male Spontaneously Hypertensive Rat (SHR) and the 
male Stroke-Prone Spontaneously Hypertensive rat (SHRSP) show increased blood 
pressure compared to females (Ely et al. 1997). The Y chromosome of these strains 
has been found to be responsible for the elevated blood pressure after the breeding of 
strains of rats with a hypertensive Y chromosome on a normotensive background. 
However, blood pressure was not as high as for the SHR strain indicating that the Y 
chromosome and autosomal genes interact to produce this phenotype (Negrin et al.
2001). It is intriguing that the SHR rat is also one of the best animal models of ADHD 
(Russell 2007).
In humans, paternal hypertension has been found to increase blood pressure in male 
offspring (Uehara et al. 1998). The first study of the Y chromosome and hypertension 
was performed in a sample of Australian men and used the Hindlll centromeric 
alphoid satellite polymorphism. This polymorphism is present in two allelic forms 
HindIII(+) and Hindlll(-). An association of Hindlll(-) and increased blood pressure 
was found (Ellis et al. 2000). The same polymorphism was genotyped in two more 
samples, one of Polish and one of Scottish ancestry but the opposite allele HindIII(+) 
was associated with increased blood pressure (Charchar et al. 2002). This presence of 
association in three different populations points to an involvement of the Y 
chromosome in regulation of blood pressure, although not necessarily of this 
polymorphism. The use of haplogroup analysis could be more fruitful in this case.
This approach has been followed in the most comprehensive study of the Y 
chromosome and blood pressure. By genotyping five SNPs and two microsatellites in 
2,743 Caucasian men, Rodriguez et al. (2005) failed to replicate the association of Y 
chromosome haplogroups and elevated blood pressure.
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Similar to animal studies, there is evidence from humans that the Y chromosome 
interacts with autosomal loci. An epistatic interaction between the Hindlll 
polymorphism and the aldosterone synthase gene (CYP11B2) to increase blood 
pressure was demonstrated in the Scottish sample, although it was not replicated in a 
study of three white populations (Charchar et al. 2002).
Another interesting phenotype of the SHR rat is the high levels of triglycerides and 
high-density lipoprotein (HDL) compared with normotensive rats (Kren et al. 2001). 
In humans, lipid levels exhibit ethnic differences (Cappuccio 1997), which cannot 
totally be attributed to diet, and they indicate a possible involvement of certain Y 
chromosome haplogroups. The Hindlll(-) allele has been implicated in increased lipid 
levels in a Polish sample and the association was independent of testosterone levels 
and alcohol consumption (Charchar et al. 2004). It is also interesting that in men of 
African origin a Y chromosome haplogroup is linked to a favourable lipoprotein 
pattern, thus reducing their susceptibility to cardiovascular disease (Russo et al.
2008).
4.5.4 Psychiatric phenotypes
Psychiatric disorders, such as autism, ADHD, schizophrenia and alcohol dependence 
as well as behavioural traits, such as aggression, have higher incidence in males.
For this reason, the role of Y chromosome haplogroups has been investigated in some 
of these phenotypes.
An association study genotyping 10 Y chromosome SNPs in individuals with autism 
did not result in a positive association. However, it should be pointed out that the 
sample used was not homogeneous (Jamain et al. 2002). In contrast, Kittles et al. 
(1999) used only one Y chromosome SNP and seven microsatellite markers to 
genotype a sample of Finnish men with alcohol dependence. They found that three Y 
chromosome clades were more frequent amongst the individuals with alcohol 
dependence than in controls. They also tested for an association with antisocial 
personality disorder comorbid with alcohol dependence but they did not find any 
difference between cases and controls. Nevertheless, their use of microsatellites, 
which have a high mutation and recurrence rate, is not ideal and it is striking that their
results indicate three different Y chromosome mutations predisposing to alcohol 
dependence in Finland (Kittles et al. 1999).
Finally, the role of the Y chromosome in aggressive behaviour has been studied in a 
sample of Pakistani men. There was no difference in the mean scores of aggression 
across the five different haplogroups captured in the study but effect-size comparisons 
showed an association of two haplogroups with lower scores of aggression (Shah et 
al. 2009).
4.6 Y chromosome and brain function
It is well established that sex differences exist in cognition and behaviour in both 
humans and animals. What we do not know yet is how much of this differentiation is 
a result of differential hormonal environment and how much is a direct effect of sex 
chromosome genes. The Y chromosome, specifically, contains genes that are only 
expressed by males making it a suspect for contribution to sex differences.
4.6.1 Animal studies
In mammals it is common for male embryos to develop faster than female embryos 
before the differentiation of the gonads (Erickson 1997). A microarray analysis of 
foetal mouse brain has shown that more than fifty genes were differentially expressed 
in foetal brains of male and female mice. It is remarkable that this analysis was 
performed at 10.5 days post coitum (dpc) before gonadal hormones have started to be 
produced (Dewing et al. 2003).
Sex chromosome genes are expressed in the brain. A large number of X chromosome 
genes have been implicated in mental retardation (Skuse 2005). At least ten Y 
chromosome genes are also expressed in the brain (Xu et al. 2002) with genes like 
SRY, ZFY and protocadherin expressed in brain of both human and mouse.
Several studies in mice have implicated the Y chromosome in aggression (Guillot et 
al. 1995; Maxson 1996; Maxson et al. 1979), the distribution of hippocampal mossy 
fibres (Hensbroek et al. 1995), levels of dopamine (Sluyter et al. 1995) and serotonin
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in the brain (Tordjman et al. 1995) but with uncertainty about the possible 
involvement of androgens.
A method that can be used in order to test how much difference can be attributed to 
sex chromosomes is to use animals of the same sex but with different genetic 
background. Male mice differing only in their Y chromosome have different levels of 
aggression (Guillot et al. 1995). However, this effect could be mediated by increased 
levels of testosterone. Comparisons between mice with and without the SHR 
(Spontaneously Hyperactive Rat) Y chromosome against the same genetic 
background showed that the SHR Y chromosome was associated with increased 
aggression due to increased levels of testosterone and decreased levels of serotonin in 
the brains of mice with the SHR Y chromosome (Toot et al. 2004).
4.6.2 Four core genotypes model
An interesting animal model has been used to dissociate the effect of the Y 
chromosome from hormonal effects. The four core genotypes mice model utilises the 
Sry gene and its unique property of initialising male sex differentiation. The SRY is 
deleted from the Y chromosome (Y*) resulting in XY' female mice. When an Sry 
transgene is inserted in an autosome, mice develop to males irrespective of their sex 
chromosome complement. With appropriate crossings it is possible to have four 
genotypes: XX females, XY‘ females, XXSry males and XY'Sry  males (De Vries et 
al. 2002). By comparing XX and XY female mice with XY and XX male mice it 
became possible to evaluate the effect of sex chromosomes independent of the 
hormonal milieu. A large number of sexually dimorphic neural and behavioural 
phenotypes have been assessed to date. Some of the phenotypes correlated with the 
presence of testes or ovaries indicating a strong hormonal effect. However, sex 
chromosome complement had an effect on aggression and parental behaviour that was 
not related to the hormonal milieu (Gatewood et al. 2006). In addition, both male and 
female mice with a Y chromosome were more masculine than those without it in 
terms of their density of vasopressin-immunoreactive fibres in the lateral septum (De 
Vries et al. 2002).
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4.6.3 Y chromosome abnormalities in humans
Case or small-scale studies have suggested a role of Y chromosome genes in some 
neuropsychiatric disorders. For example, individuals with 47,XYY syndrome appear 
to be at increased risk of developing antisocial behaviour (Gotz et al. 1999), as well as 
being at risk of developing bipolar disorder and schizophrenia (Mors et al. 2001), 
which could be due to MSY gene over-expression. A potential role of Y-linked genes 
in the pathogenesis of schizophrenia is also supported by the observation of an 
isodicentric Y chromosome in a patient with schizophrenia (Yoshitsugu et al. 2003).
A case study has implicated Y-linked genes in ADHD susceptibility; in this case, the 
affected boy possessed a rare deletion of Yq with duplication of Yp (Mulligan et al. 
2008). Interestingly, the duplicated region included the SRY  gene, suggesting that 
overdosage of this specific gene may be responsible (either directly or indirectly) for 
the observed behavioural phenotype. One important caveat with studies such as these 
is that the co-occurrence of a particular cytogenetic mutation and a particular 
neuropsychiatric manifestation does not necessarily imply that the two are linked but 
they can constitute an important starting point for studying certain regions in detail.
4.7 SRY  (Sex-determining region of chromosome Y)
SRY is probably one of the most interesting Y chromosome genes as it is the gene 
responsible for male sex differentiation. It was first discovered in 1990 by Sinclair in 
XX males by analysis of fragments of the Y chromosome that had translocated in the 
X chromosome of these individuals. It was then proved that SRY is the TDF (Testis 
Determining Factor) gene on the Y chromosome that researchers were looking for 
(Sinclair et al. 1990). Its presence or absence determines the sex of an individual 
irrespective of Y chromosome complement.
The human SRY is a single-copy gene in the MSY region of the Y chromosome and 
belongs to the X-degenerate class of sequences (Skaletsky et al. 2003). In humans it is 
an intronless gene which spans 897 bp. It codes for a protein of 204 aminoacids and 
molecular mass of 24 kD. The protein can be divided into three domains. The HMG 
(High-Mobility Group) domain is in the middle of the gene and is conserved in 
rodents and sheep among other species. It is responsible for binding and bending
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DNA. The other two domains, the C-terminal and N-terminal domains are not 
conserved. The mouse SRY protein has a long glutamine-rich domain, which is absent 
from the human SRY (Harley et al. 2003).
In mice and humans, Sry is a single copy gene; in contrast, in rats and certain other 
rodent species multiple copies of the Sry gene have been reported on the Y 
chromosome (Turner et al. 2007).
4.7.1 SR Y transcription regulation
The promoter of SRY contains a number of regulatory elements, although their 
position is not conserved across species. In addition, multiple transcription initiation 
sites have been detected in human and mice (Clepet et al. 1993). Transcription factor 
binding sites have been found within the promoter of the SRY gene. Among them 
there is a binding site for SF1 (Steroidogenic Factor 1), a protein that could be 
responsible for the activation of SRY. SF1 is a nuclear hormone receptor. When 
knocked down in mice, it causes the arrest of the developing gonad (Luo et al. 1995). 
Furthermore, an SF1 mutation has been found in a sex-reversed individual (Luo et al. 
1995). However, the most likely scenario is that SRY transcription regulation requires 
coordinated action of transcription factors like SF1, SP1 (Specificity Protein 1) and 
WT1 (Wilms Tumour 1). Other genes that are potential candidates for activating SRY 
are IR (Insulin Receptor), IRR (Insulin-Related Receptor), IGF1R (Insulin-like 
Growth Factor 1 Receptor) and FOG2 (GATA4-Friend of gata2) (Sekido and Lovell- 
Badge 2009) (Figure 4-5) . DAX1 (dosage-sensitive sex-reversal adrenal hyperplasia 
congenital X chromosome 1) is hypothesised to be an antagonist of SF1 by recruiting 
a nuclear corepressor (Harley et al. 2003).
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SRY a n ta g o n is ts :  
DAX1
T ranscription
factors:
SF1
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G e n e s  activatin g  SRY:
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F 0G 2
IRR
Figure 4-5. Diagram summarising the genes involved in SRY transcription regulation (SF1: 
Steroidogenic Factor 1; SP1: Specificity Protein 1; WT1: Wilms Tumour 1; IR: Insulin Receptor; 
IRR: Insulin-Related Receptor; IGF1R: Insulin-like Growth Factor 1 Receptor; FOG2: GATA4- 
Friend of gata2; DAX1: Dosage-sensitive sex-reversal adrenal hyperplasia congenital X
chromosome 1)
4.7.2 SRY expression
Although SRY  is chiefly expressed in the testes, it is also expressed to some extent in 
other tissues including heart, liver and kidney, and certain brain regions. For this 
reason, besides influencing male-specific traits indirectly, it is possible that it 
influences neurodevelopment and brain function in a direct manner. In humans, SRY 
expression has been described in the hypothalamus, frontal and temporal cortex 
(Mayer et al. 1998). In adult rodents, the gene is expressed in the hypothalamus and 
midbrain (notably the substantia nigra and the ventral tegmental area) (Dewing et al.
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2006; Lahr et al. 1995). However, the expression of SRY in brain is developmentally 
regulated. Circular and probably untranslatable SRY mRNA was found in mouse 
brain prenatally. This changed to linear and likely translatable transcripts postnatally 
(Mayer et al. 2000). The transition between expressed forms is presumably due to a 
developmental switch in promoter usage, but the evolutionary and functional 
significance remains to be investigated. Moreover, it has not been shown whether 
such a switch is evident in humans. Although SRY transcripts have been found, it has 
been very difficult to prove they are translated due to very low levels of SRY protein 
produced even in testes where SRY function is unquestionable. At the moment, there 
is only one report of SRY protein detection by immunohistochemistry in human 
embryonic testes (Poulat et al. 1995) and none in other species or tissue.
4.8 The main function of SRY is the initiation of male sex 
development
4.8.1 SRY mutations and the phenotype they cause
Since SRY is responsible for the initiation of testis formation, it is very difficult to 
disentangle its direct effects from the effects of testosterone. In humans, research is 
restricted to studying individuals with SRY mutations. Most SRY mutations have been 
found within the HMG box and they cause sex reversal in XY individuals. They 
usually present as normal females with female internal and external genitalia but they 
suffer from complete gonadal dysgenesis and ovarian dysfunction (Hawkins et al.
1992). Since gonadal dysgenesis is associated with high risk of gonadal tumours, their 
ovaries are usually preventatively removed. Their psychosexual behaviour is normal 
and some of them have managed to become mothers with the use of IVF treatment 
(McCarty et al. 2006). Most of the SRY mutations are de novo and they tend to be 
missense mutations clustering in the HMG box highlighting its role in the function of 
the gene. It is intriguing that familial SRY mutations have been found in fathers of XY 
sex-reversed individuals indicating that some SRY mutations are not completely 
dominant (Harley et al. 2003).
Although SRY can be found in most cases of XX males, SRY mutations are only 
responsible for 15% of cases of XY females (Harley et al. 2003). This means that the
103
presence of SRY commits sexual differentiation to the male pathway but it is not 
enough to complete the process. Sexual differentiation requires a coordinated network 
of genes, where their interactions and timing is essential. Unfortunately, we are still a 
long way of fully understanding this fundamental process.
4.8.2 SRY and male sex differentiation
Sexual differentiation can be seen just after conception in the reproductively bipotent 
embryo with male embryos having more cells and being more metabolically active 
than female embryos (Mittwoch 2000). The undifferentiated genital ridge is formed 
from the surfaces of the mesonephros under the influence of transcription factors, 
such as WT1 and SF1. Since SRY is a transcription factor, it has been proposed that it 
either represses a repressor of male development or that it activates a gene responsible 
for male development (Sekido and Lovell-Badge 2009). The finding that SRY 
expression must reach a threshold at an appropriate time to initiate male development 
is in line with a role in initiation but not maintenance of male development.
There is accumulating evidence that the direct target gene of SRY is SOX9 (SRY- 
related HMG Box 9). This belongs to a gene family along with SRY and more than 20 
genes that have a HMG domain. It is located on chromosome 17 with mutations 
causing campomelic dysplasia, a form of severe bone malformation. All patients with 
campomelic dysplasia also suffer from sex reversal highlighting the vital role of SOX9 
in sexual development (Harley et al. 2003). SOX9 expression is upregulated 
immediately after the expression of SRY while it is decreased in the ovary and it has 
been found that all S7?7-expressing cells also express SOX9. Transgenic XX mice 
ectopically expressing SOX9 under the Wtl promoter developed to males showing that 
the only function of SRY  during sexual development is the activation of SOX9 (Vidal 
et al. 2001).
SRY is downregulated after testis determination. In mouse the genital ridge forms at 
10 dpc (days post coitum) and SRY  is detected in it from 10.5 dpc but by 12.5 dpc its 
levels are very low. In humans, the genital ridge forms at 33 days gestation and SRY is 
detected from 41 days, peaking at 44 days gestation. Sertoli cells continue to express
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SRY (although at lower levels) even after testis formation suggesting a possible role of 
SRY in spermatogenesis.
The target cells for SOX9 are the pre-Sertoli cells within the Wolffian ducts. SOX9 
upregulation triggers them to develop to Sertoli cells, which in turn produce AMH 
(Anti-Mullerian hormone). This causes the regression of the Mullerian ducts and 
migration of the cells that will develop to Leydig cells, the main producers of 
testosterone. Primordial germ cells migrate into the testicular cords and enter meiotic 
arrest (Yao et al. 2002). In the absence of SRY, DAX1 inhibits expression of SOX9 and 
SF1. Although female sexual development has not been studied as extensively as 
male, DAX1 is considered an essential gene, since its duplication has been found to 
result in female development even in the presence of SRY (Swain et al. 1998).
4.9 SRY involvement in brain function and behaviour
The fact that SRY is expressed in the brain has led to attempts to link it with specific 
brain functions and behaviours. It is very interesting that SRY expression has been 
found in catecholaminergic regions (Milsted et al. 2004). Catecholamines, such as 
dopamine have been implicated in a number of neuropsychiatric disorders with higher 
male prevalence, such as ADHD, Parkinson’s disease and schizophrenia. They are 
also part of the sympathetic nervous system, thus affecting cardiovascular functions 
(cardiovascular disease is also more prevalent in males).
SRY has been found to be able to increase reporter gene activity under the control of 
the tyrosine hydroxylase (TH) promoter (Milsted et al. 2004). TH is the rate-limiting 
enzyme in dopamine synthesis and it will be discussed in a following chapter. Dewing 
et al. (2006) found that Sry is expressed in the substantia nigra of the adult mouse 
brain in TH-expressing neurons. Downregulation of Sry using antisense 
oligonucleotides caused a decrease in TH expression. This led to motor deficits in 
male rats providing robust evidence for a direct effect of Sry on the brain without 
involvement of gonadal hormones. The authors came up with the interesting 
hypothesis that SRY is the factor responsible for increasing the number of TH- 
expressing neurons in males. Thus, it is compensating for the lack of oestrogen in 
males, which in females acts to increase TH-expressing neurons (Dewing et al. 2006).
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The presence of SRY exclusively in men and its involvement in dopaminergic function 
regulation suggests that it can be an interesting candidate for increasing male 
susceptibility to certain neuropsychiatric disorders involving dysregulation of 
dopaminergic function, such as ADHD, schizophrenia and Parkinson’s disease.
4.10 Other Y chromosome genes expressed in brain
As mentioned before, Y chromosome gene expression is not restricted to the gonads. 
Apart from Sry another six genes from the MSY region are expressed in mouse brain 
(Xu and Disteche 2006). Three of them ( Smcy/Jaridlc, Uty and Eif2s3y), although 
they have an X chromosome homologue, escape X chromosome inactivation 
indicating that there is a dosage difference between males and females in their 
expression. It is interesting that Smcy/Jaridlc and Uty are expressed in human brain 
as well.
ZFY is another MSY gene which is expressed in the hypothalamus, frontal and 
temporal cortex of adult human brain (Mayer et al. 1998). This gene does not have a 
mouse counterpart and its function is poorly understood apart from the fact that it 
might be involved in male sex differentiation.
Protocadherin 11Y (PCDH11Y) is another Y chromosome gene which has received a 
lot of interest regarding its role in neurodevelopment. This gene and its counterpart on 
the X chromosome are located within a hominid-specific region of the sex 
chromosomes and encode members of the protocadherin superfamily responsible for 
cell-cell interactions during development of the central nervous system (Blanco et al, 
2000). The fact that the PCDH11Y gene is expressed in males in a highly regulated 
and spatiotemporally dynamic manner (Blanco et al. 2000) and is involved in synapse 
formation and neuronal path finding in the brain, processes which go awry in a 
number of common male-biased mental conditions (Blanco et al. 2000), make it an 
attractive candidate for involvement in the male excess of neuropsychiatric disorders. 
Finally, as mentioned previously, PCDH11Y is absent in non-human primates such as 
chimpanzees and gorillas (Wilson et al. 2006); both PCDH11Y and PCDH11YX were 
created by duplicative translocation that occurred close to chimpanzee-human 
bifurcation 6 million years ago. Moreover, the gene has shown accelerated sequence
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change in the hominid lineage (Wilson et al. 2006). For this reason, it has been 
proposed, most vociferously by Timothy Crow and colleagues, that aberrant 
expression of the protein encoded by PCDH11Y could predispose males to disorders 
of human-specific functions (Crow 2002), notably schizophrenia and autism (Hill et 
al. 2008). However, candidate gene studies examining possible association between 
SNPs within PCDH11Y and a number of neuropsychiatric disorders have failed to 
find evidence for a link to date (Giouzeli et al. 2004). Alternatively, it may be that it is 
the expression pattern of the gene (which may be modulated epigenetically via 
environmental influences) which is more important in modulating its effect on male 
disease vulnerability than its sequence.
Another candidate gene that could potentially influence neuropsychiatric phenotypes 
is NLGN4Y (neuroligin 4 Y-linked), the Y homologue of NLGN4X. Neuroligin genes 
encode cell adhesion molecules involved in the process of synaptogenesis (Ylisaukko- 
oja et al. 2005). Early findings that mutations in NLGN4X were present in families 
with mental retardation and autism spectrum disorders suggested a possible causal 
link between the disorders and the gene mutation (Jamain et al. 2003; Laumonnier et 
al. 2004). The results of subsequent studies have suggested that, if mutations in 
NLGN4X are pathogenic, they are likely to be rare, and are not likely to explain the 
majority of cases of autism (e.g. (Gauthier et al. 2005; Talebizadeh et al. 2004; 
Vincent et al. 2004).
The Y chromosome, the smallest chromosome in the human genome, defines the sex 
of an individual. With its unique characteristics of absence of recombination and high 
geographical differentiation poses difficulties when studying. However, the Y 
Chromosome Consortium efforts have made it easier for Y chromosome to be 
included in association studies. Since the Y chromosome is only found in men, it 
could be a candidate for involvement in disorders with a male preponderance.
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In summary, psychiatric disorders exhibit sex differences in prevalence, severity, 
manifestation and age of onset. ADHD is a highly heritable childhood-onset 
neurodevelopmental disorder with a male prevalence. Schizophrenia is also heritable 
with males having an earlier age of onset and increased disease severity. Both ADHD 
and schizophrenia are complex disorders with common variants of small effect likely 
to account for a large amount of the genetic component of the disorder. Rare variants 
also appear to be important. According to a study by the International Schizophrenia 
Consortium it is likely that thousands of common alleles of very small effect 
contribute to the risk of schizophrenia (The International Schizophrenia Consortium 
2009). Although genome-wide association studies in schizophrenia have shown 
evidence of association with several common variants, a substantial genetic 
component remains to be discovered. Due to the small effect size of common variants, 
genome-wide association studies require large samples in order to discover some of 
the common variants that are scattered across the genome (Wang et al. 2005). In 
addition, CNV studies have shown that rare variants also increase risk for psychiatric 
disorders. Although the effect sizes of large, rare variants are considerably larger than 
common variants, each one is relevant for only a very small percentage of patients 
(Sebat et al. 2009). Rare CNVs have been shown to be implicated in both 
schizophrenia (Kirov et al. 2009; The International Schizophrenia Consortium 2008) 
and ADHD (Elia et al. 2009; Lesch et al.).
However, to date none of the studies has included rare or common variants on the Y 
chromosome. The Y chromosome is only found in males and it possesses a male- 
specific region, which does not recombine with the X chromosome. Y chromosome 
variation in animals has been associated with aggression (Guillot et al. 1995), parental 
behaviour (Gatewood et al. 2006) and alterations in the levels of dopamine and 
serotonin in the brain (Tordjman et al. 1995). In humans, common Y chromosome 
variation is captured using Y chromosome haplogroups. The Y chromosome 
Consortium has compiled a catalogue of Y chromosome SNPs that have been 
validated (The Y Chromosome Consortium 2002). Common variants on the Y 
chromosome have been studied in relation to infertility and male cancers as well as 
disorders that show a male prevalence, such as hypertension, autism, alcohol 
dependence and aggression (see section 4.4 for more information). Common Y
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chromosome variation has not been studied extensively in psychiatric disorders, 
although some of these show a clear male excess. In addition, in cases where Y 
chromosome variation has been studied in psychiatric disorders, the populations 
studied were not ethnically homogeneous, which is of great importance for Y 
chromosome variation due to its high geographical distribution. Genome-wide 
association studies have only recently started to include Y chromosome markers, thus 
the Y chromosome has escaped being studied in this setting. Although the Y 
chromosome Consortium simplified studying common variation on the Y 
chromosome, this is not the same for the study of rare variants on the Y chromosome, 
which is still in its infancy.
In this project, the role of common Y chromosome variants in ADHD and 
schizophrenia was investigated after selecting Y chromosome haplogroups 
appropriate for UK populations and performing two case-control association studies, 
one for ADHD and one for schizophrenia using cases and controls of UK origin.
Since common variants can have subtle effects on the phenotype of the disorders 
rather than main effects, a possible modifying role of Y chromosome variation on 
ADHD and schizophrenia was investigated after selecting sexually dimorphic 
phenotypic measures for each disorder. A possible interaction of Y chromosome with 
tyrosine hydroxylase was investigated because of evidence in animals that the SRY 
gene on the Y chromosome interacts with tyrosine hydroxylase, which is the rate- 
limiting enzyme in dopamine metabolism.
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Chapter 5 Hypotheses and aims of the project
The aim of this project was to investigate the role of Y chromosome variation in sex 
differences in ADHD and schizophrenia and this was achieved by testing the 
following hypotheses:
1. Testing for a direct effect of Y chromosome variants on ADHD and 
schizophrenia. It was hypothesised that the Y chromosome variants can 
increase risk to ADHD and schizophrenia and this was tested by performing 
two case-control association studies, one for ADHD and one for 
schizophrenia.
2. Testing for a modifying effect of Y chromosome variants on the phenotype of 
ADHD and schizophrenia. It was hypothesised that Y chromosome variation 
can have a modifying effect on the disorders by influencing clinical 
presentation or cognitive ability. This hypothesis was tested by selecting 
sexually dimorphic clinical parameters and cognitive measures for each 
disorder and testing them for association with the Y chromosome variants.
3. Testing for an indirect effect of Y chromosome variants on ADHD and 
schizophrenia. It was hypothesised that Y chromosome variation can interact 
with the gene encoding Tyrosine Hydroxylase, which is the rate-limiting 
enzyme in dopamine metabolism, and increase risk to the disorders. Evidence 
for interaction of Tyrosine Hydroxylase and SRY (Sex Determining Region on 
chromosome Y) has been found in male rats (Dewing 2006). This hypothesis 
was tested by performing two case-control association studies, one for ADHD 
and one for schizophrenia using Tyrosine Hydroxylase tag SNPs. Then, these 
SNPs were tested for a sex-specific effect on the disorders and, finally, 
Tyrosine Hydroxylase SNPs were tested for interaction with already 
genotyped Y chromosome SNPs.
4. Investigating the role of Y chromosome variation on cognitive function in the 
general population. Due to the fact that all tests for a modifying effect would 
be performed within the sample of patients without the use of a control
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sample, we were interested in establishing whether the Y chromosome had a 
disease-specific effect or its effect could be generalised in the general 
population as well. This hypothesis was tested by genotyping two Y 
chromosome SNPs in male individuals from the AVON Longitudinal Study of 
Parents and Children (ALSPAC). The Y chromosome variants were then 
tested for association with cognitive ability in all the individuals from 
ALSPAC and in a subset of the sample with individuals who had an ADHD 
diagnosis.
I l l
Chapter 6 Materials and Methods
6.1 DNA samples
The DNA samples used in this study came from a sample of 331 patients with ADHD, 
a sample of 487 patients with schizophrenia and 1,076 individuals from the 1958 UK 
Birth Cohort. The characteristics of all samples are described in Materials and 
Methods Sections of following Results Chapters.
6.1.1 DNA extraction and storage
High molecular weight DNA was extracted from either lymphocytes in venous whole 
blood or from buccal cavity epithelial cells via saline mouthwash. The DNA 
preparation consisted of phenol/chloroform DNA extraction followed by ethanol 
precipitation according to routine procedures. All DNA samples used in this study 
were extracted by other members of the Department of Psychological Medicine 
research group. All stock and diluted samples were stored at -20°C in water or TE 
buffer.
6.1.2 DNA quantification and assessment
Extracted DNA was first quantified using a spectrophotometer (Beckmann 
Instruments, Fullerton, California, USA). Each DNA sample was diluted to a 5% 
solution in sterile water (5pi DNA sample in 95pl of water). The absorbance (A) of 
UV light at 260nm and 280nm wavelengths (A.) was measured, and DNA 
concentrations were calculated on the assumption that an A260nm value of 1 was 
equivalent to 50pg of DNA. A ratio of A260nm to A280nm above a value of 1.8 
indicated a suitable level of clean DNA and the absence of contaminating protein.
Samples were more accurately quantified using a Fluoroskan Ascent fluorometer 
(Thermo Labsystems, Altrincham, UK) and the PicoGreen doubled-stranded DNA 
quantification kit (Invitrogen, Oregon, USA). The PicoGreen reagent specifically
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interacts with double-stranded DNA and is therefore a more accurate quantifying 
method than spectrometry. The samples were first diluted to less than 50ng/pl using 
spectrometer readings. Next the samples were diluted 1/100 with IX TBE in a white 
96 well cliniplate (Thermo Labsystems, Altrincham, UK). The PicoGreen working 
solution is prepared by adding 5pl of PicoGreen to 995pl of IX TE.
In order to measure the DNA concentration, lOOpl of the PicoGreen working dilution 
was dispensed into each diluted sample. The fluorometer measures the concentration 
of the sample using an UV excitation wavelength of 485nm and an emission 
wavelength of 538nm. A standard curve is then used to calculate the concentration of 
DNA for each sample. These values are adjusted so that each sample is at a 
concentration of 4ng/ml ± 0.5 pg /ml.
6.2 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) is an enzymatic in vitro cycling technique for 
the amplification of a specific DNA sequence that lies between two regions of known 
sequence. The enzyme used is a thermostable Taq polymerase (HotStart Taq, Qiagen, 
Valencia, California, USA) which performs the synthesis of a complementary strand 
from the DNA template in the presence of suitable buffers and deoxyribonucleotide 
triphosphates (dNTPs). Two oligonucleotide primers are designed to flank the specific 
region of DNA to be amplified and it is these primers which provide the double 
stranded starting point for the Taq polymerase to begin its 5’ to 3’ synthesis.
A PCR reaction is comprised of three basis steps, a denaturation step which produces 
a single stranded DNA template, a primer annealing step where the primers bind their 
complimentary sequence and an elongation step when the synthesis of DNA occurs. 
Each step is accompanied by controlled temperature changes using a MJ tetrad 
thermocycler (MJ Research, Rayne, UK) and there are typically 30-45 cycles per 
reaction. PCR primers in this study were synthesised by Sigma-Aldrich Company Ltd. 
(Dorset, UK) and Metabion (Martinsried, Germany).
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6.3 Agarose Gel Electrophoresis
DNA fragments can be fractioned according to their size when a potential difference 
is applied through a porous substance such as an agarose gel, as the negative 
phosphate groups allow the movement of DNA towards the anode. Analysis of pre- or 
post-PCR samples was performed using 0.5-2% agarose gels, dependent upon 
fragment size and resolution required. To construct a 1% agarose gel for 
electrophoresis, lg of agarose Sigma-Aldrich Company Ltd. (Dorset, UK) was 
dissolved in 100ml 0.5x TBE buffer (Ultra pure electrophoresis sequencing grade, 
National Diagnostics). The mixture was heated until the solution was clear and then 
cooled and lp l Ethidium Bromide solution (Fischer Scientific, UK) (lOmg/ml) added. 
The solution was then poured into a gel-former and appropriate well formers added 
before allowing the gel to cool and form a solid.
To run samples on the gel, an appropriate volume of PCR product was mixed with a 
loading buffer (6x loading buffer: 15% Ficoll, 0.25% Bromophenol blue, 0.25% 
Xylene cyanol, in water) and placed in a formed well. An aliquot of size-standard 
(lkb plus DNA ladder, Invitrogen, Oregon, USA) was also run alongside samples to 
allow size delineation. The gel and sample were then run at between 100-120V in an 
electrophoresis tank for an appropriate amount of time to see the DNA size expected.
Samples assayed by agarose gel electrophoresis were visualised using a UV 
transilluminator (UVP, Upland, California, USA) and photographs taken using an 
attached Kodak Electrophoresis Gel documentation and analysis system (Eastman 
Kodak Company, Rochester, New York, USA).
6.4 Sample Processing
In order to set up large scale PCR and post-PCR reactions, DNA and reagent 
mastermixes, were aliquoted into suitable (96 or 384 well) microtitre plates (ABgene, 
Epsom, UK) by robot liquid handling systems. DNA samples were usually stored 
within shallow well DNA boxes (ABgene, Epsom, UK). DNA samples and pre-PCR 
reagents were aliquoted using a Biomek FX Laboratory Automation Workstation 
(Beckman Coulter Inc, Fullerton, California, USA). Post-PCR reagents were
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aliquoted using a Biomek NX Laboratory Automation Workstation (Beckman Coulter 
Inc, Fullerton, California, USA). Programs for the Beckman-Coulter FX and NX 
microdispensers were written by Sarah Dwyer.
6.5 Genotyping using iPLEX MassARRAY
Genotyping for this project was performed using the MassARRAY genotyping 
platform due to its ability to provide highly accurate genotyping combined with a high 
multiplexing level. The Sequenom MassARRAY platform combines iPLEX GOLD 
primer extension chemistry with MALDI-ToF (Matrix Assisted Laser Desorption 
Ionisation -  Time of Flight) Mass Spectrometry (MS).
The initial step of MassARRAY genotyping involves the design of a multiplex assay 
using the Sequenom Design Assay software. For each polymorphism that an assay 
needs to be designed the flanking DNA sequence is obtained and other 
polymorphisms or characteristics of the sequence that are able to confound 
genotyping are highlighted to prevent an assay being designed over them. The 
software, then designs PCR and extension primers to the highest multiplex level. For 
the PCR primers to be detected by the MALDI-ToF mass spectrum a lObp non­
specific tag sequence is added to the 5’ end of the PCR primers. The primer annealing 
temperature is close to 56°C for all primers to allow them to anneal at the same time 
during PCR. Regardless of the number of SNPs, the reaction conditions are universal 
for all stages with optimisation only required for the adjustment of the extension 
primer concentration.
6.5.1 Sequenom PCR
Each PCR is performed in a 384-well microtitre plate (ABgene, Epsom, UK) by 
adding 5 pi of PCR to 3 pi of dried genomic DNA (4ng/pl). The PCR primer mix 
composition can be seen in the following table (Table 6-1).
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Table 6-1. Sequenom PCR mix composition
Reagent Volume (m.1)
Water 3.35
RCR buffer 10X (Qiagen, USA) 0.625
MgCh (25mM) (Qiagen, USA) 0.323
dNTPs (25mM) (Amersham Biosciences, UK) 0.1
HotStart Taq (Qiagen, USA) 0.1
PCR primer mix (forward and reverse) 
(lpmol/pl) 0.5
The PCR program is the following:
95°C for 15mins 
94°C for 20s 
56°C for 30s 
72°C for lmin
Repeat steps 2-6 for 44 cycles 
72°C for 3mins 
15°C for lOmins
After PCR, positive and negative control samples are electrophorised on a 2% gel to 
check for PCR efficiency and any possible contamination. If there is no sign of 
contamination, a mix of Shrimp Alkaline Phosphatase (SAP) is added. The 
consistency of the mix for one sample is shown on Table 6-2.
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Table 6-2. SAP mix composition
Reagent Volume Oil)
Water 1.53
SAP 0.3
SAP Buffer 1.53
2pl of this product is added to the previous PCR products and the reaction undergoes 
the following thermocycling conditions:
37°C for 30mins 
85°C for lOmins 
95°C for 5mins 
15°C for 1 Omins
The next stage involves the addition of an extension primer mix (Table 6-3). All 
unextended extension primers are added at the same time, along with ddNTPs and 
their concentration needs to be optimised. The extension primers are categorised into 
four groups according to their mass (group 1 has the lowest mass and group 4 has the 
highest mass) because products with lower mass generate a lower signal to noise ratio. 
The groups are then diluted to the following concentrations: 0.93 8pM, 1.17pM, 
1.425pM and 1.875pM. During the optimisation procedure concentrations are 
adjusted according to the peak height obtained. Low peaks may require an increase in 
the extension primer concentration to increase the signal to noise ratio while the 
opposite is usually true for very high peaks. Failed or abnormal assays are usually 
removed at this stage.
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Table 6-3. Extension primer mix composition
Reagent Volume (ill)
iPLEX GOLD reaction buffer 0.2
iPLEX GOLD termination mix 0.2
iPLEX GOLD enzyme 0.041
Adjusted primer mix 1.559
2pl of this product is added to the previous products and the reaction undergoes the 
following thermocycling conditions:
94°C for 30s 
94°C for 5s 
52°C for 5s 
80°C for 5s
Repeat step 3 for 5 cycles 
Repeat step 2 for 40 cycles 
72°C for 3mins 
15°C for lOmins
The next step involves removing residual salts from the solution because ions can 
interfere with analysis by affecting the spectra obtained from the MALDI-ToF. This is 
performed by adding 6mg of clean-up resin using a Sequenom dimple plate and 25 pi 
of water to the reaction mix. The samples are, then, mixed on a rotor for 20 minutes at 
least. After incubation, the resin is separated from the solution by centrifuging the 
samples for 15 minutes at 3000rpm (rotations per minute).
The samples are then ready to be spotted onto a Sequenom MassARRAY 
SpectroCHIP using a nanodispencer liquid handler (Sequenom, San Diego, California, 
USA). Each chip can accommodate up to 384 samples and it is composed of a 
combustible matrix. This matrix along with the samples ionise when excited by a
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laser. The resulting ions are carried into gas phase and into the mass analyser. The 
ions are accelerated by applying voltage and are allowed to drift inside the flight tube, 
so that they separate according to their mass to charge ratios. This means that lighter 
ions travel faster than heavy ions to the detector. The time the ions need to travel the 
flight tube is converted to mass. The MALDI-ToF analysis is performed using the 
MassARRAY RT software (SpectroAcquire, Sequenom, San Diego, California, 
USA). This software takes into account the intensity of the mass signal or peak height 
and the extension primer yield, which is the successful extension of the unextended 
primer compared to the residual unextended primer, as well the assay design output 
file. The output of the software is a genotype for each sample. Figure 6-1 shows the 
output from the Typer software (Sequenom), which is used to view and manually 
revise genotypes. The three categories of genotypes (homozygotes and two types of 
heterozygotes) are given in different colours. Red indicates failed samples or negative 
controls.
Figure 6-1. Screenshot from Typer analysis software showing two clusters of homozygotes (in 
green and blue), one cluster o f heterozygotes (yellow) and failed samples or blanks (red).
To confirm that genotyping is accurate all assays are initially optimised in 30 CEPH 
(Centre d’Etude du Polymorphisme Humain) parent-offspring trios. Genotypes from 
these samples were compared to those on the HapMap and genotyping assays were 
only followed if the genotypes matched. All plates contained affected and non- 
affected individuals, negative controls and CEU samples as positive controls.
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Genotypes were called twice with the second person blind to the genotypes called by 
the first one.
6.6 Bioinformatic and Statistical analysis
6.6.1 PLINK
PLINK is a freely available whole genome association analysis toolset 
(http://pngu.mgh.harvard.edu/~purcell/plink/), designed to perform a range of basic, 
large-scale analyses in a computationally efficient manner (Purcell et al. 2007). It has 
five main domains: data management for data recoding and formatting, summary 
statistics, which are useful for quality controls measures such as Hardy-Weinberg 
equilibrium calculations, call rates and inbreeding, population stratification detection, 
association analysis for both case-control and family-based samples and identity-by- 
descent estimation.
6.6.2 HAPLOVIEW
HAPLOVIEW is designed to simplify Linkage Disequilibrium (LD) and haplotype 
block analysis (http://www.broadinstitute.org/haploview/haploview). The software 
allows the user to import marker data such as a CEU HapMap dataset or case-control 
genotype data. The quality of the data can be assessed via the summary measures 
including Hardy-Weinberg equilibrium p values and percentage of individuals 
genotyped. LD measures for the SNPs imported are also available and they are used 
to create a graphical representation. The Tagger function uses the LD values to select 
“tag” markers for association studies after defining the selection criteria, such as r2, 
minor allele frequency and type of analysis. HAPLOVIEW can also be used to test for 
haplotype association (Barrett 2009).
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6.6.3 SPSS (Statistical Package for the Social Sciences)
SPSS is a statistical analysis software.
Some of its functions include:
• Descriptive statistics: Cross tabulation, Frequencies, Descriptives, Explore
• Bivariate statistics: Means, t-test, ANOVA, Correlation, Nonparametric tests
• Linear and logistic regression
• Prediction for identifying groups: Factor analysis, cluster analysis (two-step, 
K-means, hierarchical)
The many features of SPSS are accessible via pull-down menus or can be 
programmed with a command syntax language. SPSS datasets have a 2-dimensional 
table structure where the rows typically represent cases (such as individuals) and the 
columns represent measurements (such as age, sex). The graphical user interface has 
two views which can be toggled by clicking on one of the two tabs in the bottom left 
of the SPSS window. The Data View shows a spreadsheet view of the cases (rows) 
and variables (columns) while the Variable View shows a summary of the available 
variables. SPSS versions 12.0 and 16.0 has been used to perform statistical analysis 
for this project, including ANOVA, Mann Whitney U test, Pearson’s chi-square test, 
independent samples t-test as well as testing whether the assumptions for each test 
were met.
6.6.4 The International HapMap Project
The International HapMap Project aims to develop a haplotype map (HapMap) of the 
human genome, which will describe the common patterns of human genetic variation 
(International HapMap Consortium http://www.hapmap.org/). The information 
produced by the project is made freely available to researchers around the world. The
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International HapMap Project is a collaboration among researchers in Canada, China, 
Japan, Nigeria, the United Kingdom, and the United States. Several populations (30 
trios of Yoruba people in Ibadan, Nigeria; 45 unrelated Japanese individuals from 
Tokyo; 45 unrelated Ham Chinese individuals and 30 trios from the US with ancestry 
from Northern and Western Europe which were collected by the Centre d’Etude du 
Polymorphisme Humain (CEPH)) were genotyped as part of the project. HapMap 
now contains information, including LD, on 3.1 million SNPs (phase II).
Chapter 7 The role of Y chromosome in ADHD
7.1 Introduction
Psychiatric disorders, as well as a large number of complex disorders, exhibit sex 
differences in their prevalence rates and clinical presentation. Sex differences in 
ADHD are well-established with higher rates of males being affected in both clinical 
and population samples. The disorder is also more severe and disruptive in boys. It is 
striking that boys tend to be more hyperactive, while girls are usually more inattentive 
(Cuffe et al. 2005).
Although sex differences are recognised in ADHD, research on their causes has been 
limited. Factors that might contribute to these differences include hormones, genetic 
and environmental factors. Studying the genetic factors contributing to sex differences 
could shed light on the causes of ADHD and other psychiatric disorders with a male 
preponderance. There is evidence from animal models that sex chromosome genes 
could contribute to sexual differentiation of brain and behaviour without the 
involvement of gonadal hormones (Agate et al. 2003; Dewing et al. 2003). This 
suggests that sex chromosome genes may play an important role in psychiatric 
disorders and, as discussed elsewhere, the focus of this thesis is on the Y 
chromosome.
Y-linked genes are only expressed in males and they have been shown to play a role 
in the sexual dimorphism of the brain. At least ten Y chromosome genes are 
expressed in the brain (Xu et al. 2002). The Y chromosome has been linked to 
behavioural phenotypes using the four core genotypes mouse model (Guillot et al. 
1995). In addition, a Y chromosome gene, SRY, has been suggested to be involved in 
the regulation of the dopaminergic pathway, which is affected in ADHD. This 
regulation is mediated by an interaction of SRY with the rate-limiting enzyme in 
dopamine metabolism, tyrosine hydroxylase (TH) (Dewing et al. 2006). Individuals 
with an extra Y chromosome, 47,XYY syndrome, appear to be at increased risk of 
developing antisocial behaviour, which could be mediated by an effect on 
hyperactivity (Gotz et al. 1999). Individuals with Klinefelter’s syndrome have an 
impairment of executive function and inhibitory deficits (Temple and Sanfilippo
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2003). Finally, a case of ADHD carrying a rare deletion of the long arm and 
duplication of the short arm of the Y chromosome has been reported (Mulligan et al. 
2008).
Compared to autosomes or the X chromosome, the Y chromosome has been widely 
neglected in genetic and genomic studies. The majority of the Y chromosome does 
not recombine with the X chromosome and it is passed unchanged from one 
generation to the next apart from mutations. The lack of recombination poses 
difficulties in performing traditional family-based association studies and mapping 
studies but at the same time it provides stable haplogroups. It is important to take into 
account that the distribution of Y chromosome haplogroups depends highly on the 
geographic origin of the individuals. The confusing nomenclature makes it necessary 
to rely on a reliable source of information about Y chromosome markers. This source 
is the Y Chromosome Consortium (The Y Chromosome Consortium 2002). Using 
data from this consortium it is possible to select the appropriate haplogroups and the 
markers to genotype in order to capture them for a particular population. Comparing 
the frequencies of Y chromosome haplogroups between cases and controls will show 
if specific haplogroups are associated with or modify the phenotype of a disorder.
7.2 Aims of the study
The present study investigated the role of Y chromosome variation in ADHD. Y 
chromosome haplogroups appropriate for UK populations were selected according to 
Y Chromosome Consortium data and personal communication with experts in the 
field.
The hypothesis that Y chromosome SNPs and haplogroups are associated with ADHD 
was tested by performing a case-control association study. Both allelic and 
haplogroup analyses were performed, although they provide similar information, in 
order to confirm any positive findings. Haplogroup analysis also provided evidence 
about the population distribution of Y chromosome haplogroups, since this is the first 
study to genotype Y chromosome markers in a large sample of UK males.
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The hypothesis that Y chromosome variation is associated with modifying effects on 
ADHD by affecting clinical presentation, cognitive performance or comorbidity was 
tested within the group of patients with ADHD after stratifying them according to 
their Y chromosome SNP alleles or haplogroup.
7.3 Materials and methods
7.3.1 ADHD sample description
The ADHD sample used in this study consists of 210 boys who were consecutively 
referred to district child and adolescent psychiatry and paediatric clinics in South 
Wales, the South-West of England, Greater Manchester and Cheshire, with a 
suspected diagnosis of ADHD. To ensure genetic homogeneity, participants were 
required to be of British Caucasian origin to the index child’s grandparents. Children 
who suffered from major medical or neurological conditions, autism, Tourette’s 
syndrome or pervasive developmental disorders were excluded from the study.
Ethical approval was obtained from the North West England Multicentre Research 
Ethics Committee. Informed written consent from parents and assent from children 
was obtained for all participating families.
The age of the children was between six and sixteen years with a mean age at 
assessment of 9 years and 3 months (SD: 2 years and 6 months). The mean full scale 
IQ test score was 89 (SD: 11.2; range: 70-123). The presence of comorbid disorders 
is summarised in Table 7-1.
Table 7-1. Co-morbid disorders present in the sample of 210 boys with ADHD
Co-morbid disorder (%)
Oppositional Defiant Disorder 
(ODD) 47.6
Conduct Disorder (CD) 13.8
Anxiety disorder 5.2
Depressive disorder 0.5
Transient or chronic tics 10
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7.3.2 ADHD sample assessment
Assessments of ADHD, conduct disorder and other psychiatric disorders were 
undertaken by trained interviewers using the parent version of the Child and 
Adolescent Psychiatric Assessment (CAPA) (Angold et al. 1995). This is a semi­
structured interview used to obtain diagnoses of ADHD and common co-morbid 
conditions according to ICD-10 (World Health Organisation 1993), DSM-IV 
(American Psychiatric Association 1994) and DSM-III-R (American Psychiatric 
Association 1987) criteria. The CAPA also gave information about the total number 
of ADHD symptoms, the number of hyperactivity/impulsivity and inattention 
symptoms and the number of Conduct Disorder (CD) symptoms, according to DSM- 
IV diagnostic criteria. The DSM-IV CD symptoms were coded as present or absent 
and summed to yield a total antisocial score. Items included behaviours such as 
“physical cruelty to other people”, “sets fires” and “crime involving confrontation 
with the victim”. All DSM-IV CD symptoms used to derive the total score in this 
sample were of childhood onset (onset less than 10 years). Pervasiveness of ADHD 
symptoms in a school setting was assessed by interviewing the class teacher over the 
telephone using the Child Attention-Deficit Hyperactivity Disorder Teacher 
Telephone Interview (ChATTI) (Holmes et al. 2004).
In order to assess the Intelligence Quotient (IQ), all boys with ADHD diagnosis were 
assessed using the Wechsler Intelligence Scale for Children, version III “WISC-III- 
UK” (Wechsler 1992). This gives scores for the Full Scale IQ (FSIQ), the Verbal IQ 
(VIQ) and the Performance IQ (PIQ). Only those children with FSIQ score of > 70 
were included in the study. Reading ability was assessed using the Wechsler 
Objective Reading Dimension “WORD” (Wechsler 1992).
A range of questionnaire measures were also completed by the parents, providing 
demographic and environmental information. Mothers stated the occupation of the 
main earner in the household. Social class was obtained from this description based 
on the UK Standard Occupational Classification (2nd Edition) (Office of Population 
Censures and Surveys 1995). In an attempt to make the categories more meaningful 
and easier to interpret, they were split into three categories; high, medium and low 
social class. High social class (21%) consisted of families from professional and 
managerial jobs in classes 1 and 2; medium social class (29%) consisted of families
from skilled occupations in classes 3 and 4; low social class (50%) consisted of 
families from unskilled jobs in class 5 and unemployed or unclassified individuals.
7.3.3 1958 UK birth cohort control sample
The control sample used in this study consists of 637 men drawn from the 1958 
British Birth Cohort. This is a longitudinal study which takes as its subjects all the 
people bom in England, Scotland and Wales in one week in March 1958. For 
information see the website of the Centre of Longitudinal Studies 
(http://www.cls.ioe.ac.uk/). Permission to genotype was obtained.
7.3.4 DNA samples and genotyping
DNA was obtained from venous blood or saliva samples for the ADHD patients.
DNA samples were obtained from the 1958 UK Birth Cohort after request.
Genotyping was performed with the MassARRAY and iPLEX systems (Sequenom, 
San Diego, CA) according to the manufacturers’ recommendations. Assays were 
optimised in 30 male CEU individuals. All plates contained cases, controls, blanks, 
and CEU samples. Genotypes were called in duplicate blind to sample identity and 
blind to the other rater. All SNPs included in the association analysis had a call rate of 
>95%. Individuals were only included in analysis if they had genotypes for over 80% 
of the SNPs analysed. For more information about quality control procedures see 
Appendix I.
7.3.5 Selection of Y chromosome SNPs
The SNPs in the Y chromosome panel were chosen to reflect the origin of the 
individuals under study. Personal communication with researchers in the Y 
chromosome field and especially Professor Mark Jobling (University of Leicester) 
and Dr Peter Underhill (Stanford University Medical Center) was vital in choosing the 
Y chromosome haplogroups that were more likely to be found in a UK population. It 
is important to mention that previously there has not been a study of Y chromosome 
markers and/or haplogroups in a representative UK population. All previous studies
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have focused mainly on genotyping a large number of SNPs in a small number of 
individuals from population isolates. The largest study has been performed by Capelli 
et al. (2003) and it involved genotyping 1,772 men. However, the sample still came 
from small urban locations in the UK and it did not represent the UK as a whole. A 
high degree of haplogroup breakdown would not be desirable for a psychiatric 
genetics study such as ours. It was decided that the haplogroups most likely to be 
frequent in the UK were I and R.
The next step, after deciding which haplogroups would be more frequent in the UK, 
was to use the Y Chromosome Consortium phylogenetic map (The Y Chromosome 
Consortium 2002) to locate the SNPs that would need to be typed in order to capture 
each haplogroup. By following the branches of the tree (see Figure 6-1 in Chapter 6) 
we were able to find the relevant SNPs. In cases where there were two or more SNPs 
providing similar information, the best SNP was chosen according to information 
about the sequence characteristics around the SNP, since they can affect the 
performance of the SNP in the genotyping platform. Recurrence was also taken into 
account. Using the Sequence Assay Design software a panel of 9 Y chromosome 
SNPs was designed. Figure 7-1 shows the SNPs genotyped (Y chromosome SNPs 
start with a capital M) and the haplogroups (with capital letters) they represent.
7.3.6 Categorisation of individuals in haplogroups
Y chromosome SNPs are used to categorise each individual to a single haplogroup. 
Each Y chromosome SNP has two alleles: an ancestral allele, which is the most 
ancient evolutionarily and a derived allele, which is the most recent. The ancestral 
allele is represented with 0 and the derived allele with 1. The ancestral and derived 
alleles for the SNPs in this panel are shown in Table 7-2. Each individual is 
categorised to one haplogroup according to whether they have the ancestral or derived 
allele of each Y chromosome SNP starting from the ‘root marker’, the SNP that 
defines the clade and continuing splitting the sample into different branches. For this 
particular set of Y chromosome SNPs, M89 is the ‘root marker’ or the most ancient 
marker. M9 and M l73 also define major haplogroups. ‘Root markers’ can be seen in 
Figure 7-1, since they are in a “higher level” than the rest of the SNPs. For more
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information about the combination of Y chromosome SNP alleles in each haplogroup 
see Appendix II.
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Figure 7-1. Y chromosome haplogroup tree showing the relationship between genotyped SNPs. Y 
chromosome haplogroups are represented by capital letters and SNPs start with M. There were
no individuals belonging in haplogroup F*.
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Table 7-2. Ancestral (0) and derived allele (1) for each Y chromosome SNP
Y
chromosome
SNPs
Ancestral allele (0) Derived allele (1)
M9 C G
M89 C T
M153 T A
M170 A C
M173 A C
M201 G T
M3 04 A C
M405 C T
M410 A G
To test for association of clinical characteristics of the ADHD sample and cognitive 
measures with Y chromosome haplogroups, the 9 haplogroups were merged into 3 
according to ancestry in evolutionary terms. Root markers that define major clades 
facilitated this categorisation (they can be seen in Figure 7-2 as being in a higher level 
than the rest of the SNPs). SNP M89 defined the first group, SNP Ml 73 defined the 
second group and SNP M405 defined the third group. This way there were enough 
individuals in each group to allow statistical analysis (Figure 7-2).
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Figure 7-2. The Y chromosome haplogroups captured in this study were merged into three to 
facilitate phenotypic analysis. There were no individuals belonging in haplogroup F*. 
Percentages represent the frequencies of the three Y chromosome haplogroups in 4,950 UK men
genotyped in total in this study.
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7.3.7 Phenotypic analysis
Clinical characteristics and cognitive measures were tested for association with Y 
chromosome haplogroups and SNP alleles within the sample of patients with ADHD. 
It was not possible to use the genotyped controls for this analysis because no 
phenotypic information was available for them. The following phenotypes were 
tested:
• Total number of DSM-IV ADHD symptoms, since ADHD is usually more 
severe in boys
• Total number of DSM-IV hyperactive/impulsive symptoms, since 
hyperactivity tends to be more frequent in boys (inattentiveness tends to be 
more frequent in girls)
• Total number of DSM-IV CD symptoms, since aggression has been linked to 
the Y chromosome. Only children with ADHD and early aggression as 
indexed by CD symptoms present before the age of ten were used, since they 
are considered to be a distinct group from children with ADHD only (see 
Chapter 2 for more details)
• Total score on the WORD, since reading problems and dyslexia are also more 
prevalent in males
• Full scale IQ scores, performance IQ scores, verbal IQ scores as a general 
measure of cognitive function
7.3.8 Statistical analysis
The Pearson’s chi-square test [degree of freedom (df=l)] was used to test for allelic 
association and also for haplogroup analysis. The threshold of significance was set at 
p<0.05. Correction for multiple testing would be required in case of significant 
associations. Then, a Bonferroni correction or permutation testing would be applied. 
With this threshold of significance, this study had >95% statistical power to detect 
effect sizes of 1.5 when the risk allele frequency was 0.3-0.4. For effect sizes of 1.3
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the power was reduced to 70% and for effect sizes of 1.2 the power was 41%. For 
rarer alleles with frequencies of 0.1-0.2 the power was 90% for effect sizes of 1.5,
54% for effect sizes of 1.3 and 30% for effect sizes of 1.2. The prevalence of ADHD 
was considered to be 4% according to Cuffe et al. (2005). Statistical power 
calculations were performed using the Genetic Power Calculator (Purcell et al. 2003).
Clinical characteristics of the ADHD sample and cognitive measures were tested for 
association with Y chromosome haplogroups. All phenotypes were chosen a priori 
due to evidence of association with the Y chromosome or because they were known to 
be sexually dimorphic. Normality of distribution for each of the dependent variables 
was assessed using measures of skewness and kurtosis (they should not exceed 1 and 
3 respectively). The significance level of the Kolmogorov-Smimov test was also 
taken into account.
Haplogroups were tested for association with all the above phenotypic measures using 
ANOVA after collapsing them into three groups (Figure 7-2) to increase the numbers 
in each group. When a positive association was detected, non-parametric tests were 
performed to confirm the results. Secondary analysis was also performed in order to 
exclude a confounding effect of social class or location where there were significant 
findings. Pearson’s chi-square tests (df=4 for social class and df=2 for geographical 
location) were used to assess the effect of the two possible confounders on the 
distribution of Y chromosome haplogroups. Independent samples t-test was used to 
assess the effect of geographical location on PIQ and FSIQ and ANOVA was used to 
assess the effect of social class on PIQ and FSIQ. The threshold of significance was 
again set at p<0.05.
Clinical variables were also tested for association with single SNPs that had an 
adequate number of individuals in order to perform the analysis (MAF>15%) using 
independent samples t-test or the non-parametric Mann-Whitney U test according to 
whether or not data were normally distributed. This was performed as a secondary 
analysis to confirm the results from the haplogroup analysis and further explore the 
mutation responsible for any association with specific Y chromosome haplogroups.
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7.4 Results
7.4.1 Case-control association study
7.4.1.1 Allelic analysis
Nine Y chromosome SNPs were genotyped in the sample of 210 male patients with 
ADHD and 637 male control individuals from the 1958 Birth Cohort. Table 7-3 
summarises these data and shows the frequencies of Y chromosome SNP alleles in 
cases and controls. There was no significant difference between cases and controls 
(Table 7-3). It was not possible to perform statistical analysis for SNPs with very low 
frequencies.
Table 7-3. Allelic analysis for 9 Y chromosome SNPs
Y
chromosome
SNPs
MAF
(CASE)
%
MAF
(CONTROL)
%
p value OR 95% Cl
M9 29.4 27.9 0.66 1.08 0.77-1.51
M89 3.6 3.4 0.90 1.05 0.46- 2.4
M153 0 0.2 0.56 n/a n/a
M170 21.9 20.5 0.66 1.09 0.75-1.58
M173 31.4 28.5 0.42 1.15 0.82-1.6
M201 2.4 1.5 0.40 1.66 0.5 - 5.45
M3 04 2.8 2.3 0.71 1.20 0.46-3.13
M405 16.3 19.5 0.29 0.80 0.54-1.21
M410 1.8 1.9 0.96 0.97 0.31 -3.04
MAF: Minor Allele Frequency; OR: Odds Ratio; Cl: Confidence Interval; n/a: non-applicable 
7.4.1.2 Haplogroup analysis
The frequencies of the nine Y chromosome haplogroups captured in this study (Figure
7-1) were compared between cases with ADHD and controls. There were no 
individuals belonging in haplogroup F*. Table 7-4 summarises the results. Pearson’s 
chi-square test (df=l) showed no significant difference between cases and controls in 
terms of Y chromosome haplogroups (Table 7-4). It was not possible to perform 
statistical analysis for haplogroups with very low frequencies (J*, K* and Rlb3d).
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Table 7-4. Frequencies of Y chromosome haplogroups in 210 cases with ADHD and 637 controls
Y chromosome 
haplogroup
Cases
(%)
Controls
(%) p value
DE 2.4 3.3 0.45
G* 1.9 1.4 0.62
I* 22.3 20.7 0.52
J* 0.9 0.6 n/a
J2 1.9 1.7 0.87
K* 0.9 0.5 n/a
Rl* 53.1 52.1 0.79
Rlb3M405 16.6 19.5 0.36
Rlb3d 0 0.2 n/a
n/a: non-applicable
7.4.2 Phenotypic analysis using haplogroups
To test for an association of the previously described phenotypes with Y chromosome 
haplogroups, the 9 haplogroups were merged into 3 according to ancestry. As shown 
in the graphs, DSM-IV ADHD symptoms (N=210), DSM-IV hyperactive/impulsive 
symptoms (N=210) (Figure 7-3) and DSM-IV CD symptoms (N=78) (only in those 
with early CD) were approximately the same across each group (Figure 7-4).
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■ DSM-IV ADHD symptoms 
p=0.15
■ DSM-IV Hyperactive 
symptoms p=0.18
Y chromosome haplogroups from ancient (1) to  recent (3) evolutionary
Figure 7-3. Total number o f DSM-IV ADHD symptoms and DSM-IV hyperactive/impulsive 
symptoms (n=2I0) in 3 Y chromosome haplogroups within the sample of patients with ADHD, p 
values obtained from ANOVA comparing each of the variables separately in 3 Y chromosome
haplogroups are shown on the graph
Y chrom osom e haplogroups from ancient (1) to  recent (3) 
evolutionary
Figure 7-4. Total number o f DSM-IV CD symptoms (n=80) in 3 Y chromosome haplogroups 
within the sample of patients with ADHD, p value obtained from ANOVA comparing DSM-IV 
CD symptoms in 3 Y chromosome haplogroups is shown on the graph
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However, the total score on the WORD Reading Test (N=192) (Figure 7-5) and FSIQ 
(N=202), PIQ (N=202), VIQ (N=202) scores (Figure 7-6) were higher for 
haplogroups 2 and 3 compared to haplogroup 1.
Y chrom osom e haplogroups from ancient (1) to  recent (3) 
evolutionary
Figure 7-5. Scores on the WORD Reading Test (n=192) in 3 Y chromosome haplogroups within 
the sample of patients with ADHD, p value obtained from ANOVA comparing scores on the 
WORD Reading Test in 3 Y chromosome haplogroups is shown on the graph
Y chromosome haplogroups from ancient (1) to recent (3) evolutionary
Figure 7-6. FSIQ, PIQ and VIQ scores (n=202) in 3 Y chromosome haplogroups within the 
sample of patients with ADHD, p values obtained from ANOVA comparing each of the variables 
separately in 3 Y chromosome haplogroups are shown on the graph; *: significant at the p<0.05
level
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Performing ANOVA showed that there was no significant difference in the number of 
DSM-IV ADHD symptoms [F(2,208)=1.95, p=0.15, r=0.14], the number of DSM-IV 
hyperactive/impulsive symptoms [F(2,208=1.74, p=0.18, r=0.13], the number of 
DSM-IV CD symptoms [F(2,76)=1.15, p=0.23, r=0.19] and scores on the WORD 
Reading Test [F(2,190)=0.62, p=0.54, r=0.08].
Nevertheless, there was a significant difference between the haplogroups in terms of 
FSIQ [F(2,200)=3.82, p=0.024, r =0.19] and PIQ [F(2,200)=4.39, p=0.014, r =0.21]. 
Post hoc analysis revealed that the difference appeared between haplogroups 1 and 3 
with the third haplogroup having significantly higher scores of FSIQ (p=0.019) and 
PIQ (p=0.011) than the first one. The difference in VIQ scores was not significant 
[F(2,200)=2.26, p=0.11, r=0.15].
Secondary analysis showed that social class was not associated with Y chromosome 
haplogroups [x2 (4) = 7.1, p=0.13]. In addition, Y chromosome haplogroups were not 
associated with whether the individuals came from England or Wales [x2 (2) = 1.6, 
p=0.46]. There was also no association of social class with either FSIQ 
[F(2,179)=2.09, p=0.13] or PIQ [F(2,179)=2.41, p=0.093] and no association of 
geographical location with either FSIQ [t(199)=l .33, p=0.19] or PIQ [t(199)=l .81, 
p=0.072]. Since these two variables were associated with neither the dependent (FSIQ 
and PIQ) nor the independent variables (Y chromosome haplogroup), they could not 
have acted as confounders and no further testing was performed on them.
7.4.3 Phenotypic analysis using Y chromosome SNP alleles
Secondary analysis was performed by testing if Y chromosome SNP alleles were 
associated with certain phenotypes. Four Y chromosome SNPs (M l70, M9, M l73 and 
M405) were chosen because both their alleles were common enough (MAF>15%) to 
allow sufficient numbers of individuals in each group for testing. The number of 
individuals used for testing differs due to missing data for certain measures on some 
individuals.
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Table 7-5. Testing for association of Y chromosome SNP alleles and clinical characteristics within
the sample of patients with ADHD - Mann Whitney U test
Total 
number of 
DSM-IV 
ADHD 
symptoms
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around the 
mean
p value
M170
Ancestral 164 14.5 14.1 to 14.9
0.018*
Derived 46 15.5 14.8 to 16.1
M9
Ancestral 61 15.2 14.6 to 15.8
0.1
Derived 149 14.5 14.1 to 14.9
M173
Ancestral 63 15.1 14.6 to 15.7 0.12
Derived 147 14.5 14.1 to 14.9
M405
Ancestral 175 14.7 14.3 to 15
0.57
Derived 35 14.9 14 to 15.8
Total 
number of 
DSM-IV 
hyperactive/ 
impulsive 
symptoms
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around the 
mean
p value
M170
Ancestral 164 7.6 7.4 to 7.9 0.13
Derived 46 8 7.7 to 8.4
M9
Ancestral 61 7.9 7.6 to 8.2
0.5
Derived 149 7.6 7.4 to 7.9
M173
Ancestral 63 7.9 7.6 to 8.2 0.42
Derived 147 7.6 7.4 to 7.9
M405
Ancestral 175 7.6 7.4 to 7.9 0.34
Derived 35 7.9 7.4 to 8.4
Total 
number of 
DSM-IV 
CD 
symptoms 
within the 
sample of 
patients 
with ADHD 
and early 
CD 
symptoms
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around the 
mean
p value
M170
Ancestral 59 1.1 0.8 to 1.3 0.82
Derived 19 1.1 0.6 to 1.6
M9
Ancestral 23 1.1 0.7 to 1.5 0.57
Derived 55 1 0.8 to 1.3
Ml 73
Ancestral 25 1.1 0.8 to 1.5 0.55
Derived 53 1.1 0.8 to 1.3
M405
Ancestral 64 1 0.7 to 1.2 0.065
Derived 14 1.5 0.9 to 2.1
Cl: Confidence Interval; CD: Conduct Disorder; 
*: significant at the p<0.05 level
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Table 7-6. Testing for association of Y chromosome SNP alleles and total score on the WORD - 
________________________ Independent samples t-test______________ _________
Y
chromosome
SNPs
Allele N Mean
95% Cl around 
difference in 
means
p value
M170
Ancestral 150 90.7
1 to 8.9 0.12
Derived 42 86.7
M9
Ancestral 57 14.3
-7.3 to 1.7 0.23
Derived 135 14.5
M173
Ancestral 59 88.3
-6.7 to 2.3 0.33
Derived 143 90.5
M405
Ancestral 167 91.7
-7.8 to 3.3 0.42
Derived 35 89.4
Cl: Confidence Interval
Table 7-7. Testing for association of Y chromosome SNP alleles and cognitive measures within 
the sample of patients with ADHD - Independent samples t-test
Full Scale 
IQ scores 
(FSIQ)
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around 
difference 
in means
p value
Ml 70 Ancestral 160 90 1.1 to 8.7 0.012*Derived 42 85.1
M9 Ancestral 57 85.6 1.2 to 8 0.008**Derived 145 90.3
M173 Ancestral 59 86.2 0.5 to 7.3 0.023*Derived 143 90.1
M405 Ancestral 167 88.2 0.4 to 8.5 0.034*Derived 35 92.6
Performance 
IQ scores 
(PIQ)
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around 
difference 
in means
p value
M170 Ancestral 160 92 2.2 to 10.7 0.003**Derived 42 85.6
M9 Ancestral 57 86.6 1.8 to 9.5 0.004**
Derived 145 92.2
M173 Ancestral 59 87.3 1 to 8.6 0.014*Derived 143 92.1
M405 Ancestral 167 89.7 0.7 to 10 0.025*Derived 35 96
Verbal IQ 
scores (VIQ)
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around 
difference 
in means
p value
Ml 70 Ancestral 160 90.9 1.1 to 7.1 0.15Derived 42 87.9
M9 Ancestral 57 87.9 -7 to 0.4 0.077Derived 145 91.2
M173 Ancestral
59 11.4 -6.5 to 0.8 0.12
Derived 143 12.1
M405
Ancestral 167 89.5 -8.5 to 0.3 0.067
Derived 35 93.6
IQ: Intelligence Quotient; Cl: Confidence Interval;
*: significant at the p<0.05 level; **: significant at the p<0.01 level
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We found no association between Y chromosome SNPs and number of ADHD 
symptoms, number of hyperactive/impulsive symptoms or number of CD symptoms 
(Table 7-5). There was only a significant association of SNP Ml 70 and the number of 
DSM-IV ADHD symptoms but not for any of the other SNPs tested (Table 7-5). A 
significant association was demonstrated between all the SNPs tested and PIQ as 
shown by the independent samples t-test (Table 7-7). The same was true for FSIQ 
(Table 7-7). The results were confirmed by non-parametric tests and the p values 
obtained were similar. In three of the SNPs tested the derived allele was associated 
with higher PIQ and FSIQ scores. The ancestral allele was associated with higher IQ 
only for SNP M l70.
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7.5 Discussion
In this study, the hypothesis that Y chromosome variation is associated with ADHD 
or has a modifying effect by influencing clinical severity, cognitive performance or 
comorbidity was tested. The results of this Chapter indicate that there is no main 
effect of Y chromosome variation on ADHD. However, Y chromosome variation may 
have a modifying effect on ADHD by influencing cognitive performance, specifically, 
FSIQ [F(2,200)=3.82, p=0.024, r =0.19] and PIQ [F(2,200)=4.39, p=0.014, r =0.21] in 
patients with ADHD.
Since the Y chromosome is present only in men, the presence of Y chromosome 
genes can be responsible for sex differences in susceptibility to psychiatric disorders. 
However, the Y chromosome has been excluded from genetic studies. There have 
been very few studies o f the Y chromosome in relation to psychiatric phenotypes 
(Jamain et al. 2002; Kittles et al. 1999; Shah et al. 2009) and most of them have used 
heterogeneous populations or very small sample sizes. The same is true for genome- 
wide association studies. No Y chromosome SNPs were included in genotyping arrays 
used to test for association with psychiatric disorders up until recently. The fact that a 
whole chromosome was excluded from studies that are designed to examine the whole 
genome shows the degree of neglect that the Y chromosome has received. For these 
reasons, this study is important since it is the first study to my knowledge to have 
genotyped Y chromosome markers in a systematic way in such a large sample of UK 
men. We were able to demonstrate that Y chromosome SNPs can be genotyped using 
the same genotyping platforms as for autosomal SNPs. The selection of SNPs for 
genotyping is the most critical aspect of Y chromosome studies and it differs 
considerably from the methods used for autosomal SNPs. Since linkage 
disequilibrium (LD) measures are not applicable for the Y chromosome, they cannot 
be used to select the minimum number of SNPs needed to cover a Y chromosome 
region. The small number of SNPs genotyped in HapMap individuals and the fact that 
most of the SNPs are not present in genetic databases, such as UCSC, poses another 
problem, since it is very difficult to obtain information about the frequency of Y 
chromosome SNPs in certain populations. A more appropriate way of selecting Y 
chromosome SNPs is to decide first on the haplogroups that need to be covered
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according to the population to be studied and then resort to the Y Chromosome 
Consortium (The Y Chromosome Consortium 2002) in order to select the SNPs 
covering those haplogroups.
Phenotypic analysis was performed using both haplogroups and SNP alleles. These 
two types of analysis should yield the same pattern of results, since all the individuals 
were categorised in the Y chromosome haplogroups according to the Y chromosome 
SNP alleles that they possessed. The reason that both analyses were performed was 
because the aim was to test if any specific Y chromosome haplogroup had a 
modifying effect on ADHD and also to test if this effect was linked to a specific 
mutation on the Y chromosome.
In addition, by performing both analyses the evolutionary pattern of the results was 
observed. According to SNP analysis the ancestral allele of SNP Ml 70 is associated 
with higher IQ scores in patients with ADHD (Table 7-7). Also, for SNP M9 the 
derived allele is associated with higher IQ scores in ADHD (Table 7-7). This points to 
haplogroups K, R l*, Rlb3M405 and Rlb3d being associated with higher IQ scores, 
because they are the ones to have this combination of alleles (see Table 1 in Appendix 
II). Since the derived allele of SNP Ml 73 is associated with higher IQ scores, this 
limits the haplogroups that are associated with higher IQ scores to Rl*, Rlb3M405 
and Rlb3d. Finally, the derived allele of SNP M405 is associated with higher IQ 
scores, which means that haplogroup Rlb3M405 is the only one with the appropriate 
combination of alleles. According to haplogroup analysis, haplogroup 3, which 
includes haplogroup Rlb3M405, is associated with higher IQ scores (Figure 7-6). 
Hence, both SNP analysis and haplogroup analysis agree in pointing out that a 
haplogroup defined by a derived mutation of SNP M405 is associated with higher IQ 
scores.
There was also a significant association of SNP Ml 70 and the number of DSM-IV 
ADHD symptoms (Table 7-5). However, none of the other Y chromosome SNPs were 
significant and the difference in the mean number of ADHD symptoms between the 
two alleles was very small. In addition, there was no evidence of association in the 
haplogroup analysis. For these reasons, we conclude that the data do not provide 
convincing support for an association with the number of DSM-IV ADHD symptoms.
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In order to test for an association between Y chromosome variation and ADHD, a 
case-control association study was performed using nine Y chromosome markers. 
This is the first time that Y chromosome haplogroups and their effect have been 
investigated in ADHD. For this reason, even the fact that the case-control study 
showed that there was no evidence of an association of Y chromosome haplogroups 
with ADHD (Table 7-4) is of importance, since these are novel findings.
Our results indicated a possible modifying effect of Y chromosome variation on the 
phenotype of ADHD. Haplogroup 3 was associated with higher FSIQ (p=0.019) and 
PIQ (p=0.011) scores compared to haplogroup 1. The mean scores of all types of IQ 
increased from haplogroup 1 to 3, although not all the differences reached 
significance levels. Reading scores using the WORD Reading Test also increased 
from haplogroup 1 to 3 without reaching significance levels [F(2,190)=0.62, p=0.54, 
r=0.08]. Thus, there could be an effect of Y chromosome variation on cognitive 
functions. There can be two possible explanations for this association. One of them is 
that the functional polymorphism responsible for this association has appeared (in 
evolutionary terms) before the SNPs that define the associated haplogroup. Thus, all
Y chromosomes belonging to these haplogroups would carry the causal variant. 
However, it is most likely that the functional polymorphism has appeared against a 
specific haplogroup background and for this reason, only certain individuals within 
this haplogroup will have it (Krausz et al. 2004). If the Y chromosome is truly 
associated with cognitive function, the classic notion that the Y chromosome is only 
important for reproductive functions would be challenged and its exclusion from 
genetic studies of brain disorders would be unjustifiable. This is also supported by 
animal studies linking the Y chromosome to aggression and parental behaviour 
(Guillot et al. 1995).
One of the strengths of this study is that the population used was of UK Caucasian 
origin. Participants were required to be of British Caucasian origin to the child’s 
grandparents. The control individuals, the 1958 UK Birth Cohort, were again of the 
same origin. Sample homogeneity is important for any genetic study but it is vital for
Y chromosome studies where the haplogroup distribution can vary significantly 
between countries leading to population stratification. The fact that there was no 
difference in the frequencies of Y chromosome haplogroups between the ADHD
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cases and the controls suggests that it is valid for the 1958 UK Birth Cohort to be used 
as a control in genetic studies of the Y chromosome in the UK, since they are both of 
UK Caucasian origin.
Other advantages of this study are that the ascertainment of the sample was very 
careful using strict criteria for inclusion and providing a rich set of phenotypic 
measures to investigate. Finally, the Y chromosome markers that were genotyped 
were selected after very careful consideration and advice was sought from experts in 
the field due to the lack of information about the Y chromosome haplogroup 
distribution in the UK.
One of the most important issues that arise when interpreting these results is whether 
there is an association of Y chromosome haplogroups and IQ in the general 
population or whether this is only true for patients with ADHD. In order to test this 
alternative explanation, it would be necessary to test the same Y chromosome 
haplogroups for association with IQ in a non-clinical population of UK origin. A 
population cohort is the ideal sample to test the effect of Y chromosome on IQ. 
Although the control sample used in this study, the 1958 UK Birth Cohort, would be 
suitable, it was not possible to obtain IQ data. For this reason, another population 
cohort from the UK, the ALSPAC, was used and the results are discussed in Chapter 
9.
Another issue is that different phenotypic measures were tested for association with Y 
chromosome SNPs and haplogroups and it is possible that this significant association 
is a result of multiple testing. However, the phenotypes that were studied were chosen 
a priori from the large number of phenotypic measures collected for our sample of 
ADHD patients due to evidence of association with the Y chromosome or because 
they were known to be sexually dimorphic. Since this study presents novel findings, 
replication of these findings in an independent sample is needed to provide strong 
supporting evidence. Using data from the ASLPAC sample, which had information on 
the presence of ADHD, we attempted to replicate our findings and this is discussed in 
Chapter 9. In addition, phenotypic analysis using SNPs was performed as a secondary 
analysis to confirm haplogroup analysis results and for this reason no multiple testing 
correction was performed.
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It is possible that the association of Y chromosome variation and IQ in the ADHD 
sample is confounded by other factors or arises from population stratification effects. 
Social class can be one of these factors and it was tested for association with Y 
chromosome haplogroups. No evidence of association was found [y? (4) = 7.1, 
p=0.13]. Another possible confounder would be the geographic origin in the UK that 
our individuals come from because Y chromosome haplogroups are highly 
geographically distributed and they can vary even within countries. The ADHD 
sample consisted of both English and Welsh individuals of Caucasian origin but no 
association with Y chromosome haplogroups was found [x2 (2) = 1.6, p=0.46]. 
However, our measure of geographic origin was limited by the fact that it was based 
on the postcode of the individuals at the time of assessment and this does not always 
correlate with the person’s origin. Nevertheless, it was the only available measure of 
geographic location.
Another important issue is the sample size, as this can be one factor contributing to 
failure to detect other associations. It has become evident from recent genome-wide 
association studies (O'Donovan et al. 2008; Wolfs et al. 2009) that the effect sizes of 
common risk alleles in complex disorders are very small (OR<1.2) and as a 
consequence large sample sizes are required when multiple tests are performed. 
Although our study is the first to have genotyped such a large number of UK 
individuals for Y chromosome SNPs, the power to detect any association when the 
effect size of the risk allele is small (OR<1.2) is limited to 41% according to power 
calculations. This power is further compromised when the variant is rare. However, 
this study had >95% statistical power to detect effect sizes of 1.5 when the variant is 
common; thus it provides no evidence of the presence of risk alleles for ADHD of 
large effect sizes on the Y chromosome.
Despite the limitations of this study these results are interesting because they are the 
first systematic effort to assess the effect of Y chromosome on male susceptibility to 
ADHD. The unique properties of the Y chromosome and the problems they pose 
when studying it should not deter researchers from including it in genetic studies, 
since it is a male-only chromosome that can influence the phenotype of psychiatric 
disorders with a male preponderance. These results indicate an influence of Y 
chromosome variants on IQ in patients with ADHD but they need to be replicated.
Chapter 8 The role of Y chromosome in schizophrenia
8.1 Introduction
Schizophrenia is a debilitating psychiatric disorder which exhibits striking sex 
differences in age of onset and morbidity. Although the male/female prevalence ratio 
is moderately increased, males have an earlier age of onset that is associated with 
worse outcome and more impaired cognition. The presentation of the disorder is also 
different with men having more negative symptoms. A longitudinal study following 
patients with schizophrenia over a period of twenty years found that women 
consistently showed better functioning than men (Grossman et al. 2008). Sex 
differences in schizophrenia exist even in relation to brain morphology (see Chapter 1 
on sex differences for more details).
As previously discussed in this thesis, one of the main differences between male and 
female genomes is the presence of Y chromosome genes in males. This could be a 
factor contributing to sex differences. However, the Y chromosome has not been 
previously studied in relation to schizophrenia. In this study, Y chromosome SNPs 
were genotyped in patients with schizophrenia and controls in order to determine if 
the two groups differ in terms of Y chromosome variation.
8.2 Aims of the study
The present study investigated the role of the Y chromosome variation in 
schizophrenia. Y chromosome haplogroups appropriate for UK populations were 
chosen as described in Chapter 7.
The hypothesis that the Y chromosome SNPs and haplogroups are associated with 
schizophrenia was tested by performing a case-control association study. Both allelic 
and haplogroup analyses were performed, although they provide similar information, 
in order to confirm any positive findings.
The hypothesis that Y chromosome variation is associated with modifying effects on 
schizophrenia by affecting clinical presentation or cognitive ability was tested within
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the group of patients with schizophrenia after stratifying them according to their Y 
chromosome SNP alleles or haplogroup.
8.3 Materials and methods
8.3.1 Schizophrenia sample description
The schizophrenia sample used in this study consists of 313 unrelated British 
Caucasian men. The mean age at first psychiatric contact was 23.6 (SD 6.8) years and 
the mean age at ascertainment was 44.8 (SD 13.1) years. Both Multi Center Research 
Ethics Committee and Local Research Ethics Committee approval were obtained and 
subjects gave written informed consent to participate.
8.3.2 Schizophrenia sample assessment
All patients had a consensus diagnosis of schizophrenia according to DSM-IV criteria 
made by two independent raters following a semi-structured interview by trained 
psychiatrists or psychologists using the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) interview (Wing et al. 1990) and review of case records. 
Cases were screened to exclude substance-induced psychotic disorder or psychosis 
due to a general medical condition.
SAPS/SANS (Schedule fo r  the Assessment o f Positive/Negative Symptoms)
There are six subscales (2 for each of positive, negative and disorganised symptoms) 
assessing severity and frequency of symptoms ranging from 0 (symptom not present 
at all) to five (maximum). Positive symptom subscales assess hallucinations and 
delusions, negative symptoms subscales assess affective flattening and poverty of 
speech, disorganised symptoms subscales assess inappropriate affect and thought 
disorder. Each of the two subscales for the three categories of symptoms are 
combined to form the total number of positive, negative and disorganised symptoms 
(ranging from 0 to 10).
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Global assessment scale (GAS)
The global assessment scale (GAS) was used to rate the subject’s lowest level of 
functioning at their worst point (scale from 1 to 100, with 1 representing worst 
functioning and 100 superior functioning) (Endicott et al. 1976).
Course o f illness
Subjects were categorised into five groups according to their course of illness with 1 
corresponding to a single episode with good recovery; 2 corresponding to multiple 
episodes with good recovery between; 3 corresponding to multiple episodes with 
partial recovery between; 4 corresponding to continuous chronic illness and 5 
corresponding to continuous chronic illness with deterioration. In order to reduce the 
number of categories and facilitate analysis, individuals were placed in 2 groups a 
priori according to whether they had continuous chronic illness or not; the first group 
was considered to have good outcome (categories 1-3) and the second one was 
considered to have poor outcome (categories 4-5).
Educational level
Information was also obtained regarding the highest level of education achieved. This 
was assessed by the self-declaration of the highest level of qualifications attained. 
Subjects with no qualification and those with qualifications obtained at school up to 
but excluding A level were categorised in the “low education” group while those with 
A levels and any further educational qualifications were placed in the “high 
education” group.
8.3.3 1958 UK birth cohort control sample
The control sample used in this study was the same as in the ADHD association study 
described in Chapter 7. It consists of 637 men drawn from the 1958 British Birth 
Cohort.
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8.3.4 DNA samples and genotyping
DNA was obtained from venous blood or mouthwash sample for patients with 
schizophrenia. DNA samples were obtained from the 1958 UK Birth Cohort after 
request. Genotyping was performed as described in Chapter 7. For more information 
about quality control procedures see Appendix I.
8.3.5 Selection of SNPs and categorisation of individuals in haplogroups
Nine Y chromosome SNPs were selected, as described previously, in order to capture 
the major haplogroups present in the UK (Figure 8-1). Y chromosome SNPs were 
used to categorise each individual to only one haplogroup (see Chapter 7).
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M9
DE'
R1b3
M405
M 173
M89YAP
M 410
M 405 M 153
M201 M 170 M 304
Figure 8-1. Y chromosome haplogroup tree showing the relationship between genotyped SNPs. Y 
chromosome haplogroups are represented by capital letters and SNPs start with M. There were 
no individuals belonging in haplogroup F*. Figure is the same as in Chapter 7 and is repeated to
facilitate reading.
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To test for an association of clinical characteristics of the schizophrenia sample and 
educational level with Y chromosome haplogroups, the 9 haplogroups were merged 
into 3 according to ancestry in evolutionary terms (see Figure 8-2 and Chapter 7 for 
detailed description).
M9
DE
M 405
M89
M 153
M 173
53.3%
28.3%
M 410
18.4%
M 201 M 170 M 304
Figure 8-2. The Y chromosome haplogroups captured in this study were merged into three to 
facilitate phenotypic analysis. There were no individuals belonging in haplogroup F*. 
Percentages represent the frequencies o f the three Y chromosome haplogroups in 4,950 UK men 
genotyped in total in this study. Figure is the same as in Chapter 7 and is repeated to facilitate
reading.
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8.3.6 Phenotypic analysis
Clinical characteristics and educational level were tested for association with Y 
chromosome haplogroups and SNP alleles within the sample of patients with 
schizophrenia. It was not possible to use the genotyped controls for this analysis 
because no phenotypic information was available. The following phenotypes were 
tested:
• Age at first psychiatric contact, as a measure of age of onset of the disorder. 
This is because the age of onset of schizophrenia in men is on average four 
years earlier than in women
• Number of positive, negative and disorganised symptoms as assessed by 
SAPS/SANS, since the manifestation of the disorder differs between men and 
women
• Course of illness (good or poor outcome) and worst ever global assessment 
score (GAS) because schizophrenia is more severe in men
• Educational level as a general measure of cognitive performance given that 
low cognitive ability is a risk factor for schizophrenia (David et al. 1997). IQ 
measures were not available for the schizophrenia sample
8.3.7 Statistical analysis
The Pearson’s chi-square test [degree of freedom (dP=l)] was used to test for allelic 
association and also for haplogroup analysis. The threshold of significance was set at 
p<0.05. Correction for multiple testing would be required in case of significant 
associations. Then, a Bonferroni correction or permutation testing would be applied. 
With this threshold of significance, this study had >95% statistical power to detect 
effect sizes of 1.5 when the risk allele frequency was 0.3-0.4. For effect sizes of 1.3 
the power was reduced to 72% and for effect sizes of 1.2 the power was 45%. For 
rarer alleles with frequencies of 0.1-0.2 the power was 92% for effect sizes of 1.5, 
56% for effect sizes of 1.3 and 35% for effect sizes of 1.2. The prevalence of
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schizophrenia was considered to be 1%. Statistical power calculations were performed 
using the Genetic Power Calculator (Purcell et al. 2003).
Clinical characteristics of the schizophrenia sample and educational level were tested 
for association with Y chromosome haplogroups. Normality of distribution for each of 
the dependent variables was assessed using measures of skewness and kurtosis (they 
should not exceed 1 and 3 respectively). The significance level of the Kolmogorov- 
Smimov test was also taken into account.
Haplogroups were tested for association with all the previous phenotypic measures 
using ANOVA after collapsing them into three groups (Figure 8-2), based on 
evolutionary structure, to increase numbers in each group. When a positive 
association was detected, non-parametric tests were performed to confirm the results. 
Pearson chi-square test (df=2) was used to test for an association of categorical 
variables (course of illness and educational level) with haplogroups. The threshold of 
significance was again set at p<0.05.
All variables were tested for association with single SNPs that had an adequate 
number of individuals in order to perform the analysis (MAF>15%) using 
independent samples t-test or the non-parametric Mann-Whitney U test according to 
whether or not data were normally distributed. For categorical variables (course of 
illness and educational level) Pearson chi-square test (df=l) was used. This was 
performed as a secondary analysis to confirm the results from the haplogroup analysis 
and further explore the mutation responsible for any association with specific Y 
chromosome haplogroups.
8.4 Results
8.4.1 Case-control association study
8.4.1.1 Allelic analysis
Nine Y chromosome SNPs were genotyped in the sample of 313 male patients with 
schizophrenia and 637 male control individuals from the 1958 Birth Cohort. Table 8-1 
summarises these data and shows the frequencies of Y chromosome SNP alleles in
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cases and controls. There was no significant difference between cases and controls 
(Table 8-1). It was not possible to perform statistical analysis for SNPs with very low 
frequencies.
Table 8-1. Allelic analysis for 9 Y chromosome SNPs
Y
chromosome
SNPs
MAF
(CASE)
%
MAF
(CONTROL)
%
p value OR 95% Cl
M9 27.2 27.9 0.84 0.97 0.72- 1.31
M89 4.2 3.4 0.58 1.22 0.61 - 2.45
M153 0 0.2 0.49 0.00 n/a
M170 18.5 20.5 0.48 0.88 0.63-1.25
M173 27.8 28.5 0.82 0.97 0.72-1.3
M201 2.1 1.5 0.47 1.46 0.52-4.15
M3 04 2.9 2.3 0.61 1.24 0.54 - 2.87
M405 16.6 19.5 0.28 0.82 0.58-1.17
M410 1 1.9 0.29 0.51 0.14-1.83
MAF: Minor Allele Frequency; OR: Odds Ratio; Cl: Confidence Interval; n/a: non-applicable
8.4.1.2 Haplogroup analysis
The frequencies of the nine Y chromosome haplogroups captured in this study (Figure 
8-1) were compared between cases with schizophrenia and controls. There were no 
individuals belonging in haplogroup F*. Table 8-2 summarises the results. Pearson 
chi-square test (df=l) test showed no significant difference between cases and 
controls in terms of Y chromosome haplogroups (Table 8-2). It was not possible to 
perform statistical analysis in haplogroups with very low frequencies (J*, K* and 
Rlb3d).
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Table 8-2. Frequencies of Y chromosome haplogroups in 313 cases with schizophrenia, controls
and 637 controls
Y chromosome 
haplogroup Cases (%) Controls (%) p value
DE 4.2 3.3 0.5
G* 1.9 1.4 0.56
I* 18.5 20.7 0.43
J* 1.9 0.6 n/a
J2 1 1.7 0.36
K* 0.3 0.5 n/a
Rl* 55.6 52.1 0.31
Rlb3M405 16.6 19.5 0.29
Rlb3d 0 0.2 n/a
n/a: non-applicable
8.4.2 Phenotypic analysis using haplogroups
To test for an association of the previous phenotypes with Y chromosome 
haplogroups, the 9 haplogroups were merged into 3 according to ancestry. As shown 
in the graphs, age at first psychiatric contact increased as haplogroups became more 
recent in evolutionary terms but the difference was not significant [F(2,296)=0.44, 
p=0.65, r=0.054] (Figure 8-3).
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Figure 8-3. Age at first psychiatric contact in 3 Y chromosome haplogroups within the sample of 
patients with schizophrenia.. p value obtained from ANOVA comparing age at first psychiatric 
contact in 3 Y chromosome haplogroups is shown on the graph
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The number o f positive [F(2,301)=0.40, p=0.67, r=0.051], negative [F(2,295)=2.59, 
p=0.076, r=0.13], disorganised symptoms [F(2,291)=0.47, p=0.63, r=0.057] (Figure 
8-4) and the worst ever global assessment score [F(2,289)=2.54, p=0.08, r=0.13] were 
not associated with any haplogroup (Figures 8-5).
■ Positive symptoms 
p=0.67
■ Negative symptoms 
p=0.076
■ Disorganised symptoms 
p=0.63
Y chromosom e haplogroups from ancient (1) to  recent (3) evolutionary
Figure 8-4. Number of positive, negative and disorganised symptoms in 3 Y chromosome 
haplogroups within the sample of patients with schizophrenia, p values obtained from ANOVA  
comparing each of the variables separately in 3 Y chromosome haplogroups are shown on the
graph
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Figure 8-5. Worst ever global assessment score (GAS) (100=best function, 0=worst function) in 3 
Y chromosome haplogroups within the sample of patients with schizophrenia, p value obtained 
from ANOVA comparing worst ever global assessment score (GAS) in 3 Y chromosome
haplogroups is shown on the graph
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In terms of course of illness, there were more individuals with good than poor 
outcome in haplogroup 1 while the opposite was true for haplogroup 2 (Figure 8-6). 
The difference was significant [x2 (2) = 8.98, p=0.011, OR =2.25].
■ Good outcome
■ Bad outcome
p=0.011*
Y ch rom osom e haplogroups from ancient (1) to  recent (3) 
evolutionary
Figure 8-6. % of patients with schizophrenia in each of the three Y chromosome haplogroups 
that have good or poor outcome of illness, p value obtained from Pearson chi-square test 
comparing % of patients with good and poor outcome in 3 Y chromosome haplogroups is shown
on the graph; *: significant at the p<0.05 level
The educational level was very interesting with more individuals with high education 
than low education in haplogroup 1 and the opposite for haplogroup 3 (Figure 8-7). 
The difference was significant [x2 (2) = 6.35, p=0.042, OR =2.5]. Haplogroup 2 had 
approximately the same frequency of individuals for high and low education (Figure
8-7).
■ Low education
■ High education 
p=0.042*
Y ch rom osom e haplogroups from ancient (1) to  recent (3) 
evolutionary
Figure 8-7. % of patients with schizophrenia in each of the three Y chromosome haplogroups 
that have low or high educational level (low education: no qualification or qualifications obtained 
at school up to but excluding A level, high education: A level or any further qualifications), p 
value obtained from Pearson chi-square test comparing % of patients with low and high 
education in 3 Y chromosome haplogroups is shown on the graph; *: significant at the p<0.05
level
8.4.3 Phenotypic analysis using Y chromosome SNP alleles
Secondary analysis was performed by testing if Y chromosome SNP alleles were 
associated with certain phenotypes. Four Y chromosome SNPs (M l70, M9, M l73 and 
M405) were chosen because both their alleles were common enough (MAF>15%) to 
allow sufficient numbers of individuals in each group for testing. The number of 
individuals used for testing differs due to missing data for certain measures on some 
individuals.
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Table 8-3. Testing for association of Y chromosome SNP alleles with age at first psychiatric 
contact and worst ever global assessment score (GAS) (100=best function, 0=worst function) 
within the sample of patients with schizophrenia - Mann Whitney U test
Age at first 
psychiatric 
contact
Y chromosome 
SNPs Allele N Mean
95% Cl 
around the 
mean
p value
M170
Ancestral 245 24.0 23.1 to 24.8
0.053
Derived 53 22.0 20.4 to 23.6
M9
Ancestral 78 23.1 21.6 to 24.6
0.44
Derived 220 23.8 22.9 to 24.7
M173
Ancestral 78 23.1 21.6 to 24.6
0.44
Derived 220 23.8 22.9 to 24.7
M405
Ancestral 246 23.5 22.6 to 24.4
0.17
Derived 52 24.3 22.6 to 25.9
Worst ever 
global 
assessment 
score 
(lOO^best 
function, 
0=worst 
function)
Y chromosome 
SNPs Allele N Mean
95% Cl 
around the 
mean
p value
M170
Ancestral 241 21.5 20.5 to 22.4
0.38
Derived 50 22.2 19.6 to 24.7
M9
Ancestral 72 22.3 20.4 to 24.2
0.251
Derived 219 21.3 20.3 to 22.4
M173
Ancestral 72 22.3 20.4 to 24.2
0.251
Derived 219 21.3 20.3 to 22.4
M405
Ancestral 239 22.1 21.1 to 23.1 0.02*
Derived 52 19.4 17.2 to 21.5
Cl: Confidence Interval;
*: significant at the p<0.05 level;
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Table 8-4. Testing for association of Y chromosome SNP alleles with the number of positive, 
negative and disorganised symptoms within the sample of patients with schizophrenia - Mann
Whitney U test
Positive
symptoms
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around 
the mean
p value
M170
Ancestral 247 7.1 6.8 to 7.3
0.44
Derived 56 7 6.9 to 7.8
M9
Ancestral 81 7.3 6.8 to 7.7
0.4
Derived 222 7.1 6.8 to 7.3
M173
Ancestral 81 7.3 6.8 to 7.7
0.4
Derived 222 7.1 6.8 to 7.3
M405
Ancestral 251 7.1 6.8 to 7.3
0.88
Derived 52 7.2 6.7 to 7.7
Negative
symptoms
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around 
the mean
p value
M170
Ancestral 242 2.5 2.1 to 2.8 0.09
Derived 55 1.4 0.9 to 1.9
M9
Ancestral 79 1.8 1.3 to 1.6 0.067
Derived 218 2.5 2.1 to 2.8
M173
Ancestral 79 1.8 1.3 to 1.6 0.067
Derived 218 2.5 2.1 to 2.8
M405
Ancestral 245 2.3 2 to 2.6 0.68
Derived 52 2.2 1.5 to 2.9
Disorganised
symptoms
Y
chromosome
SNPs
Allele N Mean
95% Cl 
around 
the mean
p value
M170
Ancestral 240 2.0 1.8 to 2.3 0.77
Derived 53 1.9 1.4 to 2.4
M9
Ancestral 77 1.9 1.4 to 2.3 0.550
Derived 216 2.0 1.8 to 2.3
M173
Ancestral 77 1.9 1.4 to 2.3 0.550
Derived 216 2.0 1.8 to 2.3
M405
Ancestral 241 2.0 1.8 to 2.3 0.51
Derived 52 1.9 1.3 to 2.5
Cl: Confidence Interval
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Table 8-5. Testing for association of V chromosome SNP alleles with the course of illness (good or 
poor outcome) within the sample of patients with schizophrenia -  Pearson chi-square test (df=l)
Y
chromosome
SNP
Allele N
Good
outcome
(%)
Poor
outcome
(%)
p value
M170
Ancestral 244 45.5 54.5
0.005**
Derived 54 66.7 33.3
M9
Ancestral 79 63.3 36.7
0.004**
Derived 219 44.3 55.7
M173
Ancestral 79 63.3 36.7
0.004**
Derived 219 44.3 55.7
M405
Ancestral 247 49.4 50.6
0.961
Derived 51 49 51
**: significant at the p<0.01 level
Table 8-6. Testing for association of Y chromosome SNP alleles with educational level (low 
education: no qualification or qualifications obtained at school up to but excluding A level, high 
education: A level or any further qualifications) within the sample of patients with schizophrenia
-  Pearson chi-square test (df=l)
Y
chromosome
SNP
Allele N
Low
education
<%)
High
education
(%)
p value
M170
Ancestral 227 66.5 33.5 0.675
Derived 52 63.5 36.5
M9
Ancestral 78 55.1 44.9 0.017*
Derived 201 70.1 29.9
M173
Ancestral 79 55.7 44.3 0.023*
Derived 200 70 30
M405
Ancestral 232 63.8 36.2 0.091
Derived 47 76.6 23.4
*: significant at the p<0.05 level
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A significant association was demonstrated between three of the SNPs tested and 
course of illness (Table 8-5) as shown by Pearson chi-square analysis. The ancestral 
allele of SNP Ml 70 had an increased frequency of individuals with poor outcome 
while the derived allele had an increased frequency of individuals with good outcome. 
The ancestral alleles of SNPs M9 and Ml 73 had increased frequencies of individuals 
with good outcome while their derived alleles had increased frequencies of 
individuals with poor outcome. The frequencies of individuals with good and poor 
outcomes were very similar in the two alleles of SNP M405.
A significant association was also demonstrated between two of the SNPs tested and 
educational level as shown by Pearson chi-square analysis (Table 8-6). The ancestral 
alleles of SNPs M9 and Ml 73 had increased frequencies of individuals with high 
educational level while their derived alleles had increased frequencies of individuals 
with low educational levels. The same was true for SNP M405, although the 
difference did not reach significance.
There was also a significant association of SNP M405 and worst ever GAS (Table 8-
3).
No association was shown for the age at first psychiatric contact (Table 8-3) and the 
number of positive, negative and disorganised symptoms (Table 8-4).
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8.5 Discussion
In this study, the hypothesis that Y chromosome variation can have a direct effect on 
schizophrenia or a modifying effect by influencing clinical presentation or cognitive 
performance was tested. The results of this Chapter indicate that there is no main 
effect of Y chromosome variation on schizophrenia. However, Y chromosome 
variation may have a modifying effect on schizophrenia by influencing cognitive 
performance (as indexed by educational level) [x2 (2) = 6.35, p=0.042, OR =2.5] and 
course of illness [x2 (2) = 8.98, p=0.011, OR =2.25].
This is the first time that Y chromosome haplogroups and their effect have been 
investigated in schizophrenia. This was achieved by performing a case-control 
association study using nine Y chromosome markers. Although there was no evidence 
of an association of Y chromosome haplogroups with schizophrenia, the results are 
still important since they are novel.
Our results indicated a modifying effect of Y chromosome on clinical outcome. 
Haplogroup 1 had a significantly higher frequency of individuals with good outcome 
compared to haplogroup 2, which had a higher frequency of individuals with poor 
outcome. The OR was 2.25, which means that the odds of an individual having a good 
outcome were 2.25 times higher, if they belonged to haplogroup 1 than if they 
belonged in haplogroup 2. There was no difference in haplogroup 3.
There was also a difference between the Y chromosome haplogroups in terms of 
educational level. The frequencies of individuals with high and low educational levels 
were different in haplogroups 1 and 3. The OR was 2.5, which means that the odds of 
an individual having high education were 2.5 times higher, if they belonged to 
haplogroup 1 than if they belonged in haplogroup 3. Thus, there could be an effect of 
Y chromosome on our proxy for cognitive ability.
Phenotypic analysis was performed using both haplogroups and SNP alleles. These 
two types of analysis should yield the same pattern of results, since all the individuals 
were categorised in the Y chromosome haplogroups according to the Y chromosome 
SNP alleles that they possessed. The reason that both analyses were performed was
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because the aim was to test if any specific Y chromosome haplogroup had a 
modifying effect on ADHD and also to test if this effect was linked to a specific 
mutation on the Y chromosome. This is indeed observed for clinical outcome and 
educational level, where both SNP analyses (Tables 8-5 and 8-6) and haplogroup 
analysis (Figures 8-6 and 8-7) provide significant results. There was also a significant 
association of SNP M405 and worst ever GAS (Table 8-3). However, none of the 
other Y chromosome SNPs were significant and the difference in worst ever GAS 
between the two alleles was very small. In addition, there was no evidence of 
association in the haplogroup analysis. For these reasons, we conclude that the data do 
not provide evidence for an association with worst ever GAS.
The pattern of the results in the schizophrenia sample is interesting. Haplogroup 1 
seems to be associated with good disease outcome and high education. These results 
seem to be contradictory to the findings in the ADHD sample, where haplogroup 3 
was associated with higher IQ scores compared to haplogroup 1. However, in the 
ADHD sample, IQ scores were available, which provide a more direct estimation of 
cognitive function than educational level. Educational level is not always correlated 
with IQ. Especially in a disorder such as schizophrenia it is very difficult to estimate 
the educational level that the patients would have achieved if they had not been 
affected by schizophrenia. Even when the disease is not very severe, the age of onset 
(especially in men who have an earlier age of onset than women) could coincide with 
an important period for education in an individual’s life. Thus, the disruption that is 
caused can have devastating effects on the qualifications that the individual can 
obtain. Furthermore, cognitive impairment is common in schizophrenia and it persists, 
even when there are no other symptoms present. Thus, it could also affect the 
educational level that patients with schizophrenia can achieve.
Another explanation for the different pattern of results in ADHD and schizophrenia is 
that they are two aetiologically different disorders and the mechanism by which the Y 
chromosome operates to modify the phenotype could be different in these two 
disorders. This is likely because both disorders are complex with very poorly 
understood neuropathology. The reason that they were both studied in this study is 
that they are both neurodevelopmental disorders with a male preponderance. It is not 
implied at any point that they are aetiologically similar. It is also likely that Y
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chromosome variants have pleiotropic effects. Finally, one or even both sets of 
findings may be a false positive.
There are some important advantages in this study. Firstly, both the case and the 
control sample were of British Caucasian origin. The Y chromosome markers 
genotyped were chosen after careful consideration to represent UK populations. The 
pattern of haplogroup distribution in patients and controls samples was as expected 
for a UK population and it was comparable with the ADHD samples discussed in 
Chapter 7. The ascertainment of the patients with schizophrenia and the collection of 
phenotypic measures were very careful and strict.
Apart from the fact that educational level was used as a proxy for cognitive ability in 
schizophrenia, there are other limitations in this study. Although the phenotypes that 
were studied were chosen a priori from the large number of collected phenotypic 
measures because they were known to be sexually dimorphic, it is possible that the 
significant findings are the result of multiple testing. Since this study presents novel 
findings and there have been no previous studies on the Y chromosome in 
schizophrenia, the need to correct for multiple testing for the number of phenotypic 
measures tested was considered less of a priority compared to investigating the role of 
Y chromosome in male susceptibility to schizophrenia. Replication of these findings 
in an independent sample is required to provide supporting evidence. In addition, 
phenotypic analysis using SNPs was performed as a secondary analysis to confirm 
haplogroup analysis results and for this reason no multiple testing correction was 
performed.
Another important issue is the limited power to detect associations with risk alleles of 
small effect sizes. It is likely that complex disorders, like schizophrenia, are caused by 
a large number of risk variants with small effects but detecting them requires large 
sample sizes. The power o f this study to detect an association with an OR<l .2 was 
limited to 45% provided that the risk allele was relatively common according to 
power calculations. However, for variants of large effect sizes (similar to the ones 
detected for clinical outcome and educational level) the power was increased to 
>99%.
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It is also possible that the significant associations are confounded by other factors that 
have not been measured. Social class and location of the patients could be some of 
these factors but we were not able to obtain information about these factors for the 
patients with schizophrenia.
This is the first study to assess the effect of Y chromosome on male susceptibility to 
schizophrenia. Our results indicate a possible influence of Y chromosome variants on 
the course of the illness and the educational level achieved in patients with 
schizophrenia but they would need to be replicated in order to provide solid evidence. 
IQ scores would be more suitable to assess the effect of Y chromosome on cognitive 
performance in schizophrenia than the educational level which might be severely 
compromised by the symptoms of the disorder.
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Chapter 9 Investigating the role of Y chromosome in
cognitive ability using a population cohort
9.1 Aims of the study
The aims of the present study were to investigate the role of the Y chromosome 
variation in cognitive ability using a population cohort and seek replication of our 
previous results about Y chromosome haplogroups influencing cognitive ability in 
ADHD.
In Chapter 7, an association between Y chromosome haplogroups and performance 
and full scale IQ was found in individuals with ADHD. Since this analysis was 
performed within the sample of patients with ADHD, it was not possible to delineate 
whether Y chromosome variation is associated with IQ only in individuals with 
ADHD or whether this is true for non-affected populations as well. In addition, it was 
desirable to perform phenotypic analysis using the Y chromosome haplogroups in an 
independent sample of patients with ADHD in order to try and replicate our 
significant findings.
IQ data from the control sample used to perform the case-control association studies 
on ADHD and schizophrenia, the 1958 UK Birth Cohort, could not be provided for 
the genotyped individuals. For this reason, we decided to use data from the AVON 
Longitudinal Study of Parents and Children (ALSPAC) (Golding 2004). Two Y 
chromosome SNPs were genotyped in 3,749 male individuals from the ALSPAC 
study and the genotypes were used to categorise each individual to one of the three 
haplogroups used in the previous phenotypic analysis for ADHD (Figure 9-1). The 
haplogroups were first tested for association with full scale (FSIQ), performance 
(PIQ) and verbal IQ (VIQ) using all available genotyped individuals in order to 
investigate the effect of Y chromosome haplogroups on IQ in a general population. 
Then, the same analysis was performed for those with an ADHD diagnosis to seek 
replication for our previous findings.
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9.2 Materials and methods
9.2.1 ALSPAC sample and data description
The Avon Longitudinal Study of Parents and Children (Golding 2004) is a general 
population cohort enrolling pregnant women resident in Avon, South West England, 
with delivery dates between December 1992 and April 1999. The cohort consisted of 
14,062 live births from 14,541 enrolled pregnant women with 13,985 surviving 
offspring at twelve months. Questionnaires were sent at regular intervals during 
pregnancy and following childbirth and biological samples were taken from parents 
and children including blood samples from which DNA was extracted. Ethical 
approval for the study was obtained from the ALSPAC Law and Ethics Committee 
and the Local Research Ethics Committees.
From age 7, all children were invited for an annual assessment of physical and 
psychological development, and up to 8,000 children continue to attend each year. 
10% of the sample, known as Children in Focus, attended clinics at the University of 
Bristol at various intervals. The present study concerns cognitive assessments 
undertaken at age 8. IQ was assessed at age 8 using the WISC-III for the children 
attending the Children in Focus clinics. DSM-IV ADHD symptoms were assessed at 
age 7.5 years from parent reports using the Development and Well-being Assessment 
(DAWBA) (Goodman et al. 2000). The DAWBA is a package of questionnaires, 
interviews, and rating techniques designed to generate ICD-10 and DSM-IV 
psychiatric diagnoses on 5-16 year-olds. Diagnosis was also confirmed by a clinician.
To increase sample homogeneity, only children of Caucasian ethnicity (95% of the 
cohort) were included in our study.
The total sample used for analysis consists of 3,749 male individuals. The DAWBA at 
7.5 years was completed for 74% of those individuals. 90 (3.3%) individuals met 
criteria for DSM-IV ADHD diagnosis. The mean full scale IQ score was 105.2 (SD 
16.7, range 49-151). 2,491 individuals (66%) completed the WISC-III at the Children 
in Focus clinics. In order to make the ALSPAC ADHD cases as comparable as 
possible with the Cardiff ones, children with IQ<70 and/or autism were excluded. 63
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children from ALSPAC had an ADHD diagnosis, full IQ data and met the inclusion 
criteria.
9.2.2 Selection of Y chromosome SNPs
In Chapter 7 ,1 have described how the initial nine haplogroups were merged into 
three haplogroups according to ancestry in order to facilitate statistical analysis. Three 
SNPs defined these three haplogroups (M89, M l73 and M405) (Figure 9-1).
DE*
R1*
R 1b 3
M 405
M9
18.4%
M 405 M 153
M89
M 173
53.3%
28.3%
M 410
M 201 M 170 M 304
Figure 9-1. The Y chrom osom e haplogroups captured in this study were merged into three to 
facilitate phenotypic analysis. There were no individuals belonging in haplogroup F*. 
Percentages represent the frequencies o f the three Y chromosome haplogroups in 4,950 UK men 
genotyped in total in this study. Figure is the same as in Chapter 7 and is repeated to facilitate
reading.
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In order to categorise the ALSPAC individuals into these three haplogroups, two 
SNPs were genotyped, M l73 and M405. M l73 defines haplogroup 2 and M405 
defines haplogroup 3. Each individual was categorised in only one haplogroup 
according to whether they possessed the ancestral (0) or derived (1) allele of these two 
SNPs (Table 9-1). There was no need to genotype SNP M89 because if individuals 
possessed the ancestral alleles for these two SNPs, they would definitely belong to 
haplogroup 1.
Table 9-1. Combination of SNP alleles for each Y chromosome haplogroup. 0 represents the 
ancestral state of each SNP and 1 the derived state
M173 Allele M405 Allele
Haplogroup 1 0 0
Haplogroup 2 1 0
Haplogroup 3 1 1
9.2.3 DNA samples and genotyping
DNA was obtained from venous blood, mouthwash samples and cell lines for the 
ALSPAC individuals. Genotyping for SNPs M l73 and M405 was performed by K 
Biosciences (Hoddesdon, UK) (http://www.kbioscience.co.uk/genotyping/) in order to 
preserve DNA stocks and reduce costs. Genotyping was approved by the ALSPAC 
committee.
9.2.4 Statistical analysis
Y chromosome haplogroups were tested for association with PIQ, VIQ and FSIQ 
using ANOVA. The threshold of significance was set at p<0.05. With this threshold 
of significance, this study had >95% statistical power to detect effect sizes of 1.5 
when the risk allele frequency was 0.3-0.4. For effect sizes of 1.3 the power was 
reduced to 70% and for effect sizes of 1.2 the power was 41%. For rarer alleles with 
frequencies of 0.1-0.2 the power was 90% for effect sizes of 1.5, 54% for effect sizes 
of 1.3 and 30% for effect sizes of 1.2. The prevalence of ADHD was considered to be 
4% according to Cuffe et al. (2005). Statistical power calculations were performed
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using the Genetic Power Calculator (Purcell et al. 2003). Normality of distribution for 
each of the dependent variables was assessed using measures of skewness and 
kurtosis (they should not exceed 1 and 3 respectively). The significance level of the 
Kolmogorov-Smimov test was also taken into account.
9.3 Results
9.3.1 Frequencies of Y chromosome haplogroups in ALSPAC
The frequencies of Y chromosome haplogroups in all the genotyped individuals from 
ALSPAC (n=3,749) are shown in Table 9-2.
Table 9-2. Y chromosome haplogroup distribution in all individuals from ASLPAC
Y chromosome 
haplogroup
Frequency (%) in 
total ALSPAC 
sample
1 27.1
2 49.5
3 23.4
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9.3.2 Testing for association of Y chromosome haplogroups with IQ in a general 
population cohort
The full sample of 3,749 male individuals from ALSPAC was stratified according to 
the Y chromosome haplogroup they belonged to. Due to incomplete data, 2,495 
individuals had PIQ scores, 2,491 individuals had VIQ scores and 2,482 individuals 
had FSIQ scores.
As shown in the graph, PIQ, VIQ and FSIQ scores (Figure 9-2) do not vary in the 
three haplogroups. Performing ANOVA showed that there is no significant difference 
between the haplogroups in terms of FSIQ [F(2,2479)=2.52, p=0.081, r =0.045], PIQ 
[F(2,2492)=1.36, p=0.26, r =0.039] and VIQ [F(2,2488)=2.13, p=0.12, r =0.037].
Y chrom osom e haplogroups from ancient (1) to  recent (3) 
evolutionary
Figure 9-2. FSIQ, PIQ and VIQ scores in 3 Y chromosome haplogroups within all available 
individuals from ALSPAC population cohort, p values obtained from ANOVA comparing each 
of the variables separately in 3 Y chromosome haplogroups are shown on the graph
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9.3.3 Testing for association Y chromosome haplogroups with IQ in ALSPAC
ADHD patients
90 males from ALSPAC met criteria for DSM-IV ADHD diagnosis. 21 children did 
not complete the WISC-III while 6 children had an IQ score below 70. These 63 
individuals were stratified according to the Y chromosome haplogroup they belonged 
to. Then, PIQ, VIQ and FSIQ scores were compared in these three groups using 
ANOVA.
As shown in the graph, scores of PIQ, VIQ and FSIQ, (Figure 9-3) do not vary in the 
three haplogroups. Performing ANOVA showed that there is no significant difference 
between the haplogroups in terms of FSIQ [F(2,60)=0.54, p=0.59, r =0.12], PIQ 
[F(2,60)=0.16, p=0.85, r =0.1] and VIQ [F(2,60)=0.34, p=0.71, r =0.1].
Y chrom osom e haplogroups from ancient (1) to  recent (3) 
evolutionary
Figure 9-3. FSIQ, PIQ and VIQ scores in 3 Y chromosome haplogroups within 63 individuals 
from ALSPAC that meet diagnosis for ADHD, p values obtained from ANOVA comparing each 
of the variables separately in 3 Y chromosome haplogroups are shown on the graph
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9.4 Discussion
The aims of this study were to investigate the association between Y chromosome 
haplogroups and IQ in a non-clinical population and to attempt to replicate the finding 
that Y chromosome haplogroup 3 is associated with higher FSIQ and PIQ scores 
compared to Y chromosome haplogroup 1 in an independent sample of patients with 
ADHD. Our findings indicate that there is no association between Y chromosome 
haplogroups and IQ in the normal population (FSIQ [F(2,2479)=2.52, p=0.081, r 
=0.045], PIQ [F(2,2492)=1.36, p=0.26, r =0.039] and VIQ [F(2,2488)=2.13, p=0.12, r 
=0.037]). Although there was no significant difference between the Y chromosome 
haplogroups in terms of IQ in the sample of ADHD patients from ALSPAC (FSIQ 
[F(2,60)=0.54, p=0.59, r =0.12], PIQ [F(2,60)=0.16, p=0.85, r =0.1] and VIQ 
[F(2,60)=0.34, p=0.71, r =0.1]), an effect of Y chromosome haplogroups on IQ in 
patients with ADHD cannot be excluded due to the small number of available patients 
for the study.
This is the first study to investigate the effect of Y chromosome haplogroups on IQ in 
the general population. Although the Y chromosome has been investigated in relation 
to brain function and behaviour using animal models, research on the role of the Y 
chromosome in human behaviour has been limited. These results suggest that there is 
no effect of Y chromosome haplogroups on IQ in the general population and that our 
previous finding of association between Y chromosome haplogroups and IQ is at best 
limited to patients with ADHD only or is a false positive finding.
Our analysis within the sample of patients with an ADHD diagnosis in the ALSAC 
sample showed no significant difference in IQ scores in the different Y chromosome 
haplogroups. However, the number of individuals that could be included in the study 
was very small. Only 63 males in ALSPAC met criteria for ADHD diagnosis while 
satisfying our inclusion criteria and it is likely that this sample was underpowered to 
detect an association. Assuming an effect size of 1.2-1.3 (similar to the one that was 
achieved for the Cardiff ADHD cases), the power to detect an association with such a 
small sample was limited to <20%. In order to have >90% power to detect this effect, 
a large independent sample of UK ADHD cases (>800) with available data on IQ 
would be required.
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An important issue in this attempt to replicate our results is whether the two samples 
of patients with ADHD are comparable. In an effort to make the samples as 
comparable as possible the same exclusion criteria as for the Cardiff ADHD cases 
were applied to ALSPAC as well. Children with IQ<70 and/or autism were excluded. 
However, it is interesting that the mean FSIQ score in ADHD cases in ALSPAC was 
105 compared to a mean FSIQ score of 89 for the Cardiff sample. The reasons for this 
are likely to reflect differences in ascertainment and assessment.
In the ALSPAC sample there were only 90 male individuals that met DSM-IV criteria 
for ADHD diagnosis. Of those, 21 individuals (22%) failed to complete the WISC-III 
at the Children in Focus Clinics. It is likely that people who failed to complete the 
WISC-III are those who had more attention problems or found it more difficult to do 
so. For these reasons, it is possible that people with more severe ADHD and lower IQ 
scores failed to complete the tests and thus were not included in the study.
Another reason for the difference in the mean IQ scores between the Cardiff and the 
ALSPAC ADHD samples is that the Cardiff cases consist of children referred to 
district child and adolescent psychiatry and paediatric clinics while the ALSPAC 
ADHD sample is part o f a general population cohort, so it can include children who 
have not yet received ADHD diagnosis by a health professional. In addition, children 
with ADHD and low IQ (but still above 70) are more likely to come to the attention of 
psychiatric services compared to children with ADHD and higher IQ, where the 
impairment caused by the disorder can be masked by the IQ. Thus, it can be argued 
that the Cardiff ADHD sample includes more severe ADHD cases that are selected 
for low IQ.
To conclude, there is the possibility of selection attrition where people with low IQ 
scores and ADHD are less likely to attend the Children in Focus Clinic and/or fully 
complete the WISC-III but are more likely to come to the attention of the Cardiff 
research team.
The main advantage of this study is that a large general population sample of UK 
origin was used. This was essential in ruling out an association of Y chromosome 
haplogroups with IQ in the general population. It is also important that we attempted 
to replicate our results in a non-clinical sample of patients with ADHD applying the
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same exclusion criteria to make the samples as comparable as possible. Although the 
results did not reach statistical significance, the number of ADHD cases in ALSPAC 
is small and a large sample of cases with ADHD and IQ data would be required to 
increase confidence in our results.
Chapter 10 Testing for an indirect effect of Y chromosome
variation on ADHD and schizophrenia -  
Interaction with Tyrosine Hydroxylase
10.1 Introduction
10.1.1 SRY (Sex Determining Region of chromosome Y)
One of the most important genes on the Y chromosome is the SRY  gene (Sex 
Determining Region of chromosome Y). The SRY  gene, apart from being solely 
responsible for male sex differentiation, has been implicated in brain function. It is 
transcribed in the hypothalamus and the frontal and temporal cortex of the adult male 
human brain (Lahr et al. 1995). The expression of SRY shows developmental changes 
with circular, untranslatable transcripts seen prenatally and linear, translatable 
transcripts postnatally (Figure 10-1) (Mayer et al. 2000). However, due to the very 
low levels of mRNA there is only one report of SRY protein detected in human 
embryonic testes and none for any other species or tissue (Poulat et al. 1995).
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Figure 10-1. Different developmental profile of SRY. Linear transcripts that are translated 
postnatally and circular transcripts that are not translated prenatally. Taken from Mayer et al.
(2000)
10.1.2 Tyrosine Hydroxylase (77/) function
One way that SRY can affect brain function is by interacting with autosomal genes 
which are known to be expressed in brain. One such hypothesised interaction is with 
the Tyrosine Hydroxylase (77/) gene (see later). The TH gene codes for an enzyme 
that catalyses the conversion of tyrosine to dihydroxyphenylalanine (L-DOPA)
(Figure 10-2). This initial step is the rate-limiting step in the production of 
catecholamines. Dopamine is the next catecholamine to be produced followed by 
norepinephrine and epinephrine (Figure 10-2) (Naoi and Parvez 1993). TH is an 
oxygenase and is found in the cytosol of all cells containing catecholamines.
The dopaminergic pathway has been implicated in a number of neuropsychiatric 
disorders with higher male prevalence, such as ADHD, Parkinson’s and schizophrenia 
as well as cardiovascular disease, which is also more prevalent in males. Specifically, 
stimulant medication used in ADHD acts by increasing the availability of 
extracellular dopamine (Volkow and Swanson 2003). Further evidence about the 
involvement of dopamine in ADHD comes from nueroimaging studies (Spencer et al. 
2005) and animal studies, including that of the DA T knockout mouse (Gainetdinov 
2007). Dopamine is thought to be involved in schizophrenia according to the 
hypothesis that the disorder is caused by increased dopaminergic transmission
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(Pearlson 2000). Antipsychotic drugs work by blocking dopamine receptors and 
dopamine agonists, such as amphetamines, can provoke psychotic symptoms 
(Pearlson 2000).
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Figure 10-2. Catecholamine synthesis (Edinformatics.com 1999) 
(http://www.edinformatics.com/interactive_molecules/info/adrenaline.htm)
185
10.1.3 TH gene
The TH gene, located at 1 lpl5.5, has 14 exons and spans approximately 8 kb. There 
are four different TH isoforms resulting from alternative splicing of a single gene. All 
isoforms are expressed in the human brain and specifically, the substantia nigra and 
locus coeruleus. Isoform 1 has the highest TH activity of all other isoforms (Nagatsu 
and Ichinose 1991).
10.1.4 TH associations
The most studied polymorphism in the TH gene is an intronic polymorphic TCAT 
repeat (HUMTH01). This microsatellite is functional and has been found to regulate 
transcription (Albanese et al. 2001). Mutations in the TH gene have been associated 
with autosomal recessive Segawa Syndrome, a form of infantile parkinsonism 
(Verbeek et al. 2007).
The chromosomal region l ip  harbours another two genes, IGF2 (Insulin-like growth 
factor 2) and INS (insulin), in close proximity with TH. Due to the association of these 
genes with obesity, diabetes and hypertension, TH  has been studied in relation to 
these conditions as well (Rodriguez et al. 2004).
Due to the possible involvement of dopamine in psychiatric disorders, 77Thas been 
studied in schizophrenia, alcohol (Dahmen et al. 2005) and nicotine dependence 
(Rodriguez et al. 2006), bipolar disorder (Byerley et al. 1992), autism and ADHD 
(Comings et al. 1995). In schizophrenia, association studies have focused on the 
tetranucleotide repeat in the first intron of the gene (Meloni et al. 2002). Positive 
(Jacewicz et al. 2006; Kurumaji et al. 2001; Pae et al. 2003) and negative associations 
(Andreou et al. 2009; Ishiguro et al. 1998; Jonsson et al. 1998; Ota et al. 2001) of TH 
variants with schizophrenia have been reported, thus no safe conclusions can be 
drawn. A meta-analysis by the SzGene database showed no evidence of association 
with the SNP rs6356 in TH including four case-control studies performed in Asian 
populations (Schizophrenia Research Forum 2005). Studies on the HUMTH01 
tetranucleotide repeat were not included in the meta-analysis. In ADHD, only three 
studies have examined the association between the HUMTH01 polymorphism on TH
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and ADHD and they have all been negative (Barr et al. 2000; Comings et al. 1995; 
Payton et al. 2001).
Although this intronic microsatellite has been extensively studied in relation to 
psychiatric disorder, there is a lack of studies on the possible association of other 
polymorphisms in the TH gene and the surrounding chromosomal region. Despite this 
polymorphism being functional, it accounts for a small amount of the variation in TH 
gene, which is an important candidate gene for involvement in many psychiatric 
disorders. Another interesting point is that the TH region has not been represented in 
genotyping arrays used for genome-wide association studies up until recently; no TH 
SNPs are present in the Affymetrix GeneChip Human mapping 500K array, which 
has been used for most of the schizophrenia genome-wide association studies. This 
means that recent genome-wide association studies on ADHD, schizophrenia as well 
as other psychiatric disorder have not examined polymorphisms in TH.
10.1.5 Interaction of£/?Fwith TH
SRY can increase reporter gene activity under the control of the tyrosine hydroxylase 
promoter and therefore might mediate regulation of the dopaminergic pathway 
(Milsted et al. 2004). O f particular interest are data suggesting that SRY increases the 
number of dopaminergic neurons in males and compensates for their lack of 
oestrogen. This hypothesis stemmed from the fact that oestrogen in females is known 
to increase TH-expressing neurons (Raab et al. 1995). Most interestingly, Dewing et 
al. (2006) reported that downregulation of SRY using antisense oligonucleotides 
caused a decrease in TH expression and this led to motor deficits in male rats 
(Dewing et al. 2006). This interaction between a Y chromosome gene and an 
autosomal gene expressed in the brain points to another pathway leading to sex 
differences.
Although testing for an interaction of SRY  and TH in our samples of patients with 
ADHD and schizophrenia was of great interest, it was not possible to perform due to 
the limited amount of variation in the SRY  gene. In humans, SR Y  has only one exon 
and it spans 897 bp. We were able to locate only 3 SNPs in the SRY  region using 
UCSC genome browser. Two of these were not polymorphic in our samples and one
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failed to optimise in the genotyping platform used. For this reason, the previously 
genotyped Y chromosome SNPs were used to test for interaction with TH  SNPs that 
showed evidence of association with the disorders. Since the Y chromosome SNPs are 
co-inherited, there would be a high degree of correlation between them and any SRY 
variation. While it was not possible to directly test for interaction between TH and 
polymorphisms in SRY, it was possible to test for interaction between TH variation 
and presence or absence of SRY  i.e. sex.
10.2 Aims of the study
The aim of this study was to investigate if TH is implicated in sex differences in 
ADHD and schizophrenia and test for an interaction with Y chromosome variants. 
First, we tested for a main effect of TH on ADHD and schizophrenia. This was 
undertaken by genotyping 10 TH SNPs in 331 cases with ADHD, 487 cases with 
schizophrenia, 1,076 controls and performing two case-control association studies, 
one for ADHD and one for schizophrenia using a common set of controls. Secondly, 
the hypothesis that TH can have a stronger effect in males was tested by stratifying 
the cases and the control individuals by sex and performing separate association 
testing for males and females. Thirdly, we tested for an interaction between the Y 
chromosome SNPs we had already genotyped and TH  SNPs that showed evidence of 
association with the disorders.
10.3 Materials and methods
10.3.1 ADHD sample description
The ADHD sample used in this study consists of 331 individuals (294 males and 37 
females). It is the same sample used for the Y chromosome study described in 
Chapter 7 with the addition of 121 new male cases and 37 female cases. The sample 
characteristics and assessment remains the same.
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10.3.2 Schizophrenia sample description
The schizophrenia sample used in this study consists of 487 individuals (312 males 
and 175 females). It is the same sample used for the Y chromosome study described 
in Chapter 7 with the addition of 175 female cases. The sample characteristics and 
assessment remains the same.
10.3.3 1958 UK birth cohort control sample
The control sample used in this study consists of 1,076 individuals (646 males and 
430 females) drawn from the 1958 British Birth Cohort as discussed in Chapter 7.
10.3.4 Selection of TH SNPs
TH has 14 exons and spans 3.8 kb. A region including approximately 35 kb around 
the gene was targeted for selecting SNPs in order to capture variation in the promoter 
and any other regulatory regions. The SNPs were selected to include all SNPs that 
were located in the actual gene area and then more tagging SNPs were added to 
maximise the coverage in the surrounding 35 kb area. These extra SNPs were chosen 
using Haploview Tagger 4.1 (pairwise tagging with r2> 0.8). The MassARRAY Assay 
Design software was used to design a panel incorporating the SNPs in question.
We were able to successfully genotype 10 SNPs in both patient and controls samples. 
Table 10-1 shows the SNPs genotyped and their alleles.
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Table 10-1. SNPs in TH 35 kb area genotyped in ADHD cases, schizophrenia cases and controls
SNP rs number Minor allele Major allele
rs 10770140 C T
rs10840489 T C
rs10840490 G C
rs10840491 A G
rsl 1042978 T G
r s l1564703 G A
rsl 1564709 T C
rs2070762 G A
rs4320932 C T
rs7924316 T G
10.3.5 DNA samples and genotyping
DNA was obtained from venous blood, mouthwash sample or saliva samples for the 
ADHD and schizophrenia patients. DNA samples were obtained from the 1958 UK 
Birth Cohort after request. Genotyping was performed with the MassARRAY and 
iPLEX systems (Sequenom, San Diego, CA) according to manufacturers’ 
recommendations. Assays were optimised in 30 CEU individuals. All plates contained 
cases, controls, blanks, and CEU samples. Genotypes were called in duplicate blind to 
sample identity and blind to the other rater. All SNPs included in the association 
analysis had a call rate of >95%. Individuals were only included in analysis if they 
had genotypes for over 80% of the SNPs analysed. All SNPs included in the analysis 
were in Hardy-Weinberg (HW) equilibrium at p>0.001 for both cases and controls. 
For more information about quality control procedures see Appendix I.
10.3.6 Statistical analysis
In order to test for differences in allelic frequencies between cases and controls in the 
ADHD and the schizophrenia case-control samples, PLINK 1.06 (Purcell et al. 2007) 
(http://pngu.mgh.harvard.edu/purcell/plink/), an open-source genome-wide 
association analysis toolset was used. The same package was used to assess Hardy- 
Weinberg (HW) equilibrium for each SNP for cases and controls and to test if the
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difference in call rates for each SNP between cases and controls was statistically 
significant. Secondary analyses including testing for a sex-specific effect and testing 
for an interaction of Y chromosome SNPs with TH SNPs were also performed using 
PLNK 1.06. The same analysis toolset was used to test for interaction of TH SNPs 
with sex.
The threshold of significance was set at p<0.005 after applying a Bonferroni 
correction for the number of genotyped SNPs. With this threshold of significance, this 
study had >95% statistical power to detect effect sizes of 1.5 when the risk allele 
frequency was 0.3-0.4. For effect sizes of 1.3 the power was reduced to 85% and for 
effect sizes of 1.2 the power was 56%. For rarer alleles with frequencies of 0.1-0.2 the 
power was 86% for effect sizes of 1.5, 47% for effect sizes of 1.3 and 25% for effect 
sizes of 1.2. Power estimations were similar for both disorders. The prevalence of 
ADHD was considered to be 4% according to Cuffe et al. (2005) and the prevalence 
of schizophrenia was considered to be 1%. Statistical power calculations were 
performed using the Genetic Power Calculator (Purcell et al. 2003) 
(http://pngu.mgh.harvard.edu/~purcell/gpc/).
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10.4 Results
10.4.1 Case-control association study in ADHD
10.4.1.1 Allelic analysis
10 TH SNPs were genotyped in 331 cases with ADHD and 1076 controls. Allelic 
analysis was performed using PLINK 1.06, which compares the frequencies of each 
SNP allele in cases and controls by applying a Pearson’s chi-square test (df=l). Table 
10-2 summarises these results and shows the frequencies of TH SNP alleles in cases 
and controls.
Table 10-2. Allelic analysis for ADHD case-control association study
SNP rs 
number
MAF (cases) 
% MAF (controls) %
x2 OR 95% Cl p value
rsl 0770140 41.5 37.6 3.32 1.18 0 .99-1 .41 0.068
rsl 0840489 12.8 14.3 0.95 0.88 0 .68 -1 .14 0.33
rsl 0840490 12.8 14.1 0.7 0.9 0 .69 -1 .16 0.4
rs l0840491 13 13.3 0.03 0.98 0 .75 -1 .27 0.87
rsl 1042978 47.7 49.3 0.5 0.94 0 .79 -1 .12 0.48
r s l1564703 39.1 41.2 0.86 0.92 0 .77 -1 .1 0.35
rsl 1564709 10.8 8.8 2.42 1.26 0 .94 -1 .68 0.12
rs2070762 46.1 50.1 3.3 0.85 0 .7 -1 .01 0.069
rs4320932 20 18.8 0.46 1.08 0 .87 -1 .35 0.5
rs7924316 48 45.9 0.96 1.09 0 .92 -1 .3 0.33
MAF: Minor allele frequency, OR: Odds Ratio; Cl: Confidence Interval
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10,4.1.2 Case-control association study within each sex
The ADHD case-control sample was split according to sex. The male sample 
consisted of 294 ADHD cases and 646 controls while the female sample consisted of 
37 ADHD cases and 430 controls. Allelic analysis was performed separately in males 
and females using PLINK 1.06 as before, although the number of females is too small 
for meaningful interpretation. Table 10-3 summarises the results in males while Table 
10-4 summarises the results in females.
Table 10-3. Allelic analysis for ADHD case-control association study in males only
SNP rs 
number
MAF (cases) 
%
MAF 
(controls) % x2 OR 95% Cl p value
rsl 0770140 41 37.8 1.69 1.14 0 .9 3 -1 .4 0.19
rs l0840489 12.9 13.5 0.15 0.94 0.71 -  1.26 0.7
rs l0840490 13.1 13.5 0.07 0.96 0 .72 -1 .28 0.79
rs l0840491 13.3 12.6 0.17 1.06 0 .8 -1 .4 2 0.68
r s l1042978 48 49.5 0.41 0.94 0 .77 -1 .14 0.52
r s l1564703 39.5 39.9 0.03 0.98
<N1O00o 0.85
r s l1564709 11.5 8.7 3.66 1.37 0 .99 -1 .88 0.056
rs2070762 45.7 50.5 3.74 0.82 0.68 - 1 0.053
rs4320932 20.5 19.1 0.51 1.09 0 .8 6 -1 .4 0.48
rs7924316 48.5 46 1.01 1.11 0.91 -  1.34 0.32
MAF: Minor allele frequency, OR: Odds Ratio; Cl: Confidence Interval
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Table 10-4. Allelic analysis for ADHD case-control association study in females only
SNP rs 
number
MAF (cases) 
%
MAF 
(controls) % x2 OR 95% Cl p value
rsl0770140 45.8 37.2 2.12 1.43 0 .88 -2 .32 0.15
rsl 0840489 12.2 15.5 0.58 0.76 0 .37 -1 .56 0.45
rsl 0840490 10.8 15 0.96 0.69 0 .32 -1 .47 0.33
rsl 0840491 11.1 14.3 0.57 0.75 0 .3 5 -1 .6 0.45
rsl 1042978 46 49 0.25 0.89 0 .55-1 .43 0.62
rsl 1564703 36.1 43 1.28 0.75 0 .46 -1 .24 0.26
rsl 1564709 5.4 9.0 1.08 0.58 0 .21 -1 .64 0.3
rs2070762 48.7 49.4 0.02 0.97 0 .6 -1 .5 6 0.9
rs4320932 16.2 18.4 0.22 0.86 0 .45-1 .63 0.64
rs7924316 44.6 45.7 0.03 0.96 0 .59 -1 .54 0.86
MAF: Minor allele frequency, OR: Odds Ratio; Cl: Confidence Interval
According to the results, there is no evidence of a significant association of TH  SNPs 
and ADHD diagnosis. There is neither a male-specific effect of TH variation on 
ADHD. There are too few females to draw meaningful conclusions.
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10.4.2 Case-control association study in schizophrenia
10.4.2.1 Allelic analysis
10 TH SNPs were genotyped in 487 cases with schizophrenia and 1,076 controls. 
Allelic analysis was performed using PLINK 1.06, which compares the frequencies of 
each SNP allele in cases and controls by applying a Pearson’s chi-square test (df=l). 
Table 10-5 summarises these results and shows the frequencies of TH SNP alleles in 
cases and controls.
Table 10-5. Allelic analysis for schizophrenia case-control association study
SNP rs 
number
MAF 
(cases) %
MAF 
(controls) % x2 OR 95% Cl p value
rsl0770140 41.6 37.6 4.50 1.18 1.01 -  1.38 0.034*
rsl 0840489 13.5 14.3 0.36 0.93 0 .75-1 .17 0.55
rsl 0840490 13.6 14.1 0.18 0.95 0 .76-1 .19 0.67
rs l0840491 13 13.3 0.04 0.98 0 .78-1 .22 0.84
r s l1042978 46.1 49.3 2.82 0.88 0.75-1 .02 0.093
rsl 1564703 43.6 41.2 1.68 1.11 0 .95-1 .29 0.19
rsl 1564709 11.2 8.8 4.51 1.31 1.02-1.68 0.034*
rs2070762 48.4 50.1 0.81 0.93 0 .8 -1 .0 9 0.37
rs4320932 17.3 18.8 1.04 0.90 0 .74-1 .1 0.31
rs7924316 46.5 45.9 0.11 1.03 0 .8 8 -1 .2 0.74
MAF: Minor allele frequency, OR: Odds Ratio; Cl: Confidence Interval;
*: significant at the p<0.05 level
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10.4.2.2 Case-control association study within each sex
The schizophrenia case-control sample was split according to sex. The male sample 
consisted of 312 schizophrenia cases and 646 controls while the female sample 
consisted of 175 schizophrenia cases and 430 controls. Allelic analysis was performed 
separately in males and females using PLINK 1.06 as before. Table 10-6 summarises 
the results in males while Table 10-7 summarises the results in females.
Table 10-6. Allelic analysis for schizophrenia case-control association study in males only
SNP rs 
number
MAF 
(cases) %
MAF 
(controls) % x2 OR 95% Cl p value
rs l0770140 44.2 37.8 7.13 1.3 1.07-1.58 0.008**
rs l0840489 12.4 13.5 0.45 0.9 0.68-1.21 0.5
rs l0840490 13 13.5 0.12 0.95 0 .72 -1 .26 0.73
rs l0840491 12.4 12.6 0.01 0.99 0 .74-1 .32 0.92
r s l1042978 43.8 49.5 5.44 0.8 0.66 -  0.96 0.02*
r s l1564703 43.9 39.9 2.71 1.18 0.97-1 .43 0.1
r s l1564709 11.7 8.7 4.43 1.4 1.02-1.91 0.035*
rs2070762 47.1 50.5 1.98 0.87 0 .72-1 .06 0.16
rs4320932 18.1 19.1 0.24 0.94 0.73-1.21 0.62
rs7924316 48.2 46 0.86 1.1 0 .90-1 .33 0.35
MAF: Minor allele frequency, OR: Odds Ratio; Cl: Confidence Interval;
*: significant at the p<0.05 level; **: significant at the p<0.01 level
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Table 10-7. Allelic analysis for schizophrenia case-control association study in females only
SNP rs 
number
MAF 
(cases) %
MAF 
(controls) % x2 OR 95% Cl p value
rsl0770140 36.9 37.2 0.01 0.99 0 .76 -1 .28 0.92
rsl 0840489 15.4 15.5 0.001 0.99 0 .70-1 .41 0.97
rsl 0840490 14.6 15 0.04 0.97 0 .68 -1 .37 0.85
rsl 0840491 14.1 14.3 0.01 0.98 0 .6 9 -1 .4 0.91
rsl 1042978 50 49 0.11 1.04 0 .81 -1 .34 0.74
rsl 1564703 43.1 43 0.003 1.01 0 .78 -1 .29 0.96
rs l1564709 10.3 9 0.52 1.17 0 .77 -1 .77 0.47
rs2070762 50.6 49.4 0.13 1.05 0 .82 -1 .34 0.72
rs4320932 15.8 18.4 1.16 0.83 0 .59 -1 .16 0.28
rs7924316 43.4 45.7 0.51 0.91 0 .71 -1 .17 0.47
MAF: Minor allele frequency, OR: Odds Ratio; Cl: Confidence Interval
In the total sample, there is evidence of a nominally significant association for SNPs 
rs l0770140 (p=0.034, OR=1.18) and rsl 1564709 (p=0.034, OR=1.31) with 
schizophrenia. These associations become stronger in the male-only sample of 
patients with schizophrenia (p=0.008, OR=1.3 for rsl0770140 and p=0.035, OR=1.4 
for rsl 1564709) and also a third SNP, rsl 1042978, becomes nominally significant 
(p=0.02, OR=0.8). The direction of effects was the same between the male-only and 
the combined sample. There is no evidence of association of any SNP in the female- 
only sample of patients with schizophrenia. The three SNPs that showed evidence of 
significance were tested for interaction with sex. None of them significantly interacted 
with sex (p=0.099 for rsl0770140, p=0.1 for rsl 1042978 and p=0.57 for rsl 1564709).
The SNPs that give nominally significant p values in the sample of all schizophrenia 
patients, rsl0770140 and rsl 1564709, are not in high LD (^=0.22) (see Figure 10-3). 
The SNP that is only significant in the male-only sample, rsl 1042978, is in LD with 
rs l0770140 (i*=0.66) but not with rsl 1564709 (r2=0.16) (see Figure 10-3). These 
three SNPs are located upstream of the TH gene.
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Figure 10-3. Pairwise LD between the SNPs genotyped. The Haploview LD plot shows the r2 
values between each SNP pair in the CEU population using data from HapM ap Phases 1 and 2
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10.4.3 Testing for an interaction between Y chromosome and TH SNPs
It was decided a priori that we would test for interactions only in cases where there 
was evidence of a main effect of certain SNPs on the disorder. This was important in 
order to limit the number of tests performed and thus increase the power to detect 
significant interactions.
Since there was no evidence of a significant association of TH SNPs and ADHD 
diagnosis, no interaction testing was performed in the ADHD sample. In the 
schizophrenia sample, there was evidence of a main effect on the disorder for three 
SNPs (rsl0770140, rsl 1564709 and rsl 1042978) and these were tested for interaction 
with 9 Y chromosome SNPs previously genotyped in 313 male cases with 
schizophrenia and 637 male control samples from the 1958 Birth Cohort, as discussed 
in Chapter 7 and 8. PLINK 1.06 was used to test for interaction.
There was no evidence of a significant interaction between the TH and the Y 
chromosome SNPs tested in the schizophrenia sample. For a table with all the 
interactions, see Appendix III.
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10.5 Discussion
In this chapter the hypothesis that TH is implicated in sex differences in ADHD and 
schizophrenia was tested. The main reason for hypothesising that TH can be 
implicated in sex differences is because of previous evidence of interaction with the 
SRY gene on the Y chromosome. In addition, TH is involved in dopamine metabolism 
which is important for both ADHD and schizophrenia. Although TH seems an 
obvious candidate for neuropsychiatric disorders, there has been limited research on 
the role of polymorphisms in the TH gene apart from an intronic microsatellite. In 
addition, the TH  gene region has not been examined in genome-wide studies because 
it was not covered by previous genotyping arrays used for genome-wide association 
studies of psychiatric disorders.
In our study, there was no main effect of TH  SNPs on ADHD. This was also true 
when the sample was split according to sex. These results agree with the previous 
studies where no association between TH and ADHD was found (Barr et al. 2000; 
Comings et al. 1995; Payton et al. 2001). However, these studies are different to this 
one because they just focused on a microsatellite repeat in intron 1, while in our study 
SNPs that cover TH  and the area around the gene were chosen. Although TH seems to 
be a very strong candidate for involvement in ADHD, the neurobiology of ADHD is 
largely unknown and there is no reason why other neurotransmitter pathways or 
indeed completely novel mechanisms could not be implicated in the pathogenesis of 
ADHD.
In the schizophrenia case-control association study there were two SNPs which 
showed some evidence of association [rsl0770140 (p=0.034, OR=1.18) and 
rsl 1564709 (p=0.034, OR=1.31], although they did not reach the required level of 
significance when correcting for multiple testing. The associations were driven by the 
male individuals o f the schizophrenia sample, as shown by the fact that the 
association with the previously associated SNPs becomes more strongly significant 
(p=0.008, OR=1.3 for rsl0770140 and p=0.035, OR=1.4 for rsl 1564709) and also 
one more SNP, si 1042978, became nominally significant (p=0.02, OR=0.8).
However, all the results in the male-specific sample of the schizophrenia patients
200
were only nominally significant. In addition, there were 312 male patients and only 
175 female patients with schizophrenia. When testing TH SNPs for interaction with 
sex, there were no significant results. This means that the association of TH SNPs 
with schizophrenia could exist in the female sample as well but there was not enough 
power to detect it due to the limited number of female patients with schizophrenia. It 
is also possible that these are false positive results especially since they do not achieve 
the required level of significance when correcting for multiple testing. These results 
are in agreement with previous studies that have failed to find an association between 
TH and schizophrenia (Andreou et al. 2009; Ishiguro et al. 1998; Jonsson et al. 1998; 
Ota et al. 2001). The studies that have found an association were all performed in 
non-European populations (Jacewicz et al. 2006; Kurumaji et al. 2001; Pae et al. 
2003). In addition, all the studies have focused on the tetranucleotide repeat of the 
first intron while our study achieved a more comprehensive coverage of the gene.
It is possible that TH has a significant effect not on the disorder itself but on some 
aspect of the phenotype, as it was the case for the Y chromosome haplogroups. 
However, in the case of Y chromosome haplogroups we had a priori reasons to 
choose the specific measures due to the fact that were sexually dimorphic and thus 
could be modified by Y chromosome variation. There was no previous knowledge of 
any phenotypic aspects of ADHD or schizophrenia that is affected by TH variation 
and thus it was not possible to select measures more likely to be modified by TH.
One of the strongest points of this study was that there was a strong a priori reason 
for testing TH for involvement in sex differences in ADHD and schizophrenia. There 
is evidence that SRY  regulates TH  expression (Milsted et al. 2004) and animal studies 
have shown that TH  interacts with SRY  (Dewing et al. 2006). Since oestrogen increase 
TH expression in females, it is intriguing that SRY  was considered to be the factor that 
compensates for the lack of oestrogen in males. Another advantage of this study is 
that we achieved good coverage of the variation not only in the TH gene but also of a 
35kb area around the gene, which includes the promoter region. We decided, instead 
of focusing on the functional polymorphism in intron 1, which had been extensively 
genotyped without strong evidence of involvement in psychiatric disorders, to 
genotype other SNPs which have not been examined by candidate gene or genome- 
wide association studies. Finally, the ADHD and schizophrenia samples were large
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enough to have adequate power to detect alleles with large to medium effect sizes 
(>86%). The level of significance was a priori set at p<0.005 to reflect the number of 
tests performed in each sample.
However, there are some limitations to this study. Firstly, it was not possible to 
genotype four TH SNPs due to technical reasons. One of the SNPs leads to a non- 
synonymous aminoacid sequence change and it would have been of great interest to 
incorporate in the study. Another possible reason for the results is that TH has such a 
small effect size that our statistical power is very limited. The power to detect effect 
sizes smaller than 1.2 is less than 25% unless the risk allele is very common.
Another issue that deserves to be discussed is that SNPs in the SRY  gene that has been 
found to interact with TH  were not genotyped. The SRY  gene was so small (897kb) 
that only three polymorphisms were found. Two of them were actually non- 
polymorphic in our samples. It would have been interesting to investigate whether 
certain SRY alleles interact with TH SNP alleles to increase risk to psychiatric 
disorders.
The issue of testing for interactions has been a matter of debate recently. Power is 
limited when testing for interactions and even more in this case where the sample had 
to be limited to male cases to test for interaction of TH with Y chromosome SNPs.
For this reason it was decided that we would test for interactions only when a main 
effect is found. In this way the number of tests performed was kept to a minimum and 
the power to detect any significant association was not compromised. However, the 
objection here is that some genes may not have any main effect on the disorder and 
yet they could be important for the pathophysiology of the disorder when other 
factors, such as other gene alleles or environmental factors are taken into account.
To conclude, there is no evidence of association of TH  in ADHD. There is weak 
evidence of a male-specific effect of TH on schizophrenia but no evidence of these 
variants interacting with Y chromosome SNPs to increase risk to schizophrenia. Thus, 
replication in larger studies achieving a good coverage of the TH gene and the 
surrounding chromosomal region is needed.
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Chapter 11 General discussion
11.1 Summary of findings
The main aim of this thesis was to investigate the genetic causes of sex differences in 
ADHD and schizophrenia focusing on the previously neglected Y chromosome. Both 
disorders were studied in this thesis due to their neurodevelopmental nature and male 
excess. In ADHD there are consistently higher rates of male patients and the 
manifestation of the disorder also differs between male and female patients (Cuffe et 
al. 2005). The male excess in schizophrenia is not as profound, although there is a 
substantially earlier age of onset, more severe disorder and poorer outcome in male 
patients (Grossman et al. 2008; Ober et al. 2008). The causes of sex differences in 
psychiatric disorders as well as in brain and behaviour are likely to be multiple and 
complex. More than 600 genes are differentially expressed in mouse brain (Yang et 
al. 2006) and hormonal, genetic and environmental factors all contribute to the sexual 
dimorphism of the brain. One of the least studied factors (especially in the field of 
psychiatric genetics) is the Y chromosome.
The Y chromosome is 60 Mb in length and most of its part is covered by the male- 
specific region (MS Y), which does not recombine with the X chromosome. The lack 
of recombination contributes to the geographic differentiation of Y chromosome 
haplogroups making the choice of the appropriate haplogroups for the population 
studied crucial in Y chromosome studies. Animal studies have implicated the Y 
chromosome in brain function and behaviour (De Vries et al. 2002; Gatewood et al. 
2006; Tordjman et al. 1995) and individuals with certain Y chromosome 
abnormalities are at increased risk of psychiatric disorders (Gotz et al. 1999; Mulligan 
et al. 2008; Yoshitsugu et al. 2003). One of the most interesting genes on the Y 
chromosome is the SRY gene, which is responsible for male sex differentiation. The 
SRY gene is expressed in mouse and human brain (Dewing et al. 2006; Mayer et al.
1998) and it has been found to interact with the rate-limiting enzyme in dopamine 
metabolism, tyrosine hydroxylase (TH) (Dewing et al. 2006).
The role of Y chromosome in ADHD and schizophrenia was investigated by testing 
for a main effect on the disorders, testing for a modifying effect by influencing
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clinical presentation and/or cognitive performance and finally testing for an 
interaction with TH. The main findings are summarised below:
• No evidence of a main effect of Y chromosome SNPs and haplogroups on 
ADHD and schizophrenia.
• There was evidence of a modifying effect of Y chromosome haplogroups on 
ADHD by influencing IQ scores. Specifically, Full Scale IQ (FSIQ) 
[F(2,199)=3.82, p<.05, r =0.19] and Performance IQ (PIQ) [F(2,199)=4.39, 
p<05, r =0.21] scores were significantly higher in haplogroup 3 compared to 
haplogroup 1.
• No evidence of an effect of Y chromosome haplogroups on IQ scores in the 
general population.
• No evidence of a modifying effect of Y chromosome haplogroups on IQ 
scores in an independent sample of patients with ADHD. However, the sample 
size was very small to detect any association.
• There was evidence of a modifying effect of Y chromosome haplogroups on 
schizophrenia, specifically an association with the course of illness and the 
educational level achieved. Specifically, haplogroup 1 had a higher percentage 
of individuals with good than poor outcome while the opposite was true for 
haplogroup 2 [x2 (2) = 8.98, p=0.011, OR =2.25]. Haplogroup 1 had also a 
higher percentage of individuals with high than low educational level while 
the opposite was true for haplogroup 3 [x2 (2) = 6.35, p=0.042, OR =2.5].
• No evidence of an association of TH SNPs with ADHD was found. There was 
also no evidence of a sex-specific effect of TH SNPs on ADHD.
• There was evidence of a nominally significant association for TH SNPs 
rsl0770140 (p=0.034, OR=1.18) and rsl 1564709 (p=0.034, OR=1.31) with 
schizophrenia diagnosis. These associations became stronger in the male-only 
sample of patients with schizophrenia (p=0.008, OR=1.3 for rsl0770140 and 
p=0.035, OR=1.4 for rsl 1564709) and also a third SNP, rsl 1042978, became 
nominally significant (p=0.02, OR=0.8). There was no evidence of association
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in the female patients with schizophrenia. There was no evidence of an 
interaction of TH and Y chromosome SNPs increasing risk for schizophrenia.
11.2 Y chromosome haplogroup distribution in the UK
As discussed before, the Y chromosome haplogroup distribution depends highly on 
geography. The frequencies of these haplogroups can differ extensively even within 
areas of the same country. Research on the Y chromosome haplogroup distribution in 
the UK has mainly focused on studying small isolated populations in order to achieve 
a high degree of haplogroup breakdown (Capelli et al. 2003). However, this is not 
desirable for psychiatric genetics studies which involve a large number of individuals 
from different areas of the UK. The Y chromosome haplogroup distribution in the UK 
would be useful for researchers wishing to study the effect of Y chromosome on a 
number of disorders using populations of UK Caucasian origin.
During the course of this project a large number of UK Caucasian individuals have 
been genotyped for Y chromosome variants. Specifically, 1,160 UK Caucasian males, 
including 210 patients with ADHD, 313 patients with schizophrenia and 637 
individuals from the 1958 Birth Cohort were genotyped for nine Y chromosome 
SNPs, which covered nine Y chromosome haplogroups. This is the first time to my 
best knowledge that Y chromosome haplogroups have been genotyped in such a large 
sample of UK Caucasian men. The frequencies of the nine different haplogroups are 
very similar between these three different groups of UK men (Table 11-1).
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Table 11-1. Frequencies of Y chromosome haplogroups in patients with ADHD, patients with
schizophrenia and controls
Y chromosome 
haplogroup
ADHD cases 
(%)
SZ cases 
(%)
Controls
(%)
Total (%)
DE 2.4 4.2 3.3 3.3
G* 1.9 1.9 1.4 1.7
I* 22.3 18.5 20.7 20.5
J* 0.9 1.9 0.6 1.1
J2 1.9 1 1.7 1.5
K* 0.9 0.3 0.5 0.6
Rl* 53.1 55.6 52.1 53.6
Rlb3M405 16.6 16.6 19.5 17.6
Rlb3d 0 0 0.2 0.1
The similarity in the haplogroup distribution in the three groups of males supports our 
notion that the Y chromosome SNPs that are suitable for UK populations were chosen 
after careful consideration and after consulting members of the Y Chromosome 
Consortium (The Y Chromosome Consortium 2002) for their advice in this matter. It 
also confirms that the 1958 UK Birth Cohort is a suitable control population for Y 
chromosome studies in the UK, since there is no evidence of population stratification 
of the Y chromosome haplogroups.
The ADHD sample included individuals from both England and Wales. The 
postcodes of the individuals were available and, although they do not always correlate 
with the person’s origin, they provided a measure of geographic location. There was 
no difference in the haplogroup distribution between English and Welsh individuals, a 
finding providing more evidence that this is a panel of Y chromosome SNPs 
appropriate for any UK population.
The Y chromosome haplogroups that were expected to be frequent in the UK were I* 
and R*. As seen in Table 11.1, this is true for haplogroup I* with a total frequency of 
20.5% and haplogroup R*, which includes haplogroups Rl* with a total frequency of 
53.6% and Rlb3M405 with a total frequency of 17.6%.
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In addition to the 1,160 UK men genotyped for nine Y chromosome SNPs, another 
3,790 males from ALSPAC were genotyped for Y chromosome SNPs M l73 and 
M405. These two SNPs define the three major haplogroups that resulted when the 
nine haplogroups were merged according to ancestry in order to increase the numbers 
in each group (see Chapter 7 for more details). This means that 4,950 UK male 
individuals were genotyped for these two SNPs. It is the first time that any Y 
chromosome polymorphism has been genotyped in such a large sample of men. 
Frequencies of haplogroups 1-3 can be seen in Table 11-2 and they look remarkably 
similar between ALSPAC and the rest of the UK individuals.
Table 11-2. Frequencies of merged Y chromosome haplogroups in patients with ADHD, patients 
with schizophrenia and controls from the 1958 Birth Cohort and ALSPAC
Merged Y 
chromosome 
haplogroup
ADHD
cases (%)
SZ cases 
(% )
1958 BC 
Controls 
(%)
ALSPAC
(%) Total (%)
1 30.3 27.2 28.3 27.1 28.3
2 53.1 55.3 52.1 49.5 53.3
3 16.6 17.4 19.6 23.4 18.4
11.3 The role of the Y chromosome on ADHD
The aims of this project included testing for a main effect and a modifying effect of 
the Y chromosome on ADHD. Although this study provided no evidence for a main 
effect of Y chromosome haplogroups on ADHD, there was evidence for a possible 
modifying effect by influencing cognitive performance. IQ scores were higher in 
haplogroup 3 and the difference in FSIQ and PIQ between haplogroup 1 and 
haplogroup 3 was significant.
Although there is no knowledge about the mechanism through which the Y 
chromosome haplogroups could modify the phenotype of ADHD, it is possible to 
speculate. The most likely scenario, since the most recent in evolutionary terms 
haplogroup is associated with higher IQ scores, is that a mutation appeared at some 
point during evolution against a specific Y chromosome background. This mutation 
was beneficial to patients with ADHD by protecting them against cognitive
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impairment. The way this is achieved could be through interactions with other 
autosomal or X chromosome variants that increase risk to ADHD. This means that 
possession of certain variants that increase risk to ADHD and a certain Y 
chromosome haplogroup background leads to less cognitive impairment and thus 
higher IQ scores in patients with ADHD. Since both ADHD and IQ are complex 
traits, it is possible that environmental factors are also involved in this process 
creating an even more complicated pathway.
Another explanation for this association could be that these results are false positive 
findings. For the significance threshold used in this study (p<0.05), there is a 5% 
chance that these results would be observed even if  there are no true associations of Y 
chromosome haplogroups with any of the phenotypic measures studied. The only way 
to increase confidence on these results would be to replicate them in a large 
independent sample of patients with ADHD with available IQ scores.
11.4 The role of the Y chromosome on schizophrenia
The aims of this project included testing for a main effect and a modifying effect of 
the Y chromosome on schizophrenia. No main effect of Y chromosome on 
schizophrenia was found. However, there was a modifying effect of Y chromosome 
haplogroups on schizophrenia. Y chromosome haplogroups were associated with the 
course of illness and the educational level achieved. Haplogroup 1 had a significantly 
higher frequency of individuals with good outcome than haplogroup 2 while the same 
haplogroup also had a significantly higher frequency of individuals with high 
education. Haplogroup 1 is the most ancient in evolutionary terms from the three that 
were compared in schizophrenia. It can be speculated that in this case a mutation 
appeared against a specific Y chromosome haplogroup background that increased the 
susceptibility to a poor outcome and more impaired cognition in patients with 
schizophrenia. This mutation might have been beneficial or neutral to the general 
population; but coupled with other risk factors for schizophrenia (genetic or 
environmental), it was possible to modify the phenotype of the disorder. However, 
there are some issues with using educational level as a proxy for cognitive ability in 
schizophrenia. The onset of the disorder usually coincides with important periods for 
education in an individual’s life, thus it is difficult to estimate the educational level
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that would have been achieved otherwise. In addition, even in periods of recovery 
cognitive impairment can still be present and it will have a considerable effect on the 
educational level achieved. Nevertheless, the educational level was the only available 
measure of cognitive performance in the sample of patients with schizophrenia and 
the direction of the effect is in agreement with the results obtained for the course of 
illness (the same haplogroup is associated with both good outcome and high 
educational level).
11.5 Y chromosome interaction with Tyrosine Hydroxylase (TH)
It was hypothesised that the Y chromosome can interact with TH, which is the rate- 
limiting enzyme in dopamine metabolism, and increase risk to the disorders. Evidence 
for interaction of TH  with the SRY  gene has been found in male rats (Dewing et al. 
2006). This hypothesis was tested by performing two case-control association studies, 
one for ADHD and one for schizophrenia using TH  tag SNPs. Then, these SNPs were 
tested for a sex-specific effect on the disorders and, finally, TH SNPs were tested for 
interaction with already genotyped Y chromosome SNPs only when a main effect was 
detected.
Studies on the role of TH  in psychiatric disorders have focused on an intronic 
microsatellite. Research on other polymorphisms in and around the gene area has 
been very limited. As the name suggests genome-wide association studies are 
designed to survey the entire genome for common variants that might increase risk to 
a complex disorder. They utilise the large number of SNPs that have been discovered 
and the information on linkage disequilibrium patterns across the genome as provided 
by HapMap. However, genotyping arrays used for genome-wide association studies of 
psychiatric disorders (like the Affymetrix GeneChip Human Mapping 500K Array) 
examined -500,000 SNPs. This coverage is not 100% and this is without taking into 
account the removal of SNPs due to quality control measures which would reduce the 
coverage further. One of the regions not covered by genotyping arrays that have been 
used for genome-wide association studies of psychiatric disorders is the TH gene 
region.
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Our study achieved good coverage (>80%) of the variation not only in the TH gene 
but also of a 35kb area adjacent to the gene. However, there was no association of TH 
SNPs with ADHD and this was also true when the sample was split according to sex. 
The fact that no association was found between TH and ADHD does not exclude an 
involvement of TH in ADHD because the power to detect an association was limited 
especially when the effect size was small. This is one of the biggest problems in 
research of complex disorders at the moment. Detecting associations with alleles of 
small effects requires a large sample size. Even a common allele with a relatively 
large effect size (OR=1.5) needs to be genotyped in a large sample (1500 cases and 
1500 controls) to reach genome-wide significance. When multiple test correction is 
taken into account (as with genome-wide association studies), the sample sizes for 
detecting alleles of small effect sizes are increased to numbers that are possible to 
achieve only in large collaborative studies. In addition, variants with large effect sizes 
but very low frequencies in the population would again be very difficult to detect 
unless sample sizes are large enough. Thus, negative results cannot be conclusive and 
an involvement of TH  in ADHD cannot be excluded.
The case-control association study in schizophrenia revealed three SNPs that were 
nominally significant in the male-only sample. First of all, the required level of 
significance was not achieved, thus these results could be a false positive finding. 
However, if this is not the case, these results could indicate a possible role of TH in 
schizophrenia and especially in male patients. Since there was no association in the 
female patients with schizophrenia, it is reasonable to speculate that TH interacts with 
a male-specific factor to increase risk to schizophrenia in male patients only. One of 
the most obvious male-specific factors is the Y chromosome. Animal studies have 
already shown an interaction of TH  with the SRY  gene on the Y chromosome. Thus, it 
is possible that the mechanism by which TH increases risk to schizophrenia is by 
interacting with polymorphisms on the SRY gene or other parts of the Y chromosome, 
although this study did not provide any evidence towards this.
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11.6 Implications of research results
This thesis identified a possible modifying effect of Y chromosome haplogroups on 
ADHD and schizophrenia. Previous association studies of the Y chromosome and 
psychiatric phenotypes have failed to find any evidence of association. However, 
most of the studies have not used homogeneous samples and Y chromosome markers 
appropriate for the populations they were studying. In addition, the sample sizes in 
these studies have been small compared with the individuals genotyped for this 
project. However, the most important issue is that few studies have investigated the 
effect of Y chromosome haplogroups on different phenotypic measures. This could be 
an important reason for their failure to detect association, since the Y chromosome 
might not have a main effect on the disorder but it could be modifying the phenotype 
by affecting clinical presentation or cognitive performance.
One of the implications of this research project is that it provides a set of Y 
chromosome markers that can be used for future association studies in UK 
populations. Since these markers and the haplogroups they cover represent the UK 
and not specific areas within the country, they can be used for any UK population 
provided that the individuals are Caucasian.
The most important point highlighted by these results is that not taking the Y 
chromosome into account in genetic studies is not justified, since these results suggest 
the possibility of a modifying effect of Y chromosome haplogroups on the phenotype 
of ADHD and schizophrenia. For a number of years it has been thought that the Y 
chromosome was only important for male sex differentiation and reproduction. This 
view has changed in recent years with animal models showing that the Y chromosome 
is implicated in brain function and behaviour (De Vries et al. 2002; Gatewood et al. 
2006; Guillot et al. 1995) and evidence of its involvement in another phenotype with 
increased male susceptibility, hypertension (Charchar et al. 2003). In the previous 
years, the genetics of complex disorders have been mainly investigated using 
candidate gene association studies and linkage studies. The Y chromosome is suitable 
for neither of these two approaches: it would not be one of the obvious candidates (as, 
for example, genes related to neurotransmitter pathways) that have been the focus of 
candidate gene studies for psychiatric disorders and it is not possible to include in
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linkage studies due to the lack of recombination. In addition, before the systematic 
effort of the Y Chromosome Consortium (The Y Chromosome Consortium 2002) the 
confusing nomenclature made choosing Y chromosome SNPs for each population a 
very difficult task. Nevertheless, today there are Y chromosome SNPs appropriate for 
most populations and new ones are still being discovered.
The approach of testing for association using a large number of SNPs across the 
whole genome has revolutionised the way the genetics of complex disorders are 
investigated. However, once again the Y chromosome has been excluded from these 
studies. As already mentioned, most of the genotyping arrays for genome-wide 
association studies have not included Y chromosome SNPs. This situation has 
changed with recent genotyping arrays having Y chromosome SNPs, although most 
genome-wide association studies still ignore Y chromosome SNPs in their analysis. It 
is striking that in a disorder with such a profound male excess as in ADHD, all 
genome-wide association studies performed so far have not analysed sex 
chromosomes.
To conclude, this thesis provides evidence that there are valid reasons to include the Y 
chromosome in genetic studies. The Y chromosome and other non-autosomal sources 
of DNA, such as the X chromosome and the mitochondrial DNA, have unique 
characteristics and it can be challenging to find the appropriate way of incorporating 
them into analyses. However, these are sources of DNA which could have an effect 
on a number of disorders and the effort invested in studying them and their 
interactions with autosomes can be worthwhile.
11.7 Moving from genetic association to understanding the biology
Identifying gene alleles that are associated with disease phenotypes is the first step in 
a long process towards the investigation of risk pathways that are relevant to disease 
and could help elucidate the pathophysiology or develop therapeutic targets.
Before even considering further genetic or functional studies to enhance biological 
knowledge about the disease, it is important to confirm the initial association. In the 
case of the association of Y chromosome haplogroups with phenotypic measures in
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ADHD and schizophrenia, this would be possible only if large enough samples of 
patients with ADHD and schizophrenia and available phenotypic measures could be 
used. Genome-wide association studies have increased in number and recent 
genotyping arrays will be including SNPs on the Y chromosome. Utilising data from 
these studies, which tend to use large sample sizes to maximise power, could provide 
the means to achieve an independent replication of our current results provided that 
the studies have relevant phenotypic measures available.
If independent replication was achieved for any of the phenotypes in ADHD and 
schizophrenia associated with Y chromosome haplogroups, the next step would 
involve further genotyping of SNPs within the associated haplogroup in an attempt to 
narrow down the possible mutations involved.
Bioinformatic approaches would then be employed to gain more information about 
the chromosomal region in which the mutation is located. Greatest credibility for a 
variant being causal is usually assigned to non-synonymous coding SNPs and 
biological credibility is increased when genes are expressed in relevant tissues or code 
for a protein that takes part in interesting biological pathways. Sequencing efforts or 
utilisation of already available sequencing information could potentially increase 
confidence in specific genes or chromosomal regions, if rare mutations in the region 
are also found to be associated with the disorder.
Going a step further in implicating possible mechanisms behind the genetic 
association, would require information about the possible function of the mutation. 
Microarray technology has allowed the simultaneous assessment of the expression of 
the majority of genes in the genome and these have been named eQTLs (expression 
Quantitative Trait Locus), since the level of expression of a gene can be considered a 
quantitative trait. eQTL data are publically available for a number of tissues (Stranger 
et al. 2007) including human brain (Myers et al. 2007). Combining eQTL data with 
results from genome-wide association studies can yield findings that would otherwise 
be missed, as is demonstrated by a genome-wide association study into Crohn’s 
disease. The strongest associated SNP in this study was located in a gene desert but 
examination of an eQTL database showed that it influences expression of certain 
genes (Libioulle et al. 2007).
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Apart from in silico investigation, function can be evaluated in living organisms, 
although this can be particularly challenging. Developing cell lines is usually the first 
stage when investigating the functional impact of putative causal variants in living 
organisms but deciding on cell type, developmental stage and specific environmental 
conditions is not straightforward and can have a great impact on the experimental 
outcome. Even greater challenges are expected when using animal models to assess 
the function of putative causal variants because variants involved in complex 
disorders can have subtle effects that are not easy to observe in animals (McCarthy 
and Hirschhom 2008).
In summary, the association of Y chromosome haplogroups with phenotypic measures 
in ADHD and schizophrenia needs to be replicated in large independent samples with 
available phenotypic measures. If and when the association is replicated, 
bioinformatic approaches and detailed investigation of the region the mutation is 
located could provide more information about its possible role with the aim to 
develop cell lines or animal models where the function of the mutation can be studied 
in living organisms.
11.8 Future directions
The work presented in this thesis has provided evidence about the possible role of the 
Y chromosome in ADHD and schizophrenia. The Y chromosome can be considered a 
part of the complex picture of the causes of sex differences in psychiatric disorders. 
Research on the sex differences of psychiatric disorders can be performed separately 
or simultaneously with studies investigating the genetics of complex disorders.
Since the most recent versions o f genotyping arrays for genome-wide association 
studies include markers on non-autosomal sources of DNA, such as the sex 
chromosomes and mitochondrial DNA, they should be taken into account in future 
analysis. In some instances this will involve modifying the quality control criteria and 
the software used in order to accommodate the characteristics of these SNPs. In
addition, the threshold of significance should be taken into consideration, especially
-8for the Y chromosome which does not recombine. The stringent p value of ~p<10 , 
which is required for a variant to achieve genome-wide significance (Pe'er et al.
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2008), might be not necessary for Y chromosome SNPs that are not independent from 
each other, since they are co-inherited. Genotyping arrays for genome-wide 
association studies can also be used to investigate copy number variation (CNVs).
The degree of penetrance and the pattern of CNVs in the genome can differ between 
males and females and now it is possible to investigate this at the same time as 
genome-wide association studies. Another approach that can lead to identification of 
sex-specific risk variants, not necessarily located on the sex chromosomes, is testing 
for association separately in each sex when performing genome-wide or candidate- 
gene association studies, since sex has been found to affect association results 
(Biederman et al. 2008; Guimaraes et al. 2007; Rommelse et al. 2008).
Studying the causes of sex differences in psychiatric disorders can be another way to 
obtain clues about the pathophysiology o f disorders we know little about. Since it is 
possible that the variants leading to sex differences in psychiatric disorders would 
modify the disease phenotype without having a main effect on the disorder, it is of 
great importance to look deeper into the disease phenotype. This can be achieved by 
taking into account clinical presentation, such as comorbidity with other disorders and 
cognitive measures, which can be used as endophenotypes.
It is generally accepted that there are limitations in the current disease categories as 
defined by the diagnostic criteria. One way to overcome the lack of biological validity 
of disease diagnosis based on clinical symptoms is to further explore the phenotypic 
heterogeneity of the disorder. Comorbidity in most psychiatric disorders is the rule 
and not the exception. Identifying groups o f patients with certain comorbidities that 
exhibit more profound sex differences can facilitate the identification of factors 
contributing to them. One example of such a successful approach is the identification 
of the COMT val/val genotype as a risk factor for conduct disorder in children with 
ADHD (Thapar et al. 2005). This finding has been replicated across three independent 
samples and it justifies considering patients with ADHD and conduct disorder a 
distinct group to those with just ADHD, since there is no association of this 
polymorphism in patients with ADHD but no conduct disorder (Caspi et al. 2008).
Apart from comorbidity, looking deeper into the phenotype can also yield results. 
Endophenotypes, or intermediate phenotypes, are quantitative, heritable traits that are 
thought to be more directly associated with risk factors than the disease diagnosis
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(Castellanos and Tannock 2002). Investigating the potential of endophenotypes 
requires considerable effort in order to collect the appropriate information about the 
neuropsychological or cognitive performance of the patients. However, it is an 
approach that coupled with collaborative efforts to increase sample sizes can yield 
important results about the involvement of genetic factors in psychiatric disorders.
The advance of technology will revolutionise genetic studies and consequently the 
search for genetic causes of sex differences. The recent development of high- 
throughput sequencing or next-generation sequencing is becoming increasingly 
affordable and allows the parallel analysis of millions of sequence reads compared to 
the 96 that conventional capillary systems can process (Mardis 2008). This 
technology will be applied to sequence -1000 human genomes as part of the 1000 
genomes project (Siva 2008). The aim of this project is to discover >95 % of the 
variants (SNPs, CNVs, indels) with minor allele frequencies as low as 1%. For the 
first time an unprecedented amount of genetic variation would be available for testing 
for association with complex disorders as well as sex differences.
One of the main challenges when investigating the genetic causes of sex differences is 
to find a way of dissociating them from the hormonal effects. While this is not easy to 
do with genetic studies, animal models have provided the first evidence of hormone- 
independent effects o f Y chromosome on brain and behaviour using the four-core 
genotypes model (De Vries et al. 2002) and it is likely that they will continue yielding 
results in the field of sex differences. The effect o f the SRY  gene, which is very 
difficult to assess with genetic studies due to the limited amount of variation, has been 
investigated in rats. By microinjecting Sry antisense in specific areas of the rat brain, 
it is possible to knockdown the Sry gene in certain brain regions without affecting the 
rest of the brain. Testing these rats on behavioural tasks will provide evidence about 
the cognitive effects o f the Sry gene on the brain (Kopsida 2009 Personal 
communication).
To conclude, future directions about research in this field should include a careful 
consideration of the disease phenotype, the possibility of using large sample sizes 
while maintaining good quality in the sample characterisation, maximising the 
potential of new technologies and applying them to non-autosomal sources of DNA 
and making use of animal models.
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11.9 Conclusions
The research described in this thesis involved systematically investigating the Y 
chromosome in ADHD and schizophrenia for the first time. The possible modifying 
effect of Y chromosome on ADHD and schizophrenia supports the notion that it is 
involved in brain function and behaviour and it is vital that both sex chromosomes as 
well as other sources of non-autosomal DNA are investigated in future genetic 
studies. Although sex differences in psychiatric disorders are well-documented, 
research on their causes is still in its infancy and it will require maximising the 
potential of existing and new technologies to gain an insight into them. Nevertheless, 
the effort will definitely be worthwhile, since research on the causes of sex 
differences is likely to provide clues about the pathophysiology of psychiatric 
disorders.
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Appendix I -  Quality Control information
Standard quality control procedures were followed in all samples and SNPs 
genotyped. First, SNPs with a call rate <95% were excluded from further analysis. In 
addition, the difference in the genotyping rate for each SNP between cases and 
controls was assessed to exclude possible sources of bias. Individuals were only 
included in analysis if  they had genotypes for over 85% of the SNPs analysed.
Finally, Hardy-Weinberg (HW) equilibrium was tested for all markers in both cases 
and controls. Y chromosome SNPs were not tested for HW equilibrium, since they are 
inherited only from one parent. All quality control tests were performed using PLINK 
1.06 (Purcell et al. 2007).
Y chromosome SNPs
14 SNPs across the Y chromosome were chosen to genotype in the ADHD and 
schizophrenia cases and 1958 Birth Cohort control samples. Two SNPs completely 
failed to provide genotypes in the genotyping platform and we excluded them from 
any further analysis. Three SNPs (M45, M74 and M231) were excluded from further 
analysis for both the ADHD and the schizophrenia case-control association study due 
to low genotyping rates. The genotyping rates for these SNPs were also significantly 
different from the controls. In addition, 6 individuals from the ADHD sample and 13 
individuals from the schizophrenia sample were removed prior to association analysis 
due to having genotypes for <85% o f the SNPs analysed.
Table I: Quality control measures for the ADHD case-control association study using 12 Y
chromosome SNPs
Y chromosome 
SNPs
Call rate 
(cases) %
Call rate 
(controls) %
p value for 
difference in call 
rates
M9 99.5 99.9 0.26
M45 75.7 68.1 0.0058*
M74 85.6 92.9 0.00061**
M89 100.0 99.4 0.34
M153 100.0 99.9 1
M170 98.8 99.1 0.57
M173 99.1 99.3 0.649
M201 98.4 99.1 0.33
M231 93.2 97.7 0.00042**
M3 04 99.3 99.1 0.65
M405 99.5 99.9 0.26
M410 100.0 100.0 1
*: significant at the p<0.01 level; **: significant at the p<0.001 level
Table 2: Quality control measures for the schizophrenia case-control association study using 12
chromosome SNPs
Y
chromosome
SNPs
Call rate
(cases) %
Call rate 
(controls) %
p value for 
difference in call 
rates
M9 99.9 99.9 1
M45 76.7 68.1 0.0064*
M74 87.6 92.9 0.0008**
M89 99.5 99.4 0.16
M153 99.9 99.9 1
M170 99.9 99.1 0.57
M173 99.6 99.3 0.71
M201 98.2 99.1 0.22
M231 94.1 97.7 0.00065**
M3 04 99.8 99.1 0.59
M405 100.0 99.9 1
M410 100.0 100.0 1
*: significant at the p<0.01 level; **: significant at the p<0.001 level
THSNPs
14 SNPs across the TH gene and surrounding region were chosen to genotype in the 
ADHD and schizophrenia cases and 1958 Birth Cohort control samples. Two SNPs 
(rs6356 and rs7950050) completely failed to provide genotypes in the genotyping 
platform and we excluded them from any further analysis. Two SNPs (rsl 1042982 
and rsl 1043003) were excluded from further analysis for both the ADHD and the 
schizophrenia case-control association study due to low genotyping rates and 
deviations from HW equilibrium. The genotyping rates for these SNPs were also 
significantly different from the controls. In addition, 10 individuals from the ADHD 
sample and 19 individuals from the schizophrenia sample were removed prior to 
association analysis due to having genotypes for <85% of the SNPs analysed.
Table 3: Quality control measures for the ADHD case-control association study using 12 TH
SNPs
SNPrs
number
Call rate
(cases) %
Call rate 
(controls)
%
p value for 
difference in call 
rates
HW p 
value in
cases
HW p value 
in controls
rsl 0770140 99.2 99.8 0.45 0.91 0.85
rsl0840489 99.1 100 0.08 1 0.9
rsl0840490 100 100 1 0.81 0.38
rsl0840491 99 99.7 0.09 0.46 1
rsl 1042978 99.4 99.9 0.13 1 0.39
rsl 1042982 91 81 0.001 0.003* 0.09
rsl1043003 71 62 0.0009 0.002* 0.05
rsl1564703 99.1 99.7 0.1 1 0.41
rsl1564709 99.4 100 0.1 0.78 0.26
rs2070762 99.4 99.7 0.34 1 0.71
rs4320932 98.5 98.8 0.32 0.057 0.06
rs7924316 99.7 99.8 0.55 0.75 0.5
*: significant at the p<0.01 level; **: significant at the p<0.001 level
Table 4: Quality control measures for the schizophrenia case-control association study using 12
TH SNPs
SNP rs 
number
Call rate
(cases) %
Call rate 
(controls)
%
p value for 
difference in call 
rates
HW p 
value in
cases
HW p value 
in controls
rsl0770140 99.7 99.8 1 0.06 0.85
rsl0840489 99.3 100 0.08 0.55 0.9
rsl0840490 100 100 1 0.24 0.38
rsl0840491 99.4 99.7 0.34 0.16 1
rsl1042978 99.7 99.9 0.62 1 0.39
rsl1042982 62 81 0.00002 0.001** 0.09
rsl1043003 53 62 0.0004 0.00033** 0.05
rsl1564703 99.8 99.7 0.6 0.85 0.41
rsl1564709 100 100 1 0.1 0.26
rs2070762 100 99.7 0.62 0.72 0.71
rs4320932 98.2 98.8 0.27 1 0.06
rs7924316 99.8 99.8 1 0.65 0.5
*: significant at the p<0.01 level; **: significant at the p<0.001 level
Appendix II
Table 1: Combination of SNP alleles for each Y chromosome haplogroup. 0 represents the ancestral state of 
each SNP and 1 the derived state. YAP has not been genotyped and is present for completion, since it is the 
‘root* of the Y chromosome haplogroup tree. Y* is the most ancient haplogroup where all men belong
YAP M89 M201 M170 M3 04 M410 M9 M173 M405 M153
Y* 0 0 0 0 0 0 0 0 0 0
DE 1 0 0 0 0 0 0 0 0 0
p* 0 1 0 0 0 0 0 0 0 0
G 0 1 1 0 0 0 0 0 0 0
I* 0 1 0 1 0 0 0 0 0 0
J* 0 1 0 0 1 0 0 0 0 0
J2 0 1 0 0 1 1 0 0 0 0
K* 0 1 0 0 0 0 1 0 0 0
Rl* 0 1 0 0 0 0 1 1 0 0
Rlb3M405 0 1 0 0 0 0 1 1 1 0
Rlb3d 0 1 0 0 0 0 1 1 0 1
V
Appendix III -  Interactions
Table 1: Interactions between 3 TH SNPs and 9 Y chromosome SNPs in 312 male schizophrenia cases and 
646 male controls. It was not possible to test for interaction with Y chromosome SNP M153 because it was not
polymorphic in the schizophrenia cases
TH SNP Y chromosome SNP
OR for 
interaction x2 p value
rsl0770140 M153 n/a n/a n/a
rsl0770140 M170 0.99 0.002 0.96
rsl 0770140 M173 1.09 0.56 0.46
rsl 0770140 M201 1.66 0.76 0.38
rsl 0770140 M3 04 1.15 0.17 0.68
rsl 0770140 M405 1.07 0.26 0.61
rsl 0770140 M410 1.66 1.07 0.3
rsl 0770140 M89 1.19 0.41 0.52
rsl 0770140 M9 1.08 0.4 0.53
rsl1042978 M153 n/a n/a n/a
rsl1042978 M170 1.03 0.04 0.83
rs l1042978 M173 0.94 0.27 0.61
rsl1042978 M201 1.04 0.01 0.92
rsl 1042978 M3 04 1.07 0.02 0.89
rsl1042978 M405 1.10 0.53 0.47
rs l1042978 M410 0.91 0.02 0.9
rs l1042978 M89 0.79 0.5 0.48
r s l1042978 M9 0.98 0.02 0.9
rs l1564709 M153 n/a n/a n/a
rsl 1564709 M170 1.27 1.39 0.24
rsl1564709 M173 1.22 1.17 0.28
rsl 1564709 M201 1.09 0.02 0.89
rsl 1564709 M3 04 0.99 0.001 0.98
rsl 1564709 M405 1.18 0.59 0.44
rsl1564709 M410 1.58 0.8 0.37
rsl 1564709 M89 1.08 0.02 0.89
rsl1564709 M9 1.24 1.36 0.24
TH: Tyrosine Hydroxylase; OR: Odds Ratio; n/a: non-applicable
